CA3036041A1 - Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy - Google Patents
Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy Download PDFInfo
- Publication number
- CA3036041A1 CA3036041A1 CA3036041A CA3036041A CA3036041A1 CA 3036041 A1 CA3036041 A1 CA 3036041A1 CA 3036041 A CA3036041 A CA 3036041A CA 3036041 A CA3036041 A CA 3036041A CA 3036041 A1 CA3036041 A1 CA 3036041A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- optic neuropathy
- organic solvent
- fraction
- polar organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 237
- 230000002378 acidificating effect Effects 0.000 title claims abstract description 165
- 229920000175 Pistacia lentiscus Polymers 0.000 title claims abstract description 108
- 206010061323 Optic neuropathy Diseases 0.000 title claims abstract description 91
- 208000020911 optic nerve disease Diseases 0.000 title claims abstract description 84
- 239000000284 extract Substances 0.000 title description 20
- 239000002253 acid Substances 0.000 claims description 296
- FMIMFCRXYXVFTA-FUAOEXFOSA-N (4as,6ar,6as,6br,8ar,12ar,14bs)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1h-picene-4a-carboxylic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C FMIMFCRXYXVFTA-FUAOEXFOSA-N 0.000 claims description 132
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 112
- 238000000034 method Methods 0.000 claims description 95
- 150000007513 acids Chemical class 0.000 claims description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 90
- 239000003495 polar organic solvent Substances 0.000 claims description 82
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 79
- 150000001875 compounds Chemical class 0.000 claims description 79
- VOYZLKWKVLYJHD-UHFFFAOYSA-N 24Z-masticadienonic acid Natural products CC1(C)C(=O)CCC2(C)C(CCC3(C(C(CCC=C(C)C(O)=O)C)CCC33C)C)C3=CCC21 VOYZLKWKVLYJHD-UHFFFAOYSA-N 0.000 claims description 66
- FMIMFCRXYXVFTA-UHFFFAOYSA-N 3-Oxo-12-oleanen-28-oic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C FMIMFCRXYXVFTA-UHFFFAOYSA-N 0.000 claims description 66
- FFDHYUFECJTEAY-UHFFFAOYSA-N epimacherinic acid Natural products CC1(C)CCC2(CCC3(C)C(CCC4C5(C)CCCC(C)(C)C5CCC34C)C2C1)C(=O)O FFDHYUFECJTEAY-UHFFFAOYSA-N 0.000 claims description 66
- VOYZLKWKVLYJHD-UZEUFRBSSA-N (z,6s)-2-methyl-6-[(5r,9r,10r,13s,14s,17s)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]hept-2-enoic acid Chemical compound CC1(C)C(=O)CC[C@]2(C)[C@@H](CC[C@]3([C@H]([C@H](CC\C=C(\C)C(O)=O)C)CC[C@@]33C)C)C3=CC[C@H]21 VOYZLKWKVLYJHD-UZEUFRBSSA-N 0.000 claims description 57
- VOYZLKWKVLYJHD-FTORBOHPSA-N masticadienonic acid Natural products C[C@@H](CCC=C(C)C(=O)O)[C@@H]1CC[C@]2(C)C3=CC[C@H]4C(C)(C)C(=O)CC[C@]4(C)[C@H]3CC[C@@]12C VOYZLKWKVLYJHD-FTORBOHPSA-N 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 56
- KDCSSVADTHDYGI-KEBDBYFISA-N Isomasticadienonic acid Chemical compound CC12CCC(=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CC\C=C(/C)C(O)=O)C)CCC21C KDCSSVADTHDYGI-KEBDBYFISA-N 0.000 claims description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- UILQHUKSFUOOLH-NHSHZOTLSA-N 6-[(5S,9S,10R,13S,14S,17R)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid Chemical compound CC(CCC=C(C)C(O)=O)[C@H]1CC[C@]2(C)C3=CC[C@@H]4C(C)(C)C(O)CC[C@]4(C)[C@@H]3CC[C@@]12C UILQHUKSFUOOLH-NHSHZOTLSA-N 0.000 claims description 47
- UMYJVVZWBKIXQQ-QALSDZMNSA-N (4aS,6aR,6bR,8aR,12aR,12bR,14aS)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14,14a-icosahydropicene-4a-carboxylic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C=C5[C@H]4CC[C@@H]3[C@]21C UMYJVVZWBKIXQQ-QALSDZMNSA-N 0.000 claims description 45
- UMYJVVZWBKIXQQ-UHFFFAOYSA-N Moronic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)C=C5C4CCC3C21C UMYJVVZWBKIXQQ-UHFFFAOYSA-N 0.000 claims description 45
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 37
- 239000007864 aqueous solution Substances 0.000 claims description 27
- 239000003960 organic solvent Substances 0.000 claims description 27
- -1 acetyl masticadienolic acid Chemical compound 0.000 claims description 25
- 238000000605 extraction Methods 0.000 claims description 25
- 239000000126 substance Substances 0.000 claims description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 239000003937 drug carrier Substances 0.000 claims description 24
- 208000010412 Glaucoma Diseases 0.000 claims description 22
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 21
- 230000003287 optical effect Effects 0.000 claims description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 18
- 230000008021 deposition Effects 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000007823 neuropathy Effects 0.000 claims description 14
- 201000001119 neuropathy Diseases 0.000 claims description 14
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 210000005036 nerve Anatomy 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- 238000003860 storage Methods 0.000 claims description 12
- 239000012051 hydrophobic carrier Substances 0.000 claims description 11
- 150000003648 triterpenes Chemical class 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 8
- 206010044245 Toxic optic neuropathy Diseases 0.000 claims description 8
- 231100000265 Toxic optic neuropathy Toxicity 0.000 claims description 8
- 230000002438 mitochondrial effect Effects 0.000 claims description 8
- 201000002761 non-arteritic anterior ischemic optic neuropathy Diseases 0.000 claims description 8
- 201000005799 nutritional optic neuropathy Diseases 0.000 claims description 8
- 208000029517 toxic amblyopia Diseases 0.000 claims description 8
- QPRQEDXDYOZYLA-UHFFFAOYSA-N 2-methylbutan-1-ol Chemical compound CCC(C)CO QPRQEDXDYOZYLA-UHFFFAOYSA-N 0.000 claims description 7
- 208000003435 Optic Neuritis Diseases 0.000 claims description 7
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 7
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002274 desiccant Substances 0.000 claims description 6
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 6
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims description 6
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 claims description 6
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 230000000472 traumatic effect Effects 0.000 claims description 6
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical class CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 5
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000002015 acyclic group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 238000001361 intraarterial administration Methods 0.000 claims description 4
- 238000000185 intracerebroventricular administration Methods 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000007913 intrathecal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- VOYZLKWKVLYJHD-LQZQKTEASA-N (E,6S)-2-methyl-6-[(5R,9R,10R,13S,14S,17S)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]hept-2-enoic acid Chemical compound C[C@@H](CC\C=C(/C)C(O)=O)[C@@H]1CC[C@]2(C)C3=CC[C@H]4C(C)(C)C(=O)CC[C@]4(C)[C@H]3CC[C@@]12C VOYZLKWKVLYJHD-LQZQKTEASA-N 0.000 claims description 3
- NVJUHMXYKCUMQA-UHFFFAOYSA-N 1-ethoxypropane Chemical compound CCCOCC NVJUHMXYKCUMQA-UHFFFAOYSA-N 0.000 claims description 3
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 3
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims description 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims description 3
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 claims description 3
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 3
- 150000001924 cycloalkanes Chemical class 0.000 claims description 3
- 229940093476 ethylene glycol Drugs 0.000 claims description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 238000007915 intraurethral administration Methods 0.000 claims description 3
- VNKYTQGIUYNRMY-UHFFFAOYSA-N methoxypropane Chemical compound CCCOC VNKYTQGIUYNRMY-UHFFFAOYSA-N 0.000 claims description 3
- 229940017219 methyl propionate Drugs 0.000 claims description 3
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 3
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 3
- 229940090181 propyl acetate Drugs 0.000 claims description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012223 aqueous fraction Substances 0.000 claims 3
- MXLMTQWGSQIYOW-UHFFFAOYSA-N 3-methyl-2-butanol Chemical compound CC(C)C(C)O MXLMTQWGSQIYOW-UHFFFAOYSA-N 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 35
- 210000001328 optic nerve Anatomy 0.000 description 37
- 240000005428 Pistacia lentiscus Species 0.000 description 32
- 235000012343 cottonseed oil Nutrition 0.000 description 30
- 239000002385 cottonseed oil Substances 0.000 description 30
- 238000011282 treatment Methods 0.000 description 30
- 210000003994 retinal ganglion cell Anatomy 0.000 description 27
- 241000700159 Rattus Species 0.000 description 26
- 239000008194 pharmaceutical composition Substances 0.000 description 26
- 241000196324 Embryophyta Species 0.000 description 24
- 235000003445 Pistacia Nutrition 0.000 description 20
- 241000543704 Pistacia Species 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 239000004480 active ingredient Substances 0.000 description 19
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 19
- 239000002798 polar solvent Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 239000003456 ion exchange resin Substances 0.000 description 18
- 229920003303 ion-exchange polymer Polymers 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 17
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000006378 damage Effects 0.000 description 16
- 229940093499 ethyl acetate Drugs 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 210000001508 eye Anatomy 0.000 description 16
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 239000012454 non-polar solvent Substances 0.000 description 14
- 210000001525 retina Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 239000013521 mastic Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 11
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 11
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 11
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229940100243 oleanolic acid Drugs 0.000 description 11
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 239000002198 insoluble material Substances 0.000 description 10
- 230000002207 retinal effect Effects 0.000 description 10
- 239000001993 wax Substances 0.000 description 10
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- SLJTWDNVZKIDAU-SVAFSPIFSA-N Betulonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C SLJTWDNVZKIDAU-SVAFSPIFSA-N 0.000 description 9
- SLJTWDNVZKIDAU-CKURCAGRSA-N Betulonic acid Natural products CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@@H](CC[C@@H]4[C@@]5(C)CCC(=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O SLJTWDNVZKIDAU-CKURCAGRSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 9
- MUCRYNWJQNHDJH-UHFFFAOYSA-N Ursonic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(C)C5C4=CCC3C21C MUCRYNWJQNHDJH-UHFFFAOYSA-N 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 229940096998 ursolic acid Drugs 0.000 description 9
- VOYZLKWKVLYJHD-GGERGLNBSA-N (z,6s)-2-methyl-6-[(10r,13s,14s)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]hept-2-enoic acid Chemical compound CC1(C)C(=O)CC[C@]2(C)C(CC[C@]3(C([C@H](CC\C=C(\C)C(O)=O)C)CC[C@@]33C)C)C3=CCC21 VOYZLKWKVLYJHD-GGERGLNBSA-N 0.000 description 8
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 239000002480 mineral oil Substances 0.000 description 8
- 235000010446 mineral oil Nutrition 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- KDCSSVADTHDYGI-LNBBASHESA-N (z,6s)-2-methyl-6-[(10s,13s,14s)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]hept-2-enoic acid Chemical compound C([C@@]12C)CC(=O)C(C)(C)C1CCC1=C2CC[C@@]2(C)C([C@H](CC\C=C(\C)C(O)=O)C)CC[C@@]21C KDCSSVADTHDYGI-LNBBASHESA-N 0.000 description 7
- KDCSSVADTHDYGI-UHFFFAOYSA-N Masticadienonsaeure Natural products CC12CCC(=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C(O)=O)C)CCC21C KDCSSVADTHDYGI-UHFFFAOYSA-N 0.000 description 7
- 235000004768 Pistacia lentiscus Nutrition 0.000 description 7
- 206010038848 Retinal detachment Diseases 0.000 description 7
- 210000003050 axon Anatomy 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000004530 micro-emulsion Substances 0.000 description 7
- 230000004264 retinal detachment Effects 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 150000003505 terpenes Chemical class 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 240000006705 Pistacia terebinthus Species 0.000 description 6
- 239000003929 acidic solution Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000000649 photocoagulation Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 229960001866 silicon dioxide Drugs 0.000 description 6
- 235000007586 terpenes Nutrition 0.000 description 6
- 241000208223 Anacardiaceae Species 0.000 description 5
- 240000007354 Pistacia atlantica Species 0.000 description 5
- 244000160949 Pistacia integerrima Species 0.000 description 5
- 240000006711 Pistacia vera Species 0.000 description 5
- 241000058010 Pistacia x saportae Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 230000003376 axonal effect Effects 0.000 description 5
- 239000003637 basic solution Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 230000002025 microglial effect Effects 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000028389 Nerve injury Diseases 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 3
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 3
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 241000218657 Picea Species 0.000 description 3
- 235000005205 Pinus Nutrition 0.000 description 3
- 241000218602 Pinus <genus> Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 3
- 240000005481 Salvia hispanica Species 0.000 description 3
- 235000001498 Salvia hispanica Nutrition 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000005842 biochemical reaction Methods 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000014167 chia Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940086555 cyclomethicone Drugs 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 229940059904 light mineral oil Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229930003658 monoterpene Natural products 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 235000014571 nuts Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 241000207875 Antirrhinum Species 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 235000018062 Boswellia Nutrition 0.000 description 2
- 240000007551 Boswellia serrata Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 244000124209 Crocus sativus Species 0.000 description 2
- 235000015655 Crocus sativus Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241001558017 Gynura Species 0.000 description 2
- 101000979249 Homo sapiens Neuromodulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PPMUFCXCVKVCSV-UHFFFAOYSA-N Methyl oleanonat Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PPMUFCXCVKVCSV-UHFFFAOYSA-N 0.000 description 2
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 2
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 102100023206 Neuromodulin Human genes 0.000 description 2
- 235000011205 Ocimum Nutrition 0.000 description 2
- 241001529734 Ocimum Species 0.000 description 2
- 208000030768 Optic nerve injury Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 101150008375 Pou4f1 gene Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 241000159245 Schinus Species 0.000 description 2
- 235000005153 Schinus Nutrition 0.000 description 2
- 102100027974 Semaphorin-3A Human genes 0.000 description 2
- 108010090319 Semaphorin-3A Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 150000001983 dialkylethers Chemical class 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000004141 diterpene derivatives Chemical class 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000004060 excitotoxin Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008169 grapeseed oil Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 239000012184 mineral wax Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 230000003018 neuroregenerative effect Effects 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 239000004248 saffron Substances 0.000 description 2
- 235000013974 saffron Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 150000003535 tetraterpenes Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000009489 vacuum treatment Methods 0.000 description 2
- 239000012178 vegetable wax Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- UILQHUKSFUOOLH-UHFFFAOYSA-N (24E)-3beta-hydroxy-7,24-euphadien-26-oic acid Natural products CC1(C)C(O)CCC2(C)C(CCC3(C(C(CCC=C(C)C(O)=O)C)CCC33C)C)C3=CCC21 UILQHUKSFUOOLH-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- UILQHUKSFUOOLH-QZUUSUMPSA-N (z,6s)-6-[(3s,10r,13s,14s)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,9,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C(CC[C@]3(C([C@H](CC\C=C(\C)C(O)=O)C)CC[C@@]33C)C)C3=CCC21 UILQHUKSFUOOLH-QZUUSUMPSA-N 0.000 description 1
- KGELVXQPIUKGCO-ZJOAAQHOSA-N (z,6s)-6-[(3s,10s,13s,14s)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)C1CCC1=C2CC[C@@]2(C)C([C@H](CC\C=C(\C)C(O)=O)C)CC[C@@]21C KGELVXQPIUKGCO-ZJOAAQHOSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WAYINTBTZWQNSN-UHFFFAOYSA-N 11-methyldodecyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCCCCCCOC(=O)CC(C)CC(C)(C)C WAYINTBTZWQNSN-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- BDEHGQOUMOLWCN-UHFFFAOYSA-N 16-methylheptadecyl benzoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 BDEHGQOUMOLWCN-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- CKQNDABUGIXFCL-UHFFFAOYSA-N 2-(2-octanoyloxyethoxy)ethyl octanoate Chemical compound CCCCCCCC(=O)OCCOCCOC(=O)CCCCCCC CKQNDABUGIXFCL-UHFFFAOYSA-N 0.000 description 1
- UADWUILHKRXHMM-UHFFFAOYSA-N 2-ethylhexyl benzoate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1 UADWUILHKRXHMM-UHFFFAOYSA-N 0.000 description 1
- 229940106004 2-ethylhexyl benzoate Drugs 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- LNRUVXAPKCPQGX-UHFFFAOYSA-N 2-octyldodecyl benzoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)C1=CC=CC=C1 LNRUVXAPKCPQGX-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KEIDIOZOTSZXPK-UHFFFAOYSA-N 4-methylpentyl decanoate Chemical compound CCCCCCCCCC(=O)OCCCC(C)C KEIDIOZOTSZXPK-UHFFFAOYSA-N 0.000 description 1
- BRORPGSJXSLXKN-UHFFFAOYSA-N 6-methylheptyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCOC(=O)CC(C)CC(C)(C)C BRORPGSJXSLXKN-UHFFFAOYSA-N 0.000 description 1
- LSIDHXSWCFFFGE-UHFFFAOYSA-N 7-Methyloctyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCC(C)C LSIDHXSWCFFFGE-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000001996 DNA Polymerase beta Human genes 0.000 description 1
- 108010001132 DNA Polymerase beta Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061431 Glial scar Diseases 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 241001671311 Laurus Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
- 235000008075 Pistacia terebinthus Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 240000008202 Schinus molle Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940070312 arachidyl propionate Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940005787 behenyl benzoate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UADWUILHKRXHMM-ZDUSSCGKSA-N benzoflex 181 Natural products CCCC[C@H](CC)COC(=O)C1=CC=CC=C1 UADWUILHKRXHMM-ZDUSSCGKSA-N 0.000 description 1
- VVKREWPWSWPBGC-UHFFFAOYSA-N benzoic acid;2-(2-hydroxypropoxy)propan-1-ol Chemical compound CC(O)COC(C)CO.OC(=O)C1=CC=CC=C1 VVKREWPWSWPBGC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001987 diarylethers Chemical class 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- TVWTZAGVNBPXHU-FOCLMDBBSA-N dioctyl (e)-but-2-enedioate Chemical compound CCCCCCCCOC(=O)\C=C\C(=O)OCCCCCCCC TVWTZAGVNBPXHU-FOCLMDBBSA-N 0.000 description 1
- MYTMXVHNEWBFAL-UHFFFAOYSA-L dipotassium;carbonate;hydrate Chemical compound O.[K+].[K+].[O-]C([O-])=O MYTMXVHNEWBFAL-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 229940078469 dl- cysteine Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- IACXYDVFQDGXJF-UHFFFAOYSA-N docosyl benzoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 IACXYDVFQDGXJF-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- KGELVXQPIUKGCO-UHFFFAOYSA-N eoianwuweizic acid Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C(O)=O)C)CCC21C KGELVXQPIUKGCO-UHFFFAOYSA-N 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- OPEHDFRKFVXKNP-UHFFFAOYSA-N icosyl propanoate Chemical compound CCCCCCCCCCCCCCCCCCCCOC(=O)CC OPEHDFRKFVXKNP-UHFFFAOYSA-N 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000003077 lignite Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 238000011670 long-evans rat Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000007483 microbial process Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011356 non-aqueous organic solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KPWVFNOPNOTYNJ-UHFFFAOYSA-N octadecyl benzoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 KPWVFNOPNOTYNJ-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- YPMOZWCBANATQH-UHFFFAOYSA-N octyl 7-methyloctanoate Chemical compound CCCCCCCCOC(=O)CCCCCC(C)C YPMOZWCBANATQH-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- BTXWOKJOAGWCSN-UHFFFAOYSA-N oleanolic acid methyl ester Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C BTXWOKJOAGWCSN-UHFFFAOYSA-N 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating optic neuropathy conditions.
Description
COMPOSITIONS COMPRISING ACIDIC EXTRACTS OF MASTIC GUM AND
USES THEREOF FOR TREATING OPTIC NEUROPATHY
FIELD OF THE INVENTION
The invention relates to therapeutic uses of isolated acidic fractions of mastic gum for treating optic neuropathy, such as optical nerve ischemia and glaucoma.
More particularly, the invention relates to methods of treating such optic neuropathy conditions using compositions comprising isolated acidic fractions of mastic gum.
BACKGROUND OF THE INVENTION
Mastic, also known as gum mastic or mastic gum, is a tree resin obtained as an exudate from Pistacia lentiscus L., a member of the family Anacardiaceae.
Mastic was used in the ancient Mediterranean world for treating various conditions, such as, gastrointestinal disorders such as gastralgia, dyspepsia and peptic ulcer.
Oral administration of mastic to human patients with duodenal ulcer and to experimental rats with induced gastric and duodenal ulcers has been disclosed to have therapeutic effects (Al-Habb al et al (1984) Clin Exp Pharmacop Physio 11(5):541-4; Said et al (1986) J
Ethnopharmacol 15(3) :271 -8) .
U.S. Patent Application Publication No 2005/0238740 is directed to Use of mastic and its components for the control of microbial infections.
EP Patent Application No. 1520585 discloses use of a product obtained from a plant of the genus Pistacia for the manufacture of a medicament for treating or preventing cancer.
International Patent Application Publication No. WO 2005/112967 discloses the purification from mastic of anti-cancer material having anti-proliferative effects, which is found in a soluble fraction obtained by suspending mastic in a solvent selected from a non-acidic, aliphatic hydrocarbon, an aqueous solution containing at least 25% of a water-soluble, non-acidic, aliphatic hydrocarbon, or a combination thereof, and removing the insoluble fraction.
International Patent Application Publication No. WO 2010/100650 to some of the inventors of the present invention, is directed to therapeutic uses of mastic gum fractions.
International Patent Application Publication No. WO 2010/100651 to some of the inventors of the present invention, is directed to compositions of polymeric myrcene.
International Patent Application Publication No. WO 2012/032523 to some of the inventors of the present invention, is directed to compositions comprising acidic extracts of mastic gum.
International Patent Application Publication No. WO 2005/094837 is directed to Use of masticadienonic acid as inhibitor of DNA polymerase-beta, used for treating cancers, tumors and neurodegenerative diseases.
Marner et al (1991) disclose identification of various triterpenoids from gum mastic of P. lentiscus (Marner et al (1991) Phytochemistry, 30, 3709-3712).
Giner-Larza et al (2002) disclose anti-inflammatory triterpenes from pistacia terebinthus galls (Planta Med (2002), 68, 311-315).
The optic nerve contains axons of nerve cells that emerge from the retina, leave the eye at the optic disc, and go to the visual cortex where input from the eye is processed into vision. Optic neuropathy refers to damage to the optic nerve due to any cause.
Damage and death of these nerve cells, leads to characteristic features of optic neuropathy. The main symptom is loss of vision, with colors appearing subtly washed out in the affected eye. On medical examination, the optic nerve head can be visualized by an ophthalmoscope. A pale disc is characteristic of long-standing optic neuropathy. In many cases, only one eye is affected and patients may not be aware of the loss of color vision until the doctor asks them to cover the healthy eye.
Optic neuropathy can result from various reasons, such as, Ischemic optic neuropathy, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Traumatic optic neuropathy, mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, hereditary optic neuropathies, and the like. Very few treatments of optical neuropathy are currently used, and most have a limited effect on specific type of optic neuropathy.
Thus, there is a need in the art for compositions that are useful and effective in treating conditions of optical neuropathy, resulting from various reasons. The art does not provide any teaching that isolated acidic fractions of mastic gum can be used for treating optical neuropathy conditions.
USES THEREOF FOR TREATING OPTIC NEUROPATHY
FIELD OF THE INVENTION
The invention relates to therapeutic uses of isolated acidic fractions of mastic gum for treating optic neuropathy, such as optical nerve ischemia and glaucoma.
More particularly, the invention relates to methods of treating such optic neuropathy conditions using compositions comprising isolated acidic fractions of mastic gum.
BACKGROUND OF THE INVENTION
Mastic, also known as gum mastic or mastic gum, is a tree resin obtained as an exudate from Pistacia lentiscus L., a member of the family Anacardiaceae.
Mastic was used in the ancient Mediterranean world for treating various conditions, such as, gastrointestinal disorders such as gastralgia, dyspepsia and peptic ulcer.
Oral administration of mastic to human patients with duodenal ulcer and to experimental rats with induced gastric and duodenal ulcers has been disclosed to have therapeutic effects (Al-Habb al et al (1984) Clin Exp Pharmacop Physio 11(5):541-4; Said et al (1986) J
Ethnopharmacol 15(3) :271 -8) .
U.S. Patent Application Publication No 2005/0238740 is directed to Use of mastic and its components for the control of microbial infections.
EP Patent Application No. 1520585 discloses use of a product obtained from a plant of the genus Pistacia for the manufacture of a medicament for treating or preventing cancer.
International Patent Application Publication No. WO 2005/112967 discloses the purification from mastic of anti-cancer material having anti-proliferative effects, which is found in a soluble fraction obtained by suspending mastic in a solvent selected from a non-acidic, aliphatic hydrocarbon, an aqueous solution containing at least 25% of a water-soluble, non-acidic, aliphatic hydrocarbon, or a combination thereof, and removing the insoluble fraction.
International Patent Application Publication No. WO 2010/100650 to some of the inventors of the present invention, is directed to therapeutic uses of mastic gum fractions.
International Patent Application Publication No. WO 2010/100651 to some of the inventors of the present invention, is directed to compositions of polymeric myrcene.
International Patent Application Publication No. WO 2012/032523 to some of the inventors of the present invention, is directed to compositions comprising acidic extracts of mastic gum.
International Patent Application Publication No. WO 2005/094837 is directed to Use of masticadienonic acid as inhibitor of DNA polymerase-beta, used for treating cancers, tumors and neurodegenerative diseases.
Marner et al (1991) disclose identification of various triterpenoids from gum mastic of P. lentiscus (Marner et al (1991) Phytochemistry, 30, 3709-3712).
Giner-Larza et al (2002) disclose anti-inflammatory triterpenes from pistacia terebinthus galls (Planta Med (2002), 68, 311-315).
The optic nerve contains axons of nerve cells that emerge from the retina, leave the eye at the optic disc, and go to the visual cortex where input from the eye is processed into vision. Optic neuropathy refers to damage to the optic nerve due to any cause.
Damage and death of these nerve cells, leads to characteristic features of optic neuropathy. The main symptom is loss of vision, with colors appearing subtly washed out in the affected eye. On medical examination, the optic nerve head can be visualized by an ophthalmoscope. A pale disc is characteristic of long-standing optic neuropathy. In many cases, only one eye is affected and patients may not be aware of the loss of color vision until the doctor asks them to cover the healthy eye.
Optic neuropathy can result from various reasons, such as, Ischemic optic neuropathy, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Traumatic optic neuropathy, mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, hereditary optic neuropathies, and the like. Very few treatments of optical neuropathy are currently used, and most have a limited effect on specific type of optic neuropathy.
Thus, there is a need in the art for compositions that are useful and effective in treating conditions of optical neuropathy, resulting from various reasons. The art does not provide any teaching that isolated acidic fractions of mastic gum can be used for treating optical neuropathy conditions.
2 SUMMARY OF THE INVENTION
The present invention provides pharmaceutical compositions comprising an isolated acidic fraction of mastic gum, which contains acidic compounds that are soluble in both polar and non-polar organic solvents, and which have optical nerve neuro-regenerative properties and methods of using same for treating optic neuropathy conditions, such as, optical nerve ischemic condition, Glaucoma, and the like. More specifically, compositions comprising isolated acidic fractions extracted from mastic gum are disclosed to be able to treat related conditions, such as those resulting from ischemia and/or trauma to the optic nerve.
In some embodiments, the present invention is based in part on the unexpected discovery that isolated acidic fractions of mastic gum exhibit such enhanced optical-nerve regenerative biological activity. The isolated acidic fractions of the invention exhibit a variety of beneficial biological activities which may be exploited for various therapeutic applications.
According to some embodiments, there is thus provided the use of a composition comprising isolated acidic fractions of mastic gum and a pharmaceutically acceptable carrier, for treating an optic neuropathy condition.
According to some embodiments, there is provided a method of treating an optic neuropathy condition in a subject in need thereof, the method comprising administering a composition comprising an effective amount of an isolated acidic fraction of mastic gum, and a pharmaceutically acceptable carrier, wherein the fraction is characterized in that it is soluble in at least one polar organic solvent and in at least one non-polar organic solvent, and wherein said fraction is substantially devoid of compounds which are soluble in said polar organic solvent but insoluble in said non-polar organic solvent.
In some embodiments, the acidic fraction is obtained from an isolated fraction of mastic gum that is soluble in at least one polar organic solvent and at least one non-polar organic solvent by an acid-base extraction, thereby separating the isolated acidic fraction from the non-acidic fraction of mastic gum that is soluble in at least one polar organic solvent and one non-polar organic solvent.
In some embodiments, the isolated acidic fraction comprises at least two of:
masticadienolic acid; masticadienonic acid; isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-
The present invention provides pharmaceutical compositions comprising an isolated acidic fraction of mastic gum, which contains acidic compounds that are soluble in both polar and non-polar organic solvents, and which have optical nerve neuro-regenerative properties and methods of using same for treating optic neuropathy conditions, such as, optical nerve ischemic condition, Glaucoma, and the like. More specifically, compositions comprising isolated acidic fractions extracted from mastic gum are disclosed to be able to treat related conditions, such as those resulting from ischemia and/or trauma to the optic nerve.
In some embodiments, the present invention is based in part on the unexpected discovery that isolated acidic fractions of mastic gum exhibit such enhanced optical-nerve regenerative biological activity. The isolated acidic fractions of the invention exhibit a variety of beneficial biological activities which may be exploited for various therapeutic applications.
According to some embodiments, there is thus provided the use of a composition comprising isolated acidic fractions of mastic gum and a pharmaceutically acceptable carrier, for treating an optic neuropathy condition.
According to some embodiments, there is provided a method of treating an optic neuropathy condition in a subject in need thereof, the method comprising administering a composition comprising an effective amount of an isolated acidic fraction of mastic gum, and a pharmaceutically acceptable carrier, wherein the fraction is characterized in that it is soluble in at least one polar organic solvent and in at least one non-polar organic solvent, and wherein said fraction is substantially devoid of compounds which are soluble in said polar organic solvent but insoluble in said non-polar organic solvent.
In some embodiments, the acidic fraction is obtained from an isolated fraction of mastic gum that is soluble in at least one polar organic solvent and at least one non-polar organic solvent by an acid-base extraction, thereby separating the isolated acidic fraction from the non-acidic fraction of mastic gum that is soluble in at least one polar organic solvent and one non-polar organic solvent.
In some embodiments, the isolated acidic fraction comprises at least two of:
masticadienolic acid; masticadienonic acid; isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-
3 isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid and moronic acid.
According to further embodiments, there is provided a use of an isolated acidic fraction of mastic gum, for the preparation of a medicament for treating optic neuropathy.
According to another aspect, there is provided an isolated acidic fraction of mastic gum, for use in treating optic neuropathy.
According some embodiments, there is provided a pharmaceutical composition comprising an isolated acidic fraction of mastic gum and a pharmaceutically acceptable carrier, for use in treating optic neuropathy.
In various embodiments, the composition may be administered by parenteral route.
According to some embodiments the route of administration may be via parenteral injection. In various embodiments, the step of administering is carried out by a parenteral route selected from the group consisting of intravenous (i.v.), intramuscular, subcutaneous (sc), intradermal, intraperitoneal, intraarterial, intracerebral, intracerebroventricular, .. intraosseous, intraocular, intravitreal, and intrathecal.
In some embodiments, the optic neuropathy condition comprises any condition in which the optic nerve is damaged. In some embodiments, the optic neuropathy condition may be selected from such conditions as, but not limited to: traumatic neuropathy (that may result from any type of trauma to the optic nerve); ischemic neuropathy (such as, for example, Nonarteritic Anterir Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION), Posterior ischemic optic neuropathy); Radiation optic neuropathy (RON)), Glaucoma, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, Hereditary optic neuropathy and the like; or combinations thereof.
Each possibility is a separate embodiment.
In some embodiments, the optic neuropathy condition is resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve.
In some embodiments, the optic neuropathy condition is resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve, wherein the deposition of lipoproteinaceous substances is the result of a
According to further embodiments, there is provided a use of an isolated acidic fraction of mastic gum, for the preparation of a medicament for treating optic neuropathy.
According to another aspect, there is provided an isolated acidic fraction of mastic gum, for use in treating optic neuropathy.
According some embodiments, there is provided a pharmaceutical composition comprising an isolated acidic fraction of mastic gum and a pharmaceutically acceptable carrier, for use in treating optic neuropathy.
In various embodiments, the composition may be administered by parenteral route.
According to some embodiments the route of administration may be via parenteral injection. In various embodiments, the step of administering is carried out by a parenteral route selected from the group consisting of intravenous (i.v.), intramuscular, subcutaneous (sc), intradermal, intraperitoneal, intraarterial, intracerebral, intracerebroventricular, .. intraosseous, intraocular, intravitreal, and intrathecal.
In some embodiments, the optic neuropathy condition comprises any condition in which the optic nerve is damaged. In some embodiments, the optic neuropathy condition may be selected from such conditions as, but not limited to: traumatic neuropathy (that may result from any type of trauma to the optic nerve); ischemic neuropathy (such as, for example, Nonarteritic Anterir Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION), Posterior ischemic optic neuropathy); Radiation optic neuropathy (RON)), Glaucoma, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, Hereditary optic neuropathy and the like; or combinations thereof.
Each possibility is a separate embodiment.
In some embodiments, the optic neuropathy condition is resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve.
In some embodiments, the optic neuropathy condition is resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve, wherein the deposition of lipoproteinaceous substances is the result of a
4 storage disease.
In some embodiments, the optic neuropathy condition is resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve, wherein the deposition of lipoproteinaceous substances is the result of a storage disease, and wherein the lipoproteinaceous substance is lipofuscin.
According to some embodiments, the present invention further provides compositions comprising isolated compounds from the isolated acidic fraction of mastic gum, having therapeutic activity. In some embodiments, the compositions may include a plurality of isolated compounds selected from the individual acidic compounds found in the acidic fraction of mastic gum according to the invention. According to some embodiments, the composition includes at least three isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic .. acid and 3-oxo-lup-20(29)-en-28-oic acid. According to some embodiments, the composition includes at least three isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid.
According to some embodiments, the composition includes at least three isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-isomasticadienolic acid, oleanonic acid and moronic acid.
In some embodiments, the compositions include at least masticadienonic acid, isomasticadienonic acid and oleanonic acid. Such compositions unexpectedly exhibit a synergistic effect, whereby the combination of compounds exhibit a markedly improved therapeutic effect in the treatment of optic neuropathy conditions, as compared to the individual compounds alone.
According to some embodiments, the composition includes at least two isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and 3-oxo-lup-20(29)-en-28-oic
In some embodiments, the optic neuropathy condition is resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve, wherein the deposition of lipoproteinaceous substances is the result of a storage disease, and wherein the lipoproteinaceous substance is lipofuscin.
According to some embodiments, the present invention further provides compositions comprising isolated compounds from the isolated acidic fraction of mastic gum, having therapeutic activity. In some embodiments, the compositions may include a plurality of isolated compounds selected from the individual acidic compounds found in the acidic fraction of mastic gum according to the invention. According to some embodiments, the composition includes at least three isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic .. acid and 3-oxo-lup-20(29)-en-28-oic acid. According to some embodiments, the composition includes at least three isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid.
According to some embodiments, the composition includes at least three isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-isomasticadienolic acid, oleanonic acid and moronic acid.
In some embodiments, the compositions include at least masticadienonic acid, isomasticadienonic acid and oleanonic acid. Such compositions unexpectedly exhibit a synergistic effect, whereby the combination of compounds exhibit a markedly improved therapeutic effect in the treatment of optic neuropathy conditions, as compared to the individual compounds alone.
According to some embodiments, the composition includes at least two isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and 3-oxo-lup-20(29)-en-28-oic
5
6 acid. According to some embodiments, the composition includes at least two isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid and moronic acid. According to some embodiments, the composition includes at least two isolated compounds selected from masticadienonic acid, isomasticadienonic acid, masticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-isomasticadienolic acid, oleanonic acid, moronic acid. In some exemplary embodiments, the compositions include at least masticadienonic acid and isomasticadienonic acid. Such compositions unexpectedly exhibit a synergistic effect, whereby the combination of compounds exhibit a markedly improved therapeutic effect in the treatment of optic neuropathy conditions, as compared to the individual compounds alone.
The mastic acidic fraction according to embodiments of the invention may be distinguished over mastic fractions disclosed in the prior art, as its preparation involves use of both a polar solvent and a non-polar solvent, whereas the prior art teaches use of polar solvents only. Acidic fractions prepared by using only polar solvents contain compounds that are not soluble in apolar solvents such as hexane, whereas these compounds are not present in the acidic fraction of the current invention.
Accordingly, the fractions of the invention comprise a combination of compounds which differs from that disclosed in the prior art. Moreover, the inventors of the present invention have discovered that the acidic fraction of the invention unexpectedly possesses unexpected therapeutic activities that are not suggested by the prior art, in particular, treating a range of optic neuropathy conditions.
The teachings of the present invention have been exemplified with mastic gum extracts prepared by a three-step extraction procedure, so as to obtain an acidic fraction that is soluble in both a polar solvent and a non-polar solvent, and wherein material from the mastic gum that is soluble in the polar solvent but remains insoluble in the non-polar solvent is eliminated. In further embodiments, main compounds of the isolated acidic fraction have been isolated and identified. Various combinations of some of these compounds exhibit an unexpected synergistic effect in the treatment of optic neuropathy conditions.
It is to be further understood that the biological activity of the fractions and compositions disclosed herein is inhibited by the presence of certain compounds that are be present in acidic fractions that have been prepared without applying the first two extraction steps as disclosed herein.
According to some embodiments, the present invention provides a composition for use in treating optic neuropathy conditions, the composition comprising an effective amount of an isolated acidic fraction of mastic gum, and a pharmaceutically acceptable carrier; wherein the fraction is characterized in that it is soluble in at least one polar organic solvent and soluble in at least one non-polar organic solvent, and wherein said fraction is substantially devoid of compounds which are soluble in said polar organic solvent but insoluble in said non-polar organic solvent.
In some embodiments, the composition may be obtained by a process comprising the steps of:
(a) treating mastic gum with a polar organic solvent;
(b) isolating a fraction soluble in said polar organic solvent;
(c) optionally removing said polar organic solvent;
(d) treating the soluble fraction obtained in step (b) or (c) with a non-polar organic solvent, (e) isolating a fraction soluble in said non-polar organic solvent;
(f) optionally removing said non-polar organic solvent;
(g) dissolving the fraction obtained in step (f) in an organic solvent;
(h) treating the solution obtained in step (g) with a basic solution so as to obtain a basic fraction; and (i) acidifying the basic fraction obtained in step (h) with an acid solution;
In some embodiments, steps (d) to (f) may precede steps (a) to (c).
In some embodiments, the treatment with a basic solution (basifying) in step (h) comprises extracting the solution obtained in step (g) with one or more suitable basic aqueous solutions; or contacting the solution obtained in step (g) with a basic ion exchange resin.
The mastic acidic fraction according to embodiments of the invention may be distinguished over mastic fractions disclosed in the prior art, as its preparation involves use of both a polar solvent and a non-polar solvent, whereas the prior art teaches use of polar solvents only. Acidic fractions prepared by using only polar solvents contain compounds that are not soluble in apolar solvents such as hexane, whereas these compounds are not present in the acidic fraction of the current invention.
Accordingly, the fractions of the invention comprise a combination of compounds which differs from that disclosed in the prior art. Moreover, the inventors of the present invention have discovered that the acidic fraction of the invention unexpectedly possesses unexpected therapeutic activities that are not suggested by the prior art, in particular, treating a range of optic neuropathy conditions.
The teachings of the present invention have been exemplified with mastic gum extracts prepared by a three-step extraction procedure, so as to obtain an acidic fraction that is soluble in both a polar solvent and a non-polar solvent, and wherein material from the mastic gum that is soluble in the polar solvent but remains insoluble in the non-polar solvent is eliminated. In further embodiments, main compounds of the isolated acidic fraction have been isolated and identified. Various combinations of some of these compounds exhibit an unexpected synergistic effect in the treatment of optic neuropathy conditions.
It is to be further understood that the biological activity of the fractions and compositions disclosed herein is inhibited by the presence of certain compounds that are be present in acidic fractions that have been prepared without applying the first two extraction steps as disclosed herein.
According to some embodiments, the present invention provides a composition for use in treating optic neuropathy conditions, the composition comprising an effective amount of an isolated acidic fraction of mastic gum, and a pharmaceutically acceptable carrier; wherein the fraction is characterized in that it is soluble in at least one polar organic solvent and soluble in at least one non-polar organic solvent, and wherein said fraction is substantially devoid of compounds which are soluble in said polar organic solvent but insoluble in said non-polar organic solvent.
In some embodiments, the composition may be obtained by a process comprising the steps of:
(a) treating mastic gum with a polar organic solvent;
(b) isolating a fraction soluble in said polar organic solvent;
(c) optionally removing said polar organic solvent;
(d) treating the soluble fraction obtained in step (b) or (c) with a non-polar organic solvent, (e) isolating a fraction soluble in said non-polar organic solvent;
(f) optionally removing said non-polar organic solvent;
(g) dissolving the fraction obtained in step (f) in an organic solvent;
(h) treating the solution obtained in step (g) with a basic solution so as to obtain a basic fraction; and (i) acidifying the basic fraction obtained in step (h) with an acid solution;
In some embodiments, steps (d) to (f) may precede steps (a) to (c).
In some embodiments, the treatment with a basic solution (basifying) in step (h) comprises extracting the solution obtained in step (g) with one or more suitable basic aqueous solutions; or contacting the solution obtained in step (g) with a basic ion exchange resin.
7 In some embodiments, step (h) comprises contacting the solution obtained in step (g) with a basic ion exchange resin, and thereafter removing the basic ion exchange resin by filtration. In these embodiments, step (i) comprises treating the basic ion exchange resin with an acidic solution.
In some embodiments, the process further comprises the steps of (j) extracting the acidified fraction obtained in step (i) with an organic solvent;
k) optionally contacting the organic fraction obtained in step (j) with a drying agent so as to remove remaining water;
(1) removing organic solvent and/or excess acid from the fraction obtained in any of steps (i), (j) or (k); and (m) dissolving the isolated fraction obtained in step (1) in a carrier.
In some embodiments, steps (a) to (c) are carried out prior to steps (d) to (f); or steps (d) to (f) are carried out prior to steps (a) to (c). In some embodiments, (a) to (c) and/or steps (d) to (f) are repeated for a multiplicity of cycles.
In some embodiments, any of steps (c), (f) and (1) comprise removing the solvent by a means selected from the group consisting of rotary evaporation, application of high vacuum and a combination thereof.
In some embodiments, step (h) comprises extracting the solution obtained in step (g) with a basic aqueous solution, and collecting the organic fraction thus obtained. In some embodiments, the process further comprises combining the organic fraction obtained from step (h) with a fraction obtained in any of steps (i), (j) or (k).
In some embodiments, the organic fraction obtained in step (h) is combined with a fraction obtained in any of steps (i), (j) or (k) in an amount in the range from about 0.1%
to about 50% of the organic fraction obtained from step (h). In some embodiments, the amount is in the range from 0.5 to 50%; or 2 to 25%; or 0.1 to 10%.
Polar organic solvents suitable for use in the invention may be selected from an alcohol, an ether, an ester, an amide, an aldehyde, a ketone, a nitrile, and combinations thereof.
Specific examples of suitable polar organic solvents include methanol, ethanol, propanol, isopropanol, 1-butanol, 2-butanol, sec-butanol, t-butanol, 1-pentanol, 2-
In some embodiments, the process further comprises the steps of (j) extracting the acidified fraction obtained in step (i) with an organic solvent;
k) optionally contacting the organic fraction obtained in step (j) with a drying agent so as to remove remaining water;
(1) removing organic solvent and/or excess acid from the fraction obtained in any of steps (i), (j) or (k); and (m) dissolving the isolated fraction obtained in step (1) in a carrier.
In some embodiments, steps (a) to (c) are carried out prior to steps (d) to (f); or steps (d) to (f) are carried out prior to steps (a) to (c). In some embodiments, (a) to (c) and/or steps (d) to (f) are repeated for a multiplicity of cycles.
In some embodiments, any of steps (c), (f) and (1) comprise removing the solvent by a means selected from the group consisting of rotary evaporation, application of high vacuum and a combination thereof.
In some embodiments, step (h) comprises extracting the solution obtained in step (g) with a basic aqueous solution, and collecting the organic fraction thus obtained. In some embodiments, the process further comprises combining the organic fraction obtained from step (h) with a fraction obtained in any of steps (i), (j) or (k).
In some embodiments, the organic fraction obtained in step (h) is combined with a fraction obtained in any of steps (i), (j) or (k) in an amount in the range from about 0.1%
to about 50% of the organic fraction obtained from step (h). In some embodiments, the amount is in the range from 0.5 to 50%; or 2 to 25%; or 0.1 to 10%.
Polar organic solvents suitable for use in the invention may be selected from an alcohol, an ether, an ester, an amide, an aldehyde, a ketone, a nitrile, and combinations thereof.
Specific examples of suitable polar organic solvents include methanol, ethanol, propanol, isopropanol, 1-butanol, 2-butanol, sec-butanol, t-butanol, 1-pentanol, 2-
8 pentanol, 3 -pentanol, neopentanol, 3 -methyl-1 -butanol, 2-methyl-I -butanol, 3 -methy1-2-butanol, 2-methyl-2-butanol, ethyleneglycol, ethyleneglycol monomethyl ether, diethyl ether, methylethyl ether, ethylpropyl ether, methylpropyl ether, 1,2-dimethoxyethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran, methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methylformate, ethylformate, ethyl propionate, methyl propionate, dichloromethane, chloroform, dimethylformamide, acetamide, dimethylacetamide, N-methylpyrrolidone, acetone, ethylmethyl ketone, diethyl ketone, acetonitrile, propionitrile, and combinations thereof.
In some embodiments, the polar organic solvent is selected from methanol and ethanol or a combination thereof. In some embodiments, the polar solvent is ethanol.
Non-polar organic solvents suitable for use in the invention may be selected from acyclic or cyclic, saturated or unsaturated aliphatic hydrocarbons and aromatic hydrocarbons, each of which is optionally substituted by one or more halogens, and combinations thereof. In some embodiments, the non-polar organic solvent is selected from C5-C10 alkanes, C5-C10 cycloalkanes, C6-C14 aromatic hydrocarbons and C7-perfluoroalkanes, and combinations thereof.
In some embodiments, the non-polar organic solvent is selected from pentanes, hexanes, heptanes, octanes, nonanes, decanes, cyclopentane, cyclohexane, cycloheptane, benzene, toluene, xylene, and isomers and mixtures thereof.
In some embodiments, the C5-C10 alkane is selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclohexane, and isomers and mixtures thereof. In some embodiments, the non-polar organic solvent is hexane.
In some embodiments, the organic solvent in step (g) and in step (j) is independently selected from the group consisting of dialkyl ethers, alkyl-aryl ethers, diaryl ethers, esters, ketones, halogenated hydrocarbons, C5 -C14 aromatic hydrocarbons, C5 -C14 perfluoroalkanes.
In some embodiments, the suitable organic solvent in step (g) and in step (j) is the same or different.
In some embodiments, the organic solvent comprises a dialkyl ether. In some embodiments, the organic solvent is diethyl ether.
In some embodiments, the polar organic solvent comprises ethanol, the non-polar
In some embodiments, the polar organic solvent is selected from methanol and ethanol or a combination thereof. In some embodiments, the polar solvent is ethanol.
Non-polar organic solvents suitable for use in the invention may be selected from acyclic or cyclic, saturated or unsaturated aliphatic hydrocarbons and aromatic hydrocarbons, each of which is optionally substituted by one or more halogens, and combinations thereof. In some embodiments, the non-polar organic solvent is selected from C5-C10 alkanes, C5-C10 cycloalkanes, C6-C14 aromatic hydrocarbons and C7-perfluoroalkanes, and combinations thereof.
In some embodiments, the non-polar organic solvent is selected from pentanes, hexanes, heptanes, octanes, nonanes, decanes, cyclopentane, cyclohexane, cycloheptane, benzene, toluene, xylene, and isomers and mixtures thereof.
In some embodiments, the C5-C10 alkane is selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclohexane, and isomers and mixtures thereof. In some embodiments, the non-polar organic solvent is hexane.
In some embodiments, the organic solvent in step (g) and in step (j) is independently selected from the group consisting of dialkyl ethers, alkyl-aryl ethers, diaryl ethers, esters, ketones, halogenated hydrocarbons, C5 -C14 aromatic hydrocarbons, C5 -C14 perfluoroalkanes.
In some embodiments, the suitable organic solvent in step (g) and in step (j) is the same or different.
In some embodiments, the organic solvent comprises a dialkyl ether. In some embodiments, the organic solvent is diethyl ether.
In some embodiments, the polar organic solvent comprises ethanol, the non-polar
9 organic solvent comprises hexane and the organic solvent comprises diethyl ether.
In some embodiments, step (h) comprises basifying with a basic aqueous solution. In some embodiments, the basic aqueous solution is prepared by dissolving an inorganic base in water.
In some embodiments, the inorganic base is selected from the group consisting of sodium carbonate, sodium hydroxide, potassium carbonate potassium hydroxide, ammonium hydroxide, sodium bicarbonate, sodium phosphate, lithium hydroxide, lithium carbonate, and potassium phosphate.
In some embodiments, the inorganic base is sodium carbonate. In some embodiments, the concentration of the sodium carbonate in water is in the range from 2 to 20% w/w. In some embodiments, the concentration of sodium carbonate is in the range from 3 to 15% w/w. In some embodiments, the concentration of sodium carbonate is about 5% w/w.
In some embodiments, the inorganic base is sodium hydroxide.
In some embodiments, the basic aqueous solution is prepared by dissolving a water-soluble organic base in water.
In some embodiments, the first inorganic base is about 5% w/w aqueous sodium carbonate, followed by about 4% w/w aqueous sodium hydroxide.
In some embodiments, the basifying in step (h) comprises contacting the solution obtained in step (g) with a basic ion exchange resin. In some embodiments, the basic ion exchange resin comprises styrene divinylbenzene, polyacrylic or formophenolic copolymers.
In some embodiments, basifying the solution is done to a pH of above about 7.
In some embodiments, basifying the solution is done to a pH range of 8-10.
In some embodiments, basifying the solution is done to a pH range of 10-13.
In some embodiments, basifying the solution is done to a pH of >13.
In some embodiments, the acidic solution in step (i) comprises an acidic aqueous solution or an acidic non-aqueous solution.
In some embodiments, the acidic aqueous solution in step (i) is prepared by dissolving an inorganic acid in water or by diluting a concentrated mineral acid solution.
In some embodiments, the acidic aqueous solution is a solution of hydrochloric acid or phosphoric acid.
In some embodiments, the acidic aqueous solution is a solution of hydrochloric acid.
In some embodiments, the acidic aqueous solution in step (i) is prepared by dissolving an organic acid in water or by diluting a concentrated mineral acid solution.
In some embodiments, acidifying is done to a pH of below about 7. In some embodiments, acidifying is done to a pH of below about 6. In some embodiments, acidifying is done to a pH of below about 5. In some embodiments, acidifying is done to a .. pH of below about 4. In some embodiments, acidifying is done to a pH of below about 3.
In some embodiments, acidification is done to a pH in the range of 1-3.
In some embodiments, the acidic non-aqueous solution in step (i) is prepared by dissolving an organic acid in a non-aqueous organic solvent selected from an alcohol, an ester, an ether, an amide or mixtures thereof. In some embodiments, the non-aqueous .. solvent is methanol or ethanol or a mixture thereof.
In some embodiments, the organic acid is selected from the group consisting of formic acid, acetic acid, propionic acid, citric acid, tartaric acid, methane sulphonic acid, and para-toluenesulphonic acid.
In some embodiments, the drying agent used in step (k) is selected from the group of sodium sulfate, magnesium sulfate, calcium sulfate, calcium chloride, magnesium chloride, potassium sulfate.
In some embodiments, the composition is substantially devoid of terpene compounds which are soluble in said polar organic solvent and insoluble in said non-polar organic solvent.
In some embodiments, the composition comprises from about 0.01 to about 25%
(w/w) of the isolated acidic fraction of mastic gum, based on the total weight of the composition. In some embodiments, the composition comprises from about 0.01 to about 12% (w/w) of the isolated acidic fraction of mastic gum, based on the total weight of the composition.
In some embodiments, the isolated acidic fraction comprises at least one of:
masticadienonic acid, masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid, and 3-oxo-lup-20(29)-en-28-oic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the isolated acidic fraction comprises at least one of:
masticadienonic acid, masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid and moronic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the isolated acidic fraction further comprises at least one of:
oleanolic acid, ursonic acid, and ursolic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the isolated acidic fraction may be substantially devoid of essential oils.
In some embodiments, the isolated acidic fraction comprises at least one terpenoic acid. In some embodiments, the isolated acidic fraction comprises at least one triterpenoic acid. In some embodiments, the at least one terpenoic acid comprises at least one triterpenoic acid. In some embodiments, the at least one triterpenoic acid is selected from the group consisting of masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid, 3-oxo-lup-20(29)-en-28-oic acid and a combination thereof. Each possibility is a separate embodiment of the invention.
In some embodiments, the at least one terpenoic acid is in monomeric form. In some embodiments, the at least one terpenoic acid is in an oligomeric form. In some embodiments, the oligomeric form is selected from the group consisting of a dimer, a trimer, and a combination thereof. Each possibility is a separate embodiment of the invention.
In some embodiments, the isolated acidic fraction comprises a combination of monomeric and dimeric triterpenoic acids. In some embodiments, the isolated acidic fraction comprises a combination of monomeric, dimeric and trimeric triterpenoic acids.
In some embodiments, the composition comprises at least one of:
masticadienonic acid, masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid, and 3-oxo-lup-.. 20(29)-en-28-oic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the composition further comprises at least one of:
oleanolic acid, ursonic acid, and ursolic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the composition comprises at least one terpenoic acid.
Embodiments of terpenoic acids are as hereinbefore described.
In some embodiments, the composition comprises at least one triterpenoic acid.
Embodiments of triterpenoic acids are as hereinbefore described.
In some embodiments, the mastic gum is derived from a plant classified in the family Anacardiaceae. Suitable plants include those classified in a genus selected from the group consisting of Pistacia, Pinus, Picea, funiperus, Alsies, Lctrix, Antirrhinum, Boswellia, Citrus and Gynura. In some embodiments, suitable plants are selected from the genus Pistacia. In some embodiments, the species of Pistacia is selected from the group consisting of P. lentiscus, P. atlantica, P. palestina, P. saportae, P.
terebinthus, P. vera and P. integerrima. In some embodiments, the species of Pistacia is Pistacia lentiscus var.
Chia. In some embodiments, the species of Pistacia is Pistacia lentiscus L. In some embodiments, the species of Pistacia is Pistacia lentiscus L. var. latifolius Coss.
In some embodiments, the isolated acidic fraction is derived from a plant material selected from the group consisting of resin, leaves, twigs, roots, flowers, seeds, buds, bark, nuts and roots.
In some embodiments, the isolated acidic fraction of mastic gum is obtained by a process comprising the steps of:
(a) treating mastic gum with a polar organic solvent;
(b) isolating a fraction soluble in said polar organic solvent;
(c) optionally removing said polar organic solvent;
(d) treating the soluble fraction obtained in step (b) or (c) with a non-polar organic solvent, (e) isolating a fraction soluble in said non-polar organic solvent;
(f) optionally removing said non-polar organic solvent;
(g) dissolving the fraction obtained in step (f) in an organic solvent;
(h) treatment of the solution obtained in step (g) with a basic solution so as to obtain a basic fraction;
(i) acidifying the basic fraction obtained in step (i) with an acid solution;
(j) extracting the acidified fraction obtained in step (i with an organic solvent;
(k) optionally contacting the organic fraction obtained in step (k) with a drying agent so as to remove remaining water;
(1) removing organic solvent and/or excess acid from the fraction obtained in any of steps(i), (j) or (k); and (m) dissolving the isolated fraction obtained in step (1) in a carrier.
In additional embodiments, the invention provides a pharmaceutical composition comprising at least one triterpenoic acid; and a pharmaceutically acceptable carrier. In some embodiments, the at least one triterpenoic acid is selected from the group consisting of masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl epimasticadienolic acid, 3-0-acetyl isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, masticadienonic acid, oleanonic acid, moronic acid, 3-oxo-lup-20(29)-en-28-oic acid and a combination thereof. Each possibility is a separate embodiment of the invention.
According to some embodiments, the current invention provides a pharmaceutical composition consisting essentially of isomasticadienonic acid and masticadienonic acid as the pharmaceutically active ingredients; and a pharmaceutically acceptable carrier. The combined presence of both compounds results in an enhanced/synergistic effect with respect to the composition's efficacy in the treatment of optic neuropathy condition, when compared with the efficacy of the individual compounds. Either one of isomasticadienonic acid and masticadienonic acid may be isolated from a natural source such as mastic gum, or may be the product of a chemical synthesis.
In some embodiments, the ratio between the isomasticadienonic acid and masticadienonic acid is about 1:1 w/w.
According to some embodiments, the current invention provides a pharmaceutical composition consisting essentially of oleanonic acid, isomasticadienonic acid and masticadienonic acid as the sole pharmaceutically active ingredients; and a pharmaceutically acceptable carrier for use in treating optical neuropathy.
According to some embodiments, the current invention provides a pharmaceutical composition consisting essentially of isomasticadienonic acid and masticadienonic acid as the sole pharmaceutically active ingredients; and a pharmaceutically acceptable carrier, for treating an optic neuropathy condition. The combined presence of these two compounds results in a synergistic effect with respect to composition's efficacy in the treatment of optic neuropathy conditions when compared with the efficacy of the individual compounds.
Any one of oleanonic acid, isomasticadienonic acid and masticadienonic acid may be either isolated from a natural source, such as mastic gum, or may be the product of a chemical synthesis. In some embodiments, the ratio between the isomasticadienoic acid and masticadienonic acid and oleanonic acid is about 1:1:1 w/w/w.
In some embodiments, the at least one triterpenoic acid is a monomer. In some embodiments, the composition comprises monomers of oleanonic acid and moronic acid.
In some embodiments, the monomers of oleanonic acid and moronic acid are the products of chemical synthesis reactions.
In some embodiments, the at least one triterpenoic acid comprises an oligomeric form. In some embodiments, the oligomeric form is selected from the group consisting of a dimer, a trimer, and a combination thereof. Each possibility is a separate embodiment of the invention. In some embodiments, the oligomeric form is a dimer. In some embodiments, the at least one triterpenoic acid is the product of a chemical synthesis.
In some embodiments, the at least one triterpenoic acid comprising an oligomeric form is the product of a chemical synthesis. In some embodiments, the at least on triterpenoic acid is a dimeric form and is the product of a chemical synthesis.
In some embodiments, the at least one triterpenoic acid is derived from a natural source, in particular a plant source.
In some embodiments, the composition comprises a combination of different triterpenoic acids, wherein at least one triterpenoic acid is the product of a chemical synthesis and at least one other triterpenoic acid is derived from a plant source.
Natural sources include plants classified in the family Anacardiaceae.
Suitable plants include those classified in a genus selected from the group consisting of Pistacia, Pinus, Picea, funiperus, Alsies, Lctrix, Antirrhinum, Boswellia, Citrus and Gynura.
In some embodiments, suitable plants are selected from the genus Pistacia. In some embodiments, the species of Pistacia is selected from the group consisting of P. lentiscus, P. atlantica, P.
palestina, P. saportae, P. terebinthus, P. vera and P. integerrima. In some embodiments, the species of Pistacia is Pistacia lentiscus L.
In some embodiments, the natural source is a plant material selected from the group consisting of resin, leaves, twigs, roots, flowers, seeds, buds, bark, nuts and roots.
In some embodiments, the natural source is a plant classified in a genus selected from the group consisting of Ocimum, Lcturus and Lctvendula.
In some embodiments, the pharmaceutically acceptable carrier comprises a hydrophobic carrier. In some embodiments, the hydrophobic carrier comprises at least one oil. In some embodiments, the oil is selected from the group consisting of a mineral oil, a vegetable oil and combinations thereof. In some embodiments, the vegetable oil is selected from the group consisting of cottonseed oil, olive oil, almond oil, canola oil, coconut oil, corn oil, grape seed oil, peanut oil, saffron oil, sesame oil, soybean oil, and combinations thereof. In some embodiments, the mineral oil is light mineral oil. In some embodiments, the hydrophobic carrier comprises at least one wax. In some embodiments, the hydrophobic carrier comprises a combination of at least one oil and at least one wax. In some embodiments, the composition is a pharmaceutical composition.
In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal.
In some embodiments, there is provided a method of treating an optic neuropathy condition, the method comprising administering a composition consisting essentially of a mixture of triterpenoids comprising at least two triterpenoic acids, selected from the group consisting of: masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof; and a pharmaceutically acceptable carrier.
In some embodiments, there is provided a use of a composition comprising an effective amount of an isolated acidic fraction of mastic gum, and a pharmaceutically acceptable carrier; for treating an optic neuropathy condition, wherein the fraction is characterized in that it is soluble in at least one polar organic solvent and in at least one non-polar organic solvent, and wherein said fraction is substantially devoid of compounds which are soluble in said polar organic solvent but insoluble in said non-polar organic solvent.
In some embodiments, there is provided a composition consisting essentially of a mixture of triterpenoids comprising at least two triterpenoic acids, selected from the group consisting of: masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, 3-0-acetyl masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0- acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof; and a pharmaceutically acceptable carrier, for use in treating an optic neuropathy condition in a subject in need thereof.
In some embodiments, there is provided a kit comprising: a pharmaceutical composition comprising an effective amount of an isolated acidic fraction of mastic gum and a pharmaceutically acceptable carrier; and instructions for using the kit for the treatment of optic neuropathy condition in a subject in need thereof.
In some embodiments, there is provided a kit comprising: a pharmaceutical composition consisting essentially of a mixture of triterpenoids comprising at least two triterpenoic acids, selected from the group consisting of: masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, 3-0-acetyl masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof and a pharmaceutically acceptable carrier; and instructions for using the kit for the treatment of optic neuropathy condition in a subject in need thereof Other objects, features and advantages of the present invention will become clear from the following description and drawings.
BRIEF DESCRIPTION OF THE FIGURES
Exemplary embodiments are illustrated in referenced figures. Dimensions of components and features shown in the figures are generally chosen for convenience and clarity of presentation and are not necessarily shown to scale. The figures are listed below.
Fig. 1 - Bar graphs showing pERG measurements relative change in mean amplitude in treated rats (Eye-laser irradiated) performed at follow-up day 28 as compared to control vehicle-treated group.
Fig. 2 - Bar Graphs showing Brn3a+ RGC counts in whole-mounted retina.
Fig. 3 - Bar graphs showing number of optic nerve axons per optic nerve area in various treated rat groups, compared to naïve rats (%); and Fig. 4 - Images of semi-thin cross-sections of optic nerves obtained from rats treated with the indicated formulations (D, E,), vehicle treated or non-treated rats (Naïve).
DETAILED DESCRIPTION OF THE INVENTION
According to some embodiments, there are provided compositions comprising isolated acidic fractions extracted from mastic gum, compounds comprised therein, and uses thereof for treating optical neuropathy.
It is herein disclosed for the first time that the disclosed isolated acidic fractions of mastic gum as described herein, may be employed as an active ingredient in a pharmaceutical composition for treating optical neuropathy, (resulting from various consequences), which are severe conditions that may lead to loss of vision in afflicted subjects.
Definitions As used herein, the terms "mastic", "mastic resin", "gum mastic" and "mastic gum", are used interchangeably to refer to a tree resin (also known as an oleoresin) obtained as an exudate from any tree classified in the family Anacardiaceae. Trees in the genus Pistacia, most notably Pistacia lentiscus L., and in particular the cultivar P. lentiscus L.
cv. Chia (cultivated on the Greek island of Chios), are known for their high yield of mastic. Other varieties include P. lentiscus L. var. emarginata Engl., and P.
lentiscus L.
var. latifolia Coss. Additional species of Pistacia include for example, P.
atlantica, P.
palestina, P. saportae, P. terebinthus, P. vera and P. integerrima.
As used herein, the terms "masticadienoic acid", "masticadienonic acid", "masticadienoic" and "masticadienonic" may interchangeably be used.
In order to provide clarity with respect to the molecular structure of compounds frequently mentioned and referred to in this application, a list of structures with names and acronyms used in this application is presented below.
Masticadienonic acid refers to 24-Z-masticadienonic acid, the acronym MDA used in the current application refers to this compound. The chemical structure of masticadienonic acid is as follows:
Me Me Me\r Me Me Me me 24-Z-masticadienonic acid (MDA) Isomasticadienonic acid refers to 24-Z-isomasticadienonic acid, the acronym IMDA
used in the current application refers to this compound. The chemical structure of 24-Z-isomasticadienonic acid is as follows:
M e M e M e\=
M e M e Me ivie 24-Z-isomasticadienonic acid (IMDA) Oleanonic acid (OLN or OA) has the following molecular structure:
Oleanonic acid (OLN or OA) Moronic acid (MO or MA) has the following molecular structure:
H
OO
Moronic acid (MA) 24-Z-masticadienolic acid (MLA) has the following structure, the 3-hydroxyl group has the beta-configuration:
=Y.r HO =
MLA (3-beta-MLA; beta-MLA) 24-Z-epimasticadienolic acid (epi-MLA) has the following structure, the 3-hydroxyl group has the alpha-configuration:
=r HOµ'' epi-MLA (3-alpha-MLA; alpha-MLA) 24-Z-isomasticadienolic acid (IMLA) has the following structure, the 3-hydroxyl group has the beta-configuration:
\(( lc :5;;t::;>
HO
IMLA (3-beta-MLA; beta-MLA) 24-Z-epi-isomasticadienolic acid (epi-IMLA) has the following structure, the 3-hydroxyl group has the beta-configuration:
7r _ =.
HO' =
epi-IMLA (3-alpha-IMLA; alpha-IMLA) 24-Z-3-0-acetyl-masticadienolic acid has the following molecular structure:
Me Me Me Me Me Ac0 Me ivie 24-Z-3-0-acetyl-masticadienolic acid (3-0-acetyl-masticadienolic acid; 3-0Ac-masticadienolic acid; 3-0Ac-MLA) 24-Z-3-0-acetyl-epimasticadienolic acid has the following molecular structure:
Me Me Me _ -Me Me AcO's.
Me -me 24-Z-3-0-acetyl-epimasticadienolic acid (3-0-acetyl-epimasticadienolic acid; 3-0Ac-epimasticadienolic acid; 3-0Ac-epi-MLA) 24-Z-3-0-acetyl-isomasticadienolic acid has the following molecular structure:
Me Me Me Me Me Ac0 Me me 24-Z-3-0-acetyl-isomasticadienolic acid (3-0-acetyl-isomasticadienolic acid; 3-0Ac-isomasticadienolic acid; 3-0Ac-IMLA) 24-Z-3-0-acetyl-epiisomasticadienolic acid has the following molecular structure:
Me Me Mer Me Me Acd Me me 24-Z-3 -0- acetyl-epiisomasticadienolic acid (3-0-acetyl-epiisomasticadienolic acid; 3-0Ac-epiisomasticadienolic acid;
3-0Ac-epi-IMLA) As used herein, the term "isolated acidic fraction of mastic gum" refers to a fraction obtained following extraction of gum mastic with at least one polar and at least one non-polar organic solvent, followed by an acid-base extraction of a solution of the thus obtained material and isolation of the resulting acidic fraction. The isolated acidic fraction of the invention is soluble both in polar and non-polar organic solvents.
As used herein the term "plurality" refers to more than one, preferably more than two. As used herein the term "synergistic" means more than additive.
As used herein, the term "acid-base extraction" refers to a procedure in which an organic solvent solution containing organic acidic and organic non-acidic components is treated/extracted with one or more basic aqueous solution(s). As a result of this, the organic acidic components are deprotonated and thus converted into their corresponding ionic salt forms and as a result will dissolve in the said basic aqueous solution. The non-acidic organic components will stay behind in the original organic solution.
Subsequently, the basic aqueous solution containing the salt forms of the acidic components is acidified, resulting in the reformation of the protonated acid forms of the organic acidic components.
These protonated acid forms (acidic fraction) can be removed from the acidified aqueous solution in several ways depending on the properties of the acidic compounds.
One option for removing the acidic fraction from the acidified solution is by extraction into a suitable organic solvent. Example 1 is a non-limiting example of an acid-base extraction as described above.
Depending on the solubility of the acidic compounds in the acidified aqueous solution, the acidic fraction may be isolated via filtration of the acidified aqueous solution.
Instead of using a basic aqueous solution for the acid-base extraction, basic forms of ion-exchange resins can be used as well. In these cases, the acidic organic components (acidic fraction) are captured in their deprotonated anionic form by the resin. The resin is subsequently removed from the initial solution, leaving non-acidic components behind.
The acidic components (acidic fraction) are subsequently released from the resin by treatment of the resin with a suitable acidic solution.
The use of ion-exchange resins for acid-base extractions is especially suitable for process scale up and can be used for the development of (semi)continuous extraction processes.
Examples of the above acid-base extractions and other variations can be found in many textbooks and other publications, and are considered common knowledge to those skilled in the art. An example of a useful textbook is "Vogel's Textbook of Practical Organic Chemistry", 5th Edition, 1989,( p.162-163).
As used herein, the term "degree of purity" refers to the content of a specified chemical compound in a preparation, expressed as a percentage on a weight per weight basis of the specified chemical compound relative to other chemical compounds in the preparation.
As used herein, "terpene compounds" refers to isoprene-containing hydrocarbons, having isoprene units (CH2=C(CH3)-CH=CH2) in a head-to-tail orientation.
Terpene hydrocarbons in general, have the molecular formula (C5H8)õ, and include hemiterpenes, (C5), monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20), triterpenes (C30), and tetraterpenes (C40) which respectively have 1, 2, 3, 4, 6 and 8 isoprene units. Terpenes may be further classified as acyclic or cyclic.
As used herein, "terpenoids" and "terpenoid compounds" interchangeably refer to terpene-related compounds which contain oxygen in addition to isoprene units, and thus include alcohols, aldehydes and ketones. Terpenoids are subdivided according to the number of carbon atoms in a manner similar to terpene and thus include hemiterpenoids, (C5), monoterpenoids (C10), sesquiterpenoids (C15), diterpenoids (C20), triterpenoids (C30), and tetraterpenoids (C40) which respectively have 1, 2, 3, 4, 6 and 8 isoprene units.. The skeleton of terpenoids may differ from strict additivity of isoprene units by the loss or shift of a fragment, generally a methyl group. Examples of monoterpenoids include camphor, eugenol and borneol. Examples of diterpenoids include phytol and taxol.
Examples of triterpenoids include squalene and lanosterol.
As used herein, "terpenoic acids" refer to terpenoid compounds containing at least one carboxylic acid group. The terpenoic acids may additionally contain one or more other oxygen-containing functional groups comprising hydroxyl, keto, aldehyde, ether (cyclic and non-cyclic) and ester (cyclic and non-cyclic) groups.
As used herein, "triterpenoic acids" refer to triterpenoid compounds containing at least one carboxylic acid group. The triterpenoic acids may additionally contain one or more other oxygen-containing functional groups comprising hydroxyl, keto, aldehyde, ether (cyclic and non-cyclic) and ester (cyclic and non-cyclic) groups.
As used herein, "an oligomeric form of a terpenoic acid" refers to an oligomeric terpenoid acid in which the monomeric units are either of the same terpenoic acid or of different terpenoic acids, and are joined in any possible arrangements, and are connected one to another through any possible bond or functional group, such as a C-C
bond, an ester group or an ether group.
As used herein, "an oligomeric form of a triterpenoic acid" refers to an oligomeric triterpenoid acid in which the monomeric units are either of the same triterpenoic acid or of different triterpenoic acids, and are joined in any possible arrangements, and are connected one to another through any possible bond or functional group, such as a C-C
bond, an ester group or an ether group.
As used herein, the terms "masticadienoic acid", "masticadienonic acid", "masticadienoic" and "masticadienonic acid" may interchangeably be used.
As used herein, the terms "isomasticadienoic acid", "isomasticadienonic acid", "isomasticadienoic" and "isomasticadienonic" may interchangeably be used.
As used herein, "substantially devoid" means that a preparation or pharmaceutical composition according to the invention that generally contains less than about 5% of the .. stated substance. For example, less than about 3%, less than 1%, less than 0.5%, less than 0.1%.
As used herein, the term "consisting essentially of' means that the only active pharmaceutical ingredient in the formulation or method that treats a specified condition is the specifically recited therapeutic ingredient in the particular embodiment.
The presence .. of other ingredients, e.g., excipients and/or lubricants, etc., is not precluded. The presence of additional other pharmaceutically active agents is also not precluded, as long as the latter do not have actual effect on said condition.
As used herein, "therapeutically effective amount" refers to that amount of a pharmaceutical ingredient which substantially induces, promotes or results in a desired therapeutic effect.
As used herein, "pharmaceutically acceptable carrier" refers to a diluent or vehicle which is used to enhance the delivery and/or pharmacokinetic properties of a pharmaceutical ingredient with which it is formulated, but has no therapeutic effect of its own, nor does it induce or cause any undesirable or untoward effect or adverse reaction in the subject.
As used herein, "pharmaceutically acceptable hydrophobic carrier" refers to a hydrophobic non-polar diluent or vehicle in which a mastic fraction is dissolved or suspended.
As used herein, the terms "optic neuropathy" and "optic atrophy" may interchangeably be used. The terms refer to damage to the optic nerve due to any cause.
The terms further encompass any condition or disorder resulting from or related to optic neuropathy, such as, ischemic optic neuropathy (including nonarteritic Anterior Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION), Posterior ischemic optic neuropathy); Radiation optic neuropathy (RON)); Traumatic optic neuropathy, Glaucoma, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, Hereditary optic neuropathy, damage resulting from storage disease, and the like; or combinations thereof. Each possibility is a separate embodiment.
As used herein, the term "storage disease" refers to any type of metabolic disorder that lead to excessive accumulation of substances such as lipids, proteins, lipoproteins, carbohydrates and others, of normal or abnormal nature. Of particular importance is the accumulation of lipofuscin associated with pathological damage to the optic nerve.
Numerical values stated herein are to be understood as the stated value +/-
In some embodiments, step (h) comprises basifying with a basic aqueous solution. In some embodiments, the basic aqueous solution is prepared by dissolving an inorganic base in water.
In some embodiments, the inorganic base is selected from the group consisting of sodium carbonate, sodium hydroxide, potassium carbonate potassium hydroxide, ammonium hydroxide, sodium bicarbonate, sodium phosphate, lithium hydroxide, lithium carbonate, and potassium phosphate.
In some embodiments, the inorganic base is sodium carbonate. In some embodiments, the concentration of the sodium carbonate in water is in the range from 2 to 20% w/w. In some embodiments, the concentration of sodium carbonate is in the range from 3 to 15% w/w. In some embodiments, the concentration of sodium carbonate is about 5% w/w.
In some embodiments, the inorganic base is sodium hydroxide.
In some embodiments, the basic aqueous solution is prepared by dissolving a water-soluble organic base in water.
In some embodiments, the first inorganic base is about 5% w/w aqueous sodium carbonate, followed by about 4% w/w aqueous sodium hydroxide.
In some embodiments, the basifying in step (h) comprises contacting the solution obtained in step (g) with a basic ion exchange resin. In some embodiments, the basic ion exchange resin comprises styrene divinylbenzene, polyacrylic or formophenolic copolymers.
In some embodiments, basifying the solution is done to a pH of above about 7.
In some embodiments, basifying the solution is done to a pH range of 8-10.
In some embodiments, basifying the solution is done to a pH range of 10-13.
In some embodiments, basifying the solution is done to a pH of >13.
In some embodiments, the acidic solution in step (i) comprises an acidic aqueous solution or an acidic non-aqueous solution.
In some embodiments, the acidic aqueous solution in step (i) is prepared by dissolving an inorganic acid in water or by diluting a concentrated mineral acid solution.
In some embodiments, the acidic aqueous solution is a solution of hydrochloric acid or phosphoric acid.
In some embodiments, the acidic aqueous solution is a solution of hydrochloric acid.
In some embodiments, the acidic aqueous solution in step (i) is prepared by dissolving an organic acid in water or by diluting a concentrated mineral acid solution.
In some embodiments, acidifying is done to a pH of below about 7. In some embodiments, acidifying is done to a pH of below about 6. In some embodiments, acidifying is done to a pH of below about 5. In some embodiments, acidifying is done to a .. pH of below about 4. In some embodiments, acidifying is done to a pH of below about 3.
In some embodiments, acidification is done to a pH in the range of 1-3.
In some embodiments, the acidic non-aqueous solution in step (i) is prepared by dissolving an organic acid in a non-aqueous organic solvent selected from an alcohol, an ester, an ether, an amide or mixtures thereof. In some embodiments, the non-aqueous .. solvent is methanol or ethanol or a mixture thereof.
In some embodiments, the organic acid is selected from the group consisting of formic acid, acetic acid, propionic acid, citric acid, tartaric acid, methane sulphonic acid, and para-toluenesulphonic acid.
In some embodiments, the drying agent used in step (k) is selected from the group of sodium sulfate, magnesium sulfate, calcium sulfate, calcium chloride, magnesium chloride, potassium sulfate.
In some embodiments, the composition is substantially devoid of terpene compounds which are soluble in said polar organic solvent and insoluble in said non-polar organic solvent.
In some embodiments, the composition comprises from about 0.01 to about 25%
(w/w) of the isolated acidic fraction of mastic gum, based on the total weight of the composition. In some embodiments, the composition comprises from about 0.01 to about 12% (w/w) of the isolated acidic fraction of mastic gum, based on the total weight of the composition.
In some embodiments, the isolated acidic fraction comprises at least one of:
masticadienonic acid, masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid, and 3-oxo-lup-20(29)-en-28-oic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the isolated acidic fraction comprises at least one of:
masticadienonic acid, masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid and moronic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the isolated acidic fraction further comprises at least one of:
oleanolic acid, ursonic acid, and ursolic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the isolated acidic fraction may be substantially devoid of essential oils.
In some embodiments, the isolated acidic fraction comprises at least one terpenoic acid. In some embodiments, the isolated acidic fraction comprises at least one triterpenoic acid. In some embodiments, the at least one terpenoic acid comprises at least one triterpenoic acid. In some embodiments, the at least one triterpenoic acid is selected from the group consisting of masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid, 3-oxo-lup-20(29)-en-28-oic acid and a combination thereof. Each possibility is a separate embodiment of the invention.
In some embodiments, the at least one terpenoic acid is in monomeric form. In some embodiments, the at least one terpenoic acid is in an oligomeric form. In some embodiments, the oligomeric form is selected from the group consisting of a dimer, a trimer, and a combination thereof. Each possibility is a separate embodiment of the invention.
In some embodiments, the isolated acidic fraction comprises a combination of monomeric and dimeric triterpenoic acids. In some embodiments, the isolated acidic fraction comprises a combination of monomeric, dimeric and trimeric triterpenoic acids.
In some embodiments, the composition comprises at least one of:
masticadienonic acid, masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid, and 3-oxo-lup-.. 20(29)-en-28-oic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the composition further comprises at least one of:
oleanolic acid, ursonic acid, and ursolic acid. Each possibility is a separate embodiment of the invention.
In some embodiments, the composition comprises at least one terpenoic acid.
Embodiments of terpenoic acids are as hereinbefore described.
In some embodiments, the composition comprises at least one triterpenoic acid.
Embodiments of triterpenoic acids are as hereinbefore described.
In some embodiments, the mastic gum is derived from a plant classified in the family Anacardiaceae. Suitable plants include those classified in a genus selected from the group consisting of Pistacia, Pinus, Picea, funiperus, Alsies, Lctrix, Antirrhinum, Boswellia, Citrus and Gynura. In some embodiments, suitable plants are selected from the genus Pistacia. In some embodiments, the species of Pistacia is selected from the group consisting of P. lentiscus, P. atlantica, P. palestina, P. saportae, P.
terebinthus, P. vera and P. integerrima. In some embodiments, the species of Pistacia is Pistacia lentiscus var.
Chia. In some embodiments, the species of Pistacia is Pistacia lentiscus L. In some embodiments, the species of Pistacia is Pistacia lentiscus L. var. latifolius Coss.
In some embodiments, the isolated acidic fraction is derived from a plant material selected from the group consisting of resin, leaves, twigs, roots, flowers, seeds, buds, bark, nuts and roots.
In some embodiments, the isolated acidic fraction of mastic gum is obtained by a process comprising the steps of:
(a) treating mastic gum with a polar organic solvent;
(b) isolating a fraction soluble in said polar organic solvent;
(c) optionally removing said polar organic solvent;
(d) treating the soluble fraction obtained in step (b) or (c) with a non-polar organic solvent, (e) isolating a fraction soluble in said non-polar organic solvent;
(f) optionally removing said non-polar organic solvent;
(g) dissolving the fraction obtained in step (f) in an organic solvent;
(h) treatment of the solution obtained in step (g) with a basic solution so as to obtain a basic fraction;
(i) acidifying the basic fraction obtained in step (i) with an acid solution;
(j) extracting the acidified fraction obtained in step (i with an organic solvent;
(k) optionally contacting the organic fraction obtained in step (k) with a drying agent so as to remove remaining water;
(1) removing organic solvent and/or excess acid from the fraction obtained in any of steps(i), (j) or (k); and (m) dissolving the isolated fraction obtained in step (1) in a carrier.
In additional embodiments, the invention provides a pharmaceutical composition comprising at least one triterpenoic acid; and a pharmaceutically acceptable carrier. In some embodiments, the at least one triterpenoic acid is selected from the group consisting of masticadienolic acid, isomasticadienonic acid, isomasticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl epimasticadienolic acid, 3-0-acetyl isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, masticadienonic acid, oleanonic acid, moronic acid, 3-oxo-lup-20(29)-en-28-oic acid and a combination thereof. Each possibility is a separate embodiment of the invention.
According to some embodiments, the current invention provides a pharmaceutical composition consisting essentially of isomasticadienonic acid and masticadienonic acid as the pharmaceutically active ingredients; and a pharmaceutically acceptable carrier. The combined presence of both compounds results in an enhanced/synergistic effect with respect to the composition's efficacy in the treatment of optic neuropathy condition, when compared with the efficacy of the individual compounds. Either one of isomasticadienonic acid and masticadienonic acid may be isolated from a natural source such as mastic gum, or may be the product of a chemical synthesis.
In some embodiments, the ratio between the isomasticadienonic acid and masticadienonic acid is about 1:1 w/w.
According to some embodiments, the current invention provides a pharmaceutical composition consisting essentially of oleanonic acid, isomasticadienonic acid and masticadienonic acid as the sole pharmaceutically active ingredients; and a pharmaceutically acceptable carrier for use in treating optical neuropathy.
According to some embodiments, the current invention provides a pharmaceutical composition consisting essentially of isomasticadienonic acid and masticadienonic acid as the sole pharmaceutically active ingredients; and a pharmaceutically acceptable carrier, for treating an optic neuropathy condition. The combined presence of these two compounds results in a synergistic effect with respect to composition's efficacy in the treatment of optic neuropathy conditions when compared with the efficacy of the individual compounds.
Any one of oleanonic acid, isomasticadienonic acid and masticadienonic acid may be either isolated from a natural source, such as mastic gum, or may be the product of a chemical synthesis. In some embodiments, the ratio between the isomasticadienoic acid and masticadienonic acid and oleanonic acid is about 1:1:1 w/w/w.
In some embodiments, the at least one triterpenoic acid is a monomer. In some embodiments, the composition comprises monomers of oleanonic acid and moronic acid.
In some embodiments, the monomers of oleanonic acid and moronic acid are the products of chemical synthesis reactions.
In some embodiments, the at least one triterpenoic acid comprises an oligomeric form. In some embodiments, the oligomeric form is selected from the group consisting of a dimer, a trimer, and a combination thereof. Each possibility is a separate embodiment of the invention. In some embodiments, the oligomeric form is a dimer. In some embodiments, the at least one triterpenoic acid is the product of a chemical synthesis.
In some embodiments, the at least one triterpenoic acid comprising an oligomeric form is the product of a chemical synthesis. In some embodiments, the at least on triterpenoic acid is a dimeric form and is the product of a chemical synthesis.
In some embodiments, the at least one triterpenoic acid is derived from a natural source, in particular a plant source.
In some embodiments, the composition comprises a combination of different triterpenoic acids, wherein at least one triterpenoic acid is the product of a chemical synthesis and at least one other triterpenoic acid is derived from a plant source.
Natural sources include plants classified in the family Anacardiaceae.
Suitable plants include those classified in a genus selected from the group consisting of Pistacia, Pinus, Picea, funiperus, Alsies, Lctrix, Antirrhinum, Boswellia, Citrus and Gynura.
In some embodiments, suitable plants are selected from the genus Pistacia. In some embodiments, the species of Pistacia is selected from the group consisting of P. lentiscus, P. atlantica, P.
palestina, P. saportae, P. terebinthus, P. vera and P. integerrima. In some embodiments, the species of Pistacia is Pistacia lentiscus L.
In some embodiments, the natural source is a plant material selected from the group consisting of resin, leaves, twigs, roots, flowers, seeds, buds, bark, nuts and roots.
In some embodiments, the natural source is a plant classified in a genus selected from the group consisting of Ocimum, Lcturus and Lctvendula.
In some embodiments, the pharmaceutically acceptable carrier comprises a hydrophobic carrier. In some embodiments, the hydrophobic carrier comprises at least one oil. In some embodiments, the oil is selected from the group consisting of a mineral oil, a vegetable oil and combinations thereof. In some embodiments, the vegetable oil is selected from the group consisting of cottonseed oil, olive oil, almond oil, canola oil, coconut oil, corn oil, grape seed oil, peanut oil, saffron oil, sesame oil, soybean oil, and combinations thereof. In some embodiments, the mineral oil is light mineral oil. In some embodiments, the hydrophobic carrier comprises at least one wax. In some embodiments, the hydrophobic carrier comprises a combination of at least one oil and at least one wax. In some embodiments, the composition is a pharmaceutical composition.
In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal.
In some embodiments, there is provided a method of treating an optic neuropathy condition, the method comprising administering a composition consisting essentially of a mixture of triterpenoids comprising at least two triterpenoic acids, selected from the group consisting of: masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, 3-0-acetyl-masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof; and a pharmaceutically acceptable carrier.
In some embodiments, there is provided a use of a composition comprising an effective amount of an isolated acidic fraction of mastic gum, and a pharmaceutically acceptable carrier; for treating an optic neuropathy condition, wherein the fraction is characterized in that it is soluble in at least one polar organic solvent and in at least one non-polar organic solvent, and wherein said fraction is substantially devoid of compounds which are soluble in said polar organic solvent but insoluble in said non-polar organic solvent.
In some embodiments, there is provided a composition consisting essentially of a mixture of triterpenoids comprising at least two triterpenoic acids, selected from the group consisting of: masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, 3-0-acetyl masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0- acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof; and a pharmaceutically acceptable carrier, for use in treating an optic neuropathy condition in a subject in need thereof.
In some embodiments, there is provided a kit comprising: a pharmaceutical composition comprising an effective amount of an isolated acidic fraction of mastic gum and a pharmaceutically acceptable carrier; and instructions for using the kit for the treatment of optic neuropathy condition in a subject in need thereof.
In some embodiments, there is provided a kit comprising: a pharmaceutical composition consisting essentially of a mixture of triterpenoids comprising at least two triterpenoic acids, selected from the group consisting of: masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, 3-0-acetyl masticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof and a pharmaceutically acceptable carrier; and instructions for using the kit for the treatment of optic neuropathy condition in a subject in need thereof Other objects, features and advantages of the present invention will become clear from the following description and drawings.
BRIEF DESCRIPTION OF THE FIGURES
Exemplary embodiments are illustrated in referenced figures. Dimensions of components and features shown in the figures are generally chosen for convenience and clarity of presentation and are not necessarily shown to scale. The figures are listed below.
Fig. 1 - Bar graphs showing pERG measurements relative change in mean amplitude in treated rats (Eye-laser irradiated) performed at follow-up day 28 as compared to control vehicle-treated group.
Fig. 2 - Bar Graphs showing Brn3a+ RGC counts in whole-mounted retina.
Fig. 3 - Bar graphs showing number of optic nerve axons per optic nerve area in various treated rat groups, compared to naïve rats (%); and Fig. 4 - Images of semi-thin cross-sections of optic nerves obtained from rats treated with the indicated formulations (D, E,), vehicle treated or non-treated rats (Naïve).
DETAILED DESCRIPTION OF THE INVENTION
According to some embodiments, there are provided compositions comprising isolated acidic fractions extracted from mastic gum, compounds comprised therein, and uses thereof for treating optical neuropathy.
It is herein disclosed for the first time that the disclosed isolated acidic fractions of mastic gum as described herein, may be employed as an active ingredient in a pharmaceutical composition for treating optical neuropathy, (resulting from various consequences), which are severe conditions that may lead to loss of vision in afflicted subjects.
Definitions As used herein, the terms "mastic", "mastic resin", "gum mastic" and "mastic gum", are used interchangeably to refer to a tree resin (also known as an oleoresin) obtained as an exudate from any tree classified in the family Anacardiaceae. Trees in the genus Pistacia, most notably Pistacia lentiscus L., and in particular the cultivar P. lentiscus L.
cv. Chia (cultivated on the Greek island of Chios), are known for their high yield of mastic. Other varieties include P. lentiscus L. var. emarginata Engl., and P.
lentiscus L.
var. latifolia Coss. Additional species of Pistacia include for example, P.
atlantica, P.
palestina, P. saportae, P. terebinthus, P. vera and P. integerrima.
As used herein, the terms "masticadienoic acid", "masticadienonic acid", "masticadienoic" and "masticadienonic" may interchangeably be used.
In order to provide clarity with respect to the molecular structure of compounds frequently mentioned and referred to in this application, a list of structures with names and acronyms used in this application is presented below.
Masticadienonic acid refers to 24-Z-masticadienonic acid, the acronym MDA used in the current application refers to this compound. The chemical structure of masticadienonic acid is as follows:
Me Me Me\r Me Me Me me 24-Z-masticadienonic acid (MDA) Isomasticadienonic acid refers to 24-Z-isomasticadienonic acid, the acronym IMDA
used in the current application refers to this compound. The chemical structure of 24-Z-isomasticadienonic acid is as follows:
M e M e M e\=
M e M e Me ivie 24-Z-isomasticadienonic acid (IMDA) Oleanonic acid (OLN or OA) has the following molecular structure:
Oleanonic acid (OLN or OA) Moronic acid (MO or MA) has the following molecular structure:
H
OO
Moronic acid (MA) 24-Z-masticadienolic acid (MLA) has the following structure, the 3-hydroxyl group has the beta-configuration:
=Y.r HO =
MLA (3-beta-MLA; beta-MLA) 24-Z-epimasticadienolic acid (epi-MLA) has the following structure, the 3-hydroxyl group has the alpha-configuration:
=r HOµ'' epi-MLA (3-alpha-MLA; alpha-MLA) 24-Z-isomasticadienolic acid (IMLA) has the following structure, the 3-hydroxyl group has the beta-configuration:
\(( lc :5;;t::;>
HO
IMLA (3-beta-MLA; beta-MLA) 24-Z-epi-isomasticadienolic acid (epi-IMLA) has the following structure, the 3-hydroxyl group has the beta-configuration:
7r _ =.
HO' =
epi-IMLA (3-alpha-IMLA; alpha-IMLA) 24-Z-3-0-acetyl-masticadienolic acid has the following molecular structure:
Me Me Me Me Me Ac0 Me ivie 24-Z-3-0-acetyl-masticadienolic acid (3-0-acetyl-masticadienolic acid; 3-0Ac-masticadienolic acid; 3-0Ac-MLA) 24-Z-3-0-acetyl-epimasticadienolic acid has the following molecular structure:
Me Me Me _ -Me Me AcO's.
Me -me 24-Z-3-0-acetyl-epimasticadienolic acid (3-0-acetyl-epimasticadienolic acid; 3-0Ac-epimasticadienolic acid; 3-0Ac-epi-MLA) 24-Z-3-0-acetyl-isomasticadienolic acid has the following molecular structure:
Me Me Me Me Me Ac0 Me me 24-Z-3-0-acetyl-isomasticadienolic acid (3-0-acetyl-isomasticadienolic acid; 3-0Ac-isomasticadienolic acid; 3-0Ac-IMLA) 24-Z-3-0-acetyl-epiisomasticadienolic acid has the following molecular structure:
Me Me Mer Me Me Acd Me me 24-Z-3 -0- acetyl-epiisomasticadienolic acid (3-0-acetyl-epiisomasticadienolic acid; 3-0Ac-epiisomasticadienolic acid;
3-0Ac-epi-IMLA) As used herein, the term "isolated acidic fraction of mastic gum" refers to a fraction obtained following extraction of gum mastic with at least one polar and at least one non-polar organic solvent, followed by an acid-base extraction of a solution of the thus obtained material and isolation of the resulting acidic fraction. The isolated acidic fraction of the invention is soluble both in polar and non-polar organic solvents.
As used herein the term "plurality" refers to more than one, preferably more than two. As used herein the term "synergistic" means more than additive.
As used herein, the term "acid-base extraction" refers to a procedure in which an organic solvent solution containing organic acidic and organic non-acidic components is treated/extracted with one or more basic aqueous solution(s). As a result of this, the organic acidic components are deprotonated and thus converted into their corresponding ionic salt forms and as a result will dissolve in the said basic aqueous solution. The non-acidic organic components will stay behind in the original organic solution.
Subsequently, the basic aqueous solution containing the salt forms of the acidic components is acidified, resulting in the reformation of the protonated acid forms of the organic acidic components.
These protonated acid forms (acidic fraction) can be removed from the acidified aqueous solution in several ways depending on the properties of the acidic compounds.
One option for removing the acidic fraction from the acidified solution is by extraction into a suitable organic solvent. Example 1 is a non-limiting example of an acid-base extraction as described above.
Depending on the solubility of the acidic compounds in the acidified aqueous solution, the acidic fraction may be isolated via filtration of the acidified aqueous solution.
Instead of using a basic aqueous solution for the acid-base extraction, basic forms of ion-exchange resins can be used as well. In these cases, the acidic organic components (acidic fraction) are captured in their deprotonated anionic form by the resin. The resin is subsequently removed from the initial solution, leaving non-acidic components behind.
The acidic components (acidic fraction) are subsequently released from the resin by treatment of the resin with a suitable acidic solution.
The use of ion-exchange resins for acid-base extractions is especially suitable for process scale up and can be used for the development of (semi)continuous extraction processes.
Examples of the above acid-base extractions and other variations can be found in many textbooks and other publications, and are considered common knowledge to those skilled in the art. An example of a useful textbook is "Vogel's Textbook of Practical Organic Chemistry", 5th Edition, 1989,( p.162-163).
As used herein, the term "degree of purity" refers to the content of a specified chemical compound in a preparation, expressed as a percentage on a weight per weight basis of the specified chemical compound relative to other chemical compounds in the preparation.
As used herein, "terpene compounds" refers to isoprene-containing hydrocarbons, having isoprene units (CH2=C(CH3)-CH=CH2) in a head-to-tail orientation.
Terpene hydrocarbons in general, have the molecular formula (C5H8)õ, and include hemiterpenes, (C5), monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20), triterpenes (C30), and tetraterpenes (C40) which respectively have 1, 2, 3, 4, 6 and 8 isoprene units. Terpenes may be further classified as acyclic or cyclic.
As used herein, "terpenoids" and "terpenoid compounds" interchangeably refer to terpene-related compounds which contain oxygen in addition to isoprene units, and thus include alcohols, aldehydes and ketones. Terpenoids are subdivided according to the number of carbon atoms in a manner similar to terpene and thus include hemiterpenoids, (C5), monoterpenoids (C10), sesquiterpenoids (C15), diterpenoids (C20), triterpenoids (C30), and tetraterpenoids (C40) which respectively have 1, 2, 3, 4, 6 and 8 isoprene units.. The skeleton of terpenoids may differ from strict additivity of isoprene units by the loss or shift of a fragment, generally a methyl group. Examples of monoterpenoids include camphor, eugenol and borneol. Examples of diterpenoids include phytol and taxol.
Examples of triterpenoids include squalene and lanosterol.
As used herein, "terpenoic acids" refer to terpenoid compounds containing at least one carboxylic acid group. The terpenoic acids may additionally contain one or more other oxygen-containing functional groups comprising hydroxyl, keto, aldehyde, ether (cyclic and non-cyclic) and ester (cyclic and non-cyclic) groups.
As used herein, "triterpenoic acids" refer to triterpenoid compounds containing at least one carboxylic acid group. The triterpenoic acids may additionally contain one or more other oxygen-containing functional groups comprising hydroxyl, keto, aldehyde, ether (cyclic and non-cyclic) and ester (cyclic and non-cyclic) groups.
As used herein, "an oligomeric form of a terpenoic acid" refers to an oligomeric terpenoid acid in which the monomeric units are either of the same terpenoic acid or of different terpenoic acids, and are joined in any possible arrangements, and are connected one to another through any possible bond or functional group, such as a C-C
bond, an ester group or an ether group.
As used herein, "an oligomeric form of a triterpenoic acid" refers to an oligomeric triterpenoid acid in which the monomeric units are either of the same triterpenoic acid or of different triterpenoic acids, and are joined in any possible arrangements, and are connected one to another through any possible bond or functional group, such as a C-C
bond, an ester group or an ether group.
As used herein, the terms "masticadienoic acid", "masticadienonic acid", "masticadienoic" and "masticadienonic acid" may interchangeably be used.
As used herein, the terms "isomasticadienoic acid", "isomasticadienonic acid", "isomasticadienoic" and "isomasticadienonic" may interchangeably be used.
As used herein, "substantially devoid" means that a preparation or pharmaceutical composition according to the invention that generally contains less than about 5% of the .. stated substance. For example, less than about 3%, less than 1%, less than 0.5%, less than 0.1%.
As used herein, the term "consisting essentially of' means that the only active pharmaceutical ingredient in the formulation or method that treats a specified condition is the specifically recited therapeutic ingredient in the particular embodiment.
The presence .. of other ingredients, e.g., excipients and/or lubricants, etc., is not precluded. The presence of additional other pharmaceutically active agents is also not precluded, as long as the latter do not have actual effect on said condition.
As used herein, "therapeutically effective amount" refers to that amount of a pharmaceutical ingredient which substantially induces, promotes or results in a desired therapeutic effect.
As used herein, "pharmaceutically acceptable carrier" refers to a diluent or vehicle which is used to enhance the delivery and/or pharmacokinetic properties of a pharmaceutical ingredient with which it is formulated, but has no therapeutic effect of its own, nor does it induce or cause any undesirable or untoward effect or adverse reaction in the subject.
As used herein, "pharmaceutically acceptable hydrophobic carrier" refers to a hydrophobic non-polar diluent or vehicle in which a mastic fraction is dissolved or suspended.
As used herein, the terms "optic neuropathy" and "optic atrophy" may interchangeably be used. The terms refer to damage to the optic nerve due to any cause.
The terms further encompass any condition or disorder resulting from or related to optic neuropathy, such as, ischemic optic neuropathy (including nonarteritic Anterior Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION), Posterior ischemic optic neuropathy); Radiation optic neuropathy (RON)); Traumatic optic neuropathy, Glaucoma, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, Hereditary optic neuropathy, damage resulting from storage disease, and the like; or combinations thereof. Each possibility is a separate embodiment.
As used herein, the term "storage disease" refers to any type of metabolic disorder that lead to excessive accumulation of substances such as lipids, proteins, lipoproteins, carbohydrates and others, of normal or abnormal nature. Of particular importance is the accumulation of lipofuscin associated with pathological damage to the optic nerve.
Numerical values stated herein are to be understood as the stated value +/-
10%.
The term "about" is directed to include the stated value +/- 10% of the stated value.
In some embodiments, the present invention provides compositions comprising specific combinations of terpenoic acids, such as that found in isolated acidic fractions of mastic gum. In some embodiments, the present invention provides compositions consisting of specific triterpenoic acids compounds, these compositions are shown to have an unexpected synergetic effect compared to the same individual triterpenoic acids compounds in the treatment of optic neuropathy. The triterpenoic acid compounds may be from a plant source, in particular mastic gum, or may be the products of chemical synthesis reactions. In some cases, the compositions may correspond to combinations of compounds, in which some are chemically synthesized and some are derived from plant sources.
In some embodiments, any one of the triterpenoic acids may be the product of a biochemical reaction or a product produced by a microbial organism. In some embodiments, any one of the triterpenoic acids may be the product of a fermentation process. In some embodiments, any one of the triterpenoic acids may be produced by a combination of a chemical synthesis and a biochemical reaction. In some embodiments, any one of the triterpenoic acids may be produced by a combination of a chemical synthesis and a fermentation process. In some embodiments, the any one of triterpenoic acids may be produced by a combination of any of the above-indicated options.
In case of a biochemical reaction or microbial process, the biochemical agent and the microbial agent may be a naturally occurring agent or may be a modified agent not naturally occurring.
Modification of these agents may have been achieved using modern biochemical methods such as for example genetic engineering. Said biochemical agents and microbial agents not occurring naturally may also have been created using synthetic biology methods.
In some embodiments, obtaining from a natural source may include isolating from a natural source. In some embodiments, the isolation from the natural source may include isolation as individual compound(s) or as a group(s) of compounds. In some embodiments, the natural source may include a plant material selected from the group consisting of a resin, a gum, leaves, twigs, roots, flowers, seeds, buds, bark, nuts and roots. Each possibility is a separate embodiment. In some embodiments, the natural source may include a resin extracted from at least one plant. In some embodiments, the natural source may include mastic gum.
In some embodiments, the natural source may include at least one plant. In some embodiments, the plant may be classified in the family Anacardiaceae. In some embodiments, the plant may comprise at least one plant classified in the genus/genera Pistacia and/or Schinus. In some embodiments, Pistacia may include species selected from the group consisting of P. lentiscus, P. atlantica, P. palestina, P. saportae, P. terebinthus, P.
vera P. integerrima, and P. lentiscus L. Each possibility is a separate embodiment. In some embodiments, Pistacia may include the species Pistacia lentiscus L. In some embodiments, Schinus may include the species S. molle. In some embodiments, the Pistacia may include the species Pistacia Lentiscus vat-. Chia. In some embodiments, the Pistacia may include the species Pistacia lentiscus L. var. latifolius Coss. Each possibility is a separate embodiment of the invention.
Plant species useful for obtaining the compositions of the invention include without limitation, those of the genera Pistacia, Pinus, Picea, funiperus, Alsies, Larix, Ocimum, Laurus and Lctvendula.
Useful species of Pistacia include without limitation, P. lentiscus, P.
atlantica, P.
palestina, P. saportae, P. terebinthus, P. vera and P. integerrima. .
The method used for obtaining isolated acidic fractions of mastic gum can be described as follows. By way of a general description, collected plant material, for example mastic gum, is combined in a suitable vessel with a suitable solvent, usually a polar solvent. Suitable polar solvents include for example, alcohols, ethers, esters, amides, aldehydes, ketones, nitriles and combinations thereof.
Particular examples of polar organic solvents are methanol, ethanol, propanol, isopropanol, 1-butanol, 2-butanol, sec-butanol, t-butanol, 1-pentanol, 2-pentanol, 3-pentanol, neopentanol, 3-methyl-1-butanol, 2-methyl-1 -butanol, 3-methy1-2-butanol, 2-methy1-2-butanol, ethyleneglycol, ethyleneglycol monomethyl ether, diethyl ether, methylethyl ether, ethylpropyl ether, methylpropyl ether, 1,2-dimethoxyethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran, methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methylformate, ethylformate, ethyl propionate, methyl propionate, dichloromethane, chloroform, dimethylformamide, acetamide, dimethylacetamide, N-methylpyrrolidone, acetone, ethylmethyl ketone, diethyl ketone, acetonitrile, propionitrile, and combinations thereof.
The mastic gum and the solvent are preferably combined such that the solvent is in large excess, for example 10:1 or 20:1. The mixture may be periodically or continuously agitated over a period ranging from a few minutes to a number of hours. The solvent may be decanted without any treatment, or optionally the mixture may be first subjected to low speed centrifugation, for example at 100 to 2000 rpm, as is known in the art.
The insoluble material is recovered from the extract and a fresh aliquot of solvent is added to the insoluble material, such that the extraction and dissolution process is repeated for a number of cycles, in order to obtain as much as possible of the polar solvent soluble compounds. After the final dissolution step, the extracts containing polar solvent soluble material are combined and the polar solvent is evaporated (for example by using a rotary evaporation as is known in the art), so as to yield polar solvent soluble material, which may be referred to as a crude, or "first step" extract.
The first step extract material is combined with a non-polar organic solvent and extracted by shaking over a period of 1 to 2 hours. Suitable non-polar solvents include acyclic or cyclic, saturated or unsaturated aliphatic hydrocarbons and aromatic hydrocarbons, for example, C5-C10 alkanes, C5-C10 cycloalkanes, C6-C14 aromatic hydrocarbons, and combinations thereof. Each of the foregoing may be optionally substituted by one or more halogens, for example, C7-C14 perfluoroalkanes.
Particular examples of non-polar organic solvents are pentanes, hexanes, heptanes, octanes, nonanes, decanes, cyclopentane, cyclohexane, cycloheptane, benzene, toluene, xylene, and isomers and mixtures thereof. Material remaining insoluble or precipitating in the presence of the non-polar solvent is removed and discarded. The non-polar solvent-soluble fraction is then obtained by evaporating the non-polar solvent (for example by rotary evaporation). This fraction may be referred to as purified or "two step" extract, corresponding to an isolated fraction of mastic gum which is characterized by the fact that it is soluble in both a polar solvent and a non-polar solvent, while materials which are soluble in the polar solvent but insoluble in the non-polar solvent, have been removed.
The second step extract material is subsequently dissolved in an organic solvent and this solution is extracted repeatedly (e.g. four times) with a basic aqueous solution. A
second extraction with a different basic aqueous solution may be performed.
The basic fraction thus obtained is acidified with a dilute aqueous acid solution to acidic pH. The acidified aqueous solution is extracted several times with an organic solvent.
The thus obtained combined organic solvent extracts (also referred to as "three step extract") are treated with a drying agent. This isolated acidic fraction of mastic gum is then obtained by evaporating the organic solvent (for example by rotary evaporation). This fraction is referred to as the isolated acidic fraction of mastic gum. Additional intermediate steps of drying and/or solvent removal may be carried out between other steps, as is known in the art. Alternately, the second step extract material may be combined with a basic ion exchange resin e.g. Amberlyst A26. The isolated ion-exchange resin is treated with an non-aqueous acidic solution in order to liberate the acidic fraction from the resin. The isolated acidic fraction is then obtained by evaporating the non-aqueous solvent and any .. excess acid.
The feature that distinguishes the isolated acidic fractions of the invention over prior art extracts of mastic gum is that certain acidic compounds have been removed in the first two steps of the procedure which would otherwise end up in the final acidic fraction.
According to the teachings of the present invention, the acidic compounds removed during the first two steps of the isolation procedure have a detrimental effect on the beneficial biological activities of the isolated acidic fractions disclosed herein.
The three step extract may be dried further, for example by high vacuum treatment (for example <0.01 mbar for up to several days) to remove residual solvent and other volatile material, weighed and combined with a non-polar organic solvent or other carrier to effect its dissolution.
In some embodiments, the isolated fraction of the invention may be obtained by a process comprising one or more of the steps of:
(a) treating mastic gum with a polar organic solvent;
(b) isolating a fraction soluble in said polar organic solvent;
(c) optionally removing said polar organic solvent;
(d) treating the soluble fraction obtained in step (b) or (c) with a non-polar organic solvent, (e) isolating a fraction soluble in said non-polar organic solvent;
(f) optionally removing said non-polar organic solvent;
(g) dissolving the fraction obtained in step (f) in an organic solvent;
(h) treating the solution obtained in step (g) with a basic solution so as to obtain a basic fraction; and (i) acidifying the basic fraction obtained in step (h) with an acid solution.
In some embodiments, the treatment with a basic solution (basifying) in step (h) comprises extracting the solution obtained in step (g) with one or more suitable basic aqueous solution; or contacting the solution obtained in step (g) with a basic ion exchange resin. In case of a basic ion exchange resin, the resin may subsequently be treated with an acidic solution in order to release the captured acidic fraction. The isolated acidic fraction is than obtained by removal of any volatiles using, for example, application of vacuum.
In some embodiments, step (h) comprises contacting the solution obtained in step (g) with a basic ion exchange resin, and thereafter removing the basic ion exchange resin by filtration. The basic ion exchange resin may be subsequently treated with an acidic solution in order to liberate the captured acidic fraction. The isolated acidic fraction is than obtained by removal of any volatiles using e.g. application of vacuum.
In some embodiments, the process further comprises the steps of (j) extracting the acidified fraction obtained in step (i) with an organic solvent;
k) optionally contacting the organic fraction obtained in step (j) with a drying agent so as to remove remaining water;
(1) removing organic solvent and/or excess acid from the fraction obtained in any of steps (i), (j) or (k); and (m) dissolving the isolated fraction obtained in step (1) in a carrier.
The process may further comprise removing the solvent after any of steps (c), (f) or (1). Solvent removal may be carried out by any means known in the art, for example rotary evaporation, application of high vacuum and a combination thereof. In some embodiments, steps (a) to (c) are carried out prior to steps (d) to (f) or vice versa. In some embodiments, the polar organic solvent comprises ethanol, the non-polar organic solvent comprises hexane and the organic solvent used for the acid-base extraction comprises diethyl ether. As is readily understood by one of skill in the art, steps (a) to (c) and steps (d) to (f) may each be independently canied out for a number of cycles to optimize the extraction process and degree of purification of the product.
In some embodiments, step (h) comprises extracting the solution obtained in step (g) with a basic aqueous solution, and collecting the organic fraction obtained therefrom. In some embodiments, the process may further comprise combining the organic fraction obtained from step (h) with a fraction obtained in any of steps (i), (j) or (k).
In some embodiments, the organic fraction obtained in step (h) is combined with a fraction obtained in any of steps (i), (j) or (k) in an amount in the range from about 0.1 to 50% of the organic fraction obtained from step (h). In some embodiments, the amount is in the range from about 0.5-50%; or 2 to 25%; or 0.1 to 10%.
The isolated acidic fraction may comprise at least one terpenoic acid, such as a combination of various triterpenoic acid combinations. Triterpenoic acids include for example, masticadienonic acid; isomasticadienonic acid; isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epi-masticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid;
masticadienolic acid, oleanonic acid; oleanolic acid; ursonic acid; ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
The isolated acidic fraction may comprise at least one terpenoic acid, such as a combination of various triterpenoic acid combinations. Triterpenoic acids include for example, masticadienonic acid; isomasticadienonic acid; masticadienolic acid;
isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epi-masticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid;
oleanonic acid; oleanolic acid; ursonic acid; ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, for example, masticadienonic acid;
isomasticadienonic acid; masticadienolic acid; isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid; oleanolic acid;
ursonic acid;
ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, for example, masticadienonic acid;
isomasticadienonic acid; isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid; oleanolic acid; ursonic acid; ursolic acid; moronic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, for example, masticadienonic acid;
isomasticadienonic acid; masticadienolic acid, isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid; oleanolic acid;
ursonic acid;
ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, for example, masticadienonic acid;
isomasticadienonic acid; masticadienolic acid, isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid; oleanolic acid;
ursonic acid;
ursolic acid; moronic acid.
In some embodiments, the isolated acidic fraction may comprise at least three terpenoic acid compounds, selected from, masticadienonic acid;
isomasticadienonic acid;
isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid;
oleanonic acid; oleanolic acid; ursonic acid; ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, masticadienonic acid, isomasticadienonic acid, and oleanonic acid.
In some embodiments, the isolated acidic fraction may be substantially devoid of particular triterpenoic acids, such as, for example, masticadienolic acid or moronic acid.
Each possibility is a separate embodiment.
In some embodiments, the isolated acidic fraction may be substantially devoid of essential oils.
Furthermore, terpenoic acid and or triterpenoic acids in the isolated acidic fraction may be in monomeric form, or in an oligomeric form, such as a dimer, a trimer, or combinations thereof.
The composition for use in the invention comprises a therapeutically effective amount of an isolated acidic fraction of mastic gum described herein, and a pharmaceutically acceptable hydrophobic carrier.
The invention also provides a composition comprising at least one triterpenoic acid;
and a pharmaceutically acceptable carrier. The triterpenoic acid may be isolated from a plant product, such as mastic gum, as hereinbefore described, or it may be the product of a chemical synthesis. Furthermore, the composition may comprise a combination of triterpenoic acids, some of which are chemically synthesized, and some of which are isolated from one or more plant products. In some embodiments, the composition may .. consist of at least two triterpenoic acids compounds as the pharmaceutically active ingredients, and a pharmaceutically acceptable carrier. In addition, the composition may comprise dimeric, trimeric and higher oligomeric forms of triterpenoic acids;
the oligomers can be formed from both identical and different monomeric triterpenoic acids.
In some embodiments, the composition may consist of at least three triterpenoic acids .. compounds as the pharmaceutically active ingredients, and a pharmaceutically acceptable carrier.
For preparation of a composition for therapeutic use, suitable carriers may be used, such as hydrophobic carriers including pharmaceutically acceptable oils, optionally in combination with waxes, as described herein.
An hydrophobic carrier comprises at least one oil, such as for example a mineral oil, a vegetable oil or combinations thereof.
The term "mineral oil" refers to a clear colorless nearly odorless and tasteless liquid obtained from the distillation of petroleum. It may also be referred to as white oil, white mineral oil, liquid petrolatum, liquid paraffin or white paraffin oil. In accordance with some embodiments of the invention, the mineral oil is light mineral oil, a commercially available product which may be obtained either as a NF (National Formulary) grade product or as a USP (US Pharmacopoeia) grade product. For use in the invention, the mineral oil is preferably free of aromatics and unsaturated compounds.
Suitable vegetable oils include, but are not limited to cottonseed oil, olive oil, almond oil, canola oil, coconut oil, corn oil, grape seed oil, peanut oil, saffron oil, sesame oil, soybean oil, or combinations thereof. In some embodiments, the mineral oil is light mineral oil.
The pharmaceutically acceptable carrier may alternately or in addition comprise an oil replacement. Oil replacements include alkanes having at least 10 carbon (e.g., isohexadecane), benzoate esters, aliphatic esters, noncomodogenic esters, volatile silicone compounds (e.g., cyclomethicone), and volatile silicone substitutes. Examples of benzoate esters include C12C15 alkyl benzoate, isostearyl benzoate, 2-ethyl hexyl benzoate, dipropylene glycol benzoate, octyldodecyl benzoate, stearyl benzoate, and behenyl benzoate. Examples of aliphatic esters include C12C15 alkyl octonoate and dioctyl maleate.
Examples of noncomodogenic esters include isononyl isononanoate, isodecyl isononanoate, dilsostearyl dimer dilinoleate, arachidyl propionate, and isotridecyl isononanoate. Examples of volatile silicone substitutes include isohexyl decanoate, octyl isononanoate, isononyl octanoate, and diethylene glycol dioctanoate.
Cyclomethicone is an evaporative silicone which may be included in the carrier to assist in making the composition amenable to ejection from a spray dispenser.
Furthermore, due to its evaporative property, cyclomethicone may assist in retaining and fixing the formulation on the surface to which it is sprayed e.g. a wound site.
The hydrophobic carrier may further comprise at least one wax. Waxes include for example, beeswax; vegetable waxes, sugar cane waxes, mineral waxes, and synthetic waxes. Vegetable waxes include for example, carnauba, candelilla, ouricury and jojoba wax. Mineral waxes include for example, paraffin wax, lignite wax, microcrystalline waxes and ozokerites. Synthetic waxes include for example, polyethylene waxes.
The pharmaceutical composition may be formulated in any of a number of forms such as for example, a capsule (including a softgel capsule), a tablet, a gel, a liposome, a suppository, a suspension, an ointment, a solution, an emulsion or microemulsion, a film, a cement, a powder, a glue, an aerosol, a spray and a gel.
For preparing the pharmaceutical composition, the isolated acidic fraction of mastic gum may be suitably formulated as inclusion complexes, nanoemulsions, microemulsions, powders and liposomes. In some embodiments, an inclusion complex comprises at least one cyclodextrin. In some embodiments, cyclodextrins comprise hydroxypropy1-13-cyclodextrin. In some embodiments, nanoemulsions comprise droplets having average particle size of less than 800 nm. In some embodiments, the droplets have average particle size of less than 500 nm. In some embodiments, the droplets have average particle size of less than 200 nm. In some embodiments, powders are spray dried powders. In some embodiments, liposomes comprise multilamellar vesicles. In some embodiments, a microemulsion comprises a non-ionic surfactant. Non-ionic surfactants include, without limitation, polyoxyl castor oils, polyoxyethylene sorbitan fatty acid esters (polysorbates), a poloxamer, a vitamin E derivative, polyoxyethylene alkyl ethers, polyoxyethylene sterates, saturated polyglycolyzed glycerides or combinations thereof.
According to some embodiments, various formulations of isolated acidic fraction and preparation thereof are disclosed herein in Example 1. The pharmaceutical compositions of the invention may be administered by any means that achieve their intended purpose. In some embodiments, administration is by parenteral route.
In some embodiments, administration is a parenteral, localized administration. In some embodiments, parenteral administration may be selected from, but not limited to:
intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intraarterial, intrauterine, intraurethral, intracardial, intracerebral, intracerebroventricular, intrarenal, intrahepatic, intratendon, intraosseous, intraocular, and intrathecal routes of administration.
The dosage administered will be dependent upon the age, health, and weight of the subject, the use of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. The amount of the isolated acidic fraction of mastic gum of the present invention in any unit dosage form comprises a therapeutically effective amount which may vary depending on the recipient subject, route and frequency of administration.
The amount of the isolated acidic fraction of mastic gum present in the pharmaceutical composition may be in the range from about 0.01% to about 99%.
In general, the amount of the isolated acidic fraction of mastic gum present in the pharmaceutical composition may conveniently be in the range from about 0.01%
to about 50%, such as, 0.01% to about 25%, such as 0.01% to about 12%, on a weight per weight basis, based on the total weight of the composition. For topical use, the percentage of the isolated acidic fraction of mastic gum in the composition may be in the range from about 0.05% to about 2.5%. For administration by injection, the percentage of the isolated acidic fraction of mastic gum in the composition may be conveniently in the range from about 0.1% to about 7%.
In some embodiments, the triterpenoic acids may comprise from about 1% to about 80% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise up to 99% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 10%
to about 80% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 20% to about 80% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 30% to about 70% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 35% to about 65%
of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 40% to about 60% of the total active ingredients of the composition.
In some embodiments, the triterpenoic acids may comprise from about 0.01% to about 80% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.01% to about 50% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.01% to about 10% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.1%
to about 10% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.5% to about 4% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.1% to about 0.5% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.1%
to about 1.0% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.1% to about 2% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 1% to about 3.5% of the total composition.
In some embodiments, the triterpenoic acids may comprise from about 1.5% to about 3%
of the total composition. In some embodiments, the triterpenoic acids may comprise from about 1.75% to about 2.75% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 2% to about 2.5% of the total composition.
In some embodiments, the combination of triterpenoic acids may include as the main compounds one or more of: Moronic acid, Oleanonic acid, 24-Z-Masticadienonic acid, 24-Z-Isomasticadienonic acid, 24-Z-3-beta-OAc-masticadienolic acid, and/or 24-Z-3-beta-OAc-isomasticadienolic acid. Each possibility is a separate embodiment.
In some embodiments, the combination of triterpenoic acids may include as the main compounds: Moronic acid (12-15%), Oleanonic acid (18-20%), 24-Z-Masticadienonic acid (20-22%), 24-Z-Isomasticadienonic acid (22-26%), 24-Z-3-beta-OAc-masticadienolic acid (4-7%), and/or 24-Z-3-beta-OAc-isomasticadienolic acid (4-7%). Each possibility is a separate embodiment.
In some embodiments, these combinations of triterpenoic acids may further include (in addition to the main compounds) additional other triterpenoic acids in small amounts, typically less than 5%. Such additional possible other triterpenoic acids may be selected from one or more of: MLA: 3-beta-masticadienolic acid , IMLA: 3-beta-isomastic adienolic acid, 3 -b eta- OAc-epimastic adie nolic acid, 3 -beta- OAc-epi-isomasticadienolic acid, Epimasticadienolic acid (3-alpha-masticadienolic acid), Epi-isomasticadienolic acid (3-alpha-isomasticadienolic acid), Dihydromasticadienonic acid and/or Dihydroisomasticadienonic acid. Each possibility is a separate embodiment.
In some embodiments, the triterpenoic acids in an isolated acidic fraction of mastic gum may include as the main compounds one or more of: Moronic acid, Oleanonic acid, 24-Z-Masticadienonic acid, 24-Z-Isomasticadienonic acid, 24-Z-3-beta-OAc-masticadienolic acid, and/or 24-Z-3-beta-OAc-isomasticadienolic acid. Each possibility is a separate embodiment.
In some embodiments, the triterpenoic acids in an isolated acidic fraction of mastic gum may include as the main compounds: Moronic acid (12-15%), Oleanonic acid (18-20%), 24-Z-Masticadienonic acid (20-22%), 24-Z-Isomasticadienonic acid (22-26%), 24-Z-3 -b eta- OAc-masticadieno lic acid (4-7%), and/or 24 -Z-3 -b eta- OAc-isomasticadienolic acid (4-7%). Each possibility is a separate embodiment.
In some embodiments, these triterpenoic acids in an isolated acidic fraction of mastic gum may further include (in addition to the main compounds) additional other triterpenoic acids in small amounts, typically less than 5%. Such additional possible other triterpenoic acids may be selected from one or more of: MLA: 3-beta-masticadienolic acid , IMLA: 3-beta-isomasticadienolic acid, 3-beta-OAc-epimasticadienolic acid, 3-beta-OAc-epi-isomasticadienolic acid, Epimasticadienolic acid (3-alpha-masticadienolic acid), Epi-isomasticadienolic acid (3-alpha-isomasticadienolic acid), Dihydromasticadienonic acid and/or Dihydroisomasticadienonic acid. Each possibility is a separate embodiment.
In some embodiments, the amount of masticadienonic acid and isomasticadienonic acid in compositions consisting of these two compounds as the active ingredients may be in the range of about 0.05% to about 45% for each compound. In exemplary embodiments, the amounts of masticadienonic acid and isomasticadienonic acid in compositions consisting of these two compounds as the active ingredients may be in the range of about 0.05% to about 20% for each compound. For administration by injection, the amount for each may be in the range from about 0.1% to about 10%. For topical administration, the amount for each may be in the range from about 0.5% to about 12%. For oral administration, the amount for each may be in the range from about 0.5% to about 15%.
In some embodiments, the amount of oleanonic acid, masticadienonic acid and isomasticadienonic acid in compositions consisting of these three compounds as the active ingredients may be in the range of about 0.05% to about 30% for each compound.
In exemplary embodiments, the amount of oleanonic acid, masticadienonic acid and isomasticadienonic acid in compositions consisting of these three compounds as the active ingredients may be in the range of about 0.05% to about 15% for each compound.
For administration by injection, the amount for each may be in the range from about 0.1% to about 10%. For topical administration, the amount for each may be in the range from about 0.5% to about 12%. For oral administration, the amount for each may be in the range from about 0.5% to about 15%.
The pharmaceutical compositions of the invention may be manufactured in a manner which is itself known to one skilled in the art, for example, by means of conventional mixing, granulating, dragee-making, softgel encapsulation, dissolving, extracting, or lyophilizing processes. Pharmaceutical compositions for oral use may be obtained by combining the active compounds with solid and semi-solid excipients and suitable preservatives, and/or antioxidants. Optionally, the resulting mixture may be ground and processed. The resulting mixture of granules may be used, after adding suitable auxiliaries, if necessary, to obtain tablets, softgels, capsules, or dragee cores.
Suitable excipients are, in particular, fillers such as saccharides, e.g., lactose or sucrose, mannitol or sorbitol; cellulose preparations and/or calcium phosphates, e.g., tricalcium phosphate or calcium hydrogen phosphate; as well as binders, such as starch paste, using, e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are flow-regulating agents and lubricants, e.g., silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain .. gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate, are used.
Dye stuffs or pigments may be added to the tablets or dragee coatings, e.g., for identification or in order to characterize combinations of active compound doses.
Formulations for parenteral administration include suspensions and microparticle dispersions of the active compounds as appropriate. In some embodiments, oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, e.g., sesame oil, or synthetic fatty acid esters, e.g., ethyl oleate, triglycerides, .. polyethylene glycol-400, cremophor, or cyclodextrins. Injection suspensions may contain substances which increase the viscosity of the suspension include, e.g., sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.
Pharmaceutical compositions can also be prepared using liposomes comprising the active ingredient. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals which are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming liposomes can be used. In general, the preferred lipids are phospholipids and the phosphatidyl cholines .. (lecithins), both natural and synthetic. Methods to form liposomes are known in the art, as disclosed for example, in Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976).
The pharmaceutical composition may comprise an oil-in-water emulsion or microemulsion in order to facilitate its formulation for parenteral use Such emulsions/microemulsions generally include lipids, surfactants, optionally humectants, and water. Suitable lipids include those generally known to be useful for creating oil-in-water emulsions/microemulsions, for example fatty acid glyceride esters.
Suitable surfactants include those generally known to be useful for creating oil-in-water emulsions/microemulsions wherein lipids are used as the oil component in the emulsion.
Non-ionic surfactants may be preferred, such as for example, ethoxylated castor oil, phospholipids, and block copolymers of ethylene oxide and propylene oxide.
Suitable humectants, if used, include for example propylene glycol or polyethylene glycol.
The pharmaceutical composition may be formulated in the form of a gel, such as a hydrogel formed from a gel-forming polymer such as carrageenan, xanthan gum, gum karaya, gum acacia, locust bean gum, guar gum. A hydrogel may be combined with an oil-in-water emulsion comprising the active ingredient.
The pharmaceutical composition may be formulated in the form of a cement such as those comprising polymethylmetacrylate (PMMA) or calcium phosphate, as are used in orthopedic surgery.
The pharmaceutical composition may be formulated in the form of a powder.
According to some embodiments, there are provided therapeutic uses and methods of treating optic neuropathy. The methods comprise administering to the subject a therapeutically effective amount of a composition comprising an isolated acidic fraction of mastic gum, or combination of isolated acidic compounds, as described herein.
In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of a composition comprising an isolated acidic fraction of mastic gum, as described herein. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a combination of at least two triterpenoic acids selected from: masticadienonic acid;
isomasticadienonic acid; isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid, and moronic acid. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a combination of at least two triterpenoic acids selected from:
masticadienonic acid; isomasticadienonic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-isomasticadienolic acid; oleanonic acid; and moronic acid. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a combination of at least two triterpenoic acids selected from:
masticadienonic acid; isomasticadienonic acid; masticadienolic acid;
isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-isomasticadienolic acid;
oleanonic acid;
and moronic acid. In further embodiments, the method comprise administering to the subject a therapeutically effective amount of a composition comprising a combination of at least two triterpenoic acids selected from masticadienonic acid;
isomasticadienonic acid and oleanonic acid. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising triterpenoic acids consisting of masticadienonic acid and isomasticadienonic acid. In further exemplary embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising triterpenoic acids consisting of oleanonic acid, masticadienonic acid and isomasticadienonic acid.
In some embodiments, the step of administering the compositions may comprise any acceptable route including parenteral route. Parenteral administration includes, for example, intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intraarterial, intrauterine, intraurethral, intracardial, intracerebral, intracerebroventricular, intrarenal, intrahepatic, intratendon, intraosseous. intraocular and intrathecal routes of administration. Each possibility is a separate embodiment.
In some embodiments, the compositions disclosed herein may be administered by any suitable administration route on any suitable administration regime at any suitable dose, depending on the subject characteristics (including, for example, age, gender, treated condition, severity of the condition, and the like). For example, administration may be performed 1-7 times a week. For example, administration may be performed more than once a day. For example, the compositions may be administered on a twice weekly schedule with even intervals. In some embodiments, the compositions may be administered on a schedule of every second day. In some embodiments, the compositions may be administered on a schedule of once every seventh day (once weekly). In some embodiments, the compositions may be administered once a day.
In some embodiments, the composition may be administered on a twice weekly schedule with even intervals. In some embodiments, the composition may be administered on a schedule of every second day. In some embodiments, the composition may be administered on a schedule of once every seventh day (once weekly). In some embodiments, the composition may be administered once a day.
In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil. In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in stabilized cottonseed oil.
In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in BHT-stabilized cottonseed oil. In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, twice weekly schedule with even intervals. In some embodiments, the composition may be administered as a 5%
(w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, on a once a week schedule with even intervals (every seventh day).
In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, on a once daily schedule with even intervals.
In some embodiments, the composition may be administered in a dose of 0.4 milliliter (ML) of a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids. In some embodiments, the composition may be administered in a dose of 0.2 milliliter (ML) of a 5% (w/w) formulation. In some embodiments, the composition may be administered in a dose of 0.8 milliliter (ML) of a 5% (w/w) formulation. In some embodiments, the composition may be administered in a dose of 0.4 milliliter (ML) as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, twice weekly with even intervals. In some embodiments, the composition may be administered in a dose of 0.2 milliliter (ML) as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, twice weekly with even intervals.
In some embodiments, the composition may be administered in a dose of 0.8 milliliter (ML) as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, twice weekly with even intervals.
It is clear to a person skilled in the art that many variations of the above-indicated administration routes, schedules, doses and regimens can be envisaged and designed. It is to be understood that such variations in administration routes, schedules, doses and regimens are also within the scope of the current invention.
According to some embodiments, the methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve, such as, for example, glaucoma, Traumatic Neuropathy, Ischemic optic neuropathy (such as, for example, NAION
and AION), Glaucoma, Neuropathy caused by tumors, Neuropathy caused by infections, Mitochondrial optic neuropathies, Nutritional optic neuropathies, Radiation optic neuropathy, Toxic optic neuropathy, Retinal diabetic complications, damage caused by deposition disease, and the like, or combinations thereof.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve as a result of a deposition disease, such as, deposition of lipoproteinaceous substances in the optic nerve, deposition of lipofuscin.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with deposition of lipoproteinaceous substances in the optic nerve.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve, wherein the deposition of lipoproteinaceous substances is the result of a storage disease.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve, wherein the deposition of lipoproteinaceous substances is the result of a storage disease, and wherein the deposited lipoproteinaceous substance is lipofuscin.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve as a result of deposition of mineral substances in the optic nerve, wherein the deposition of mineral substances is the result of a storage disease, and wherein the mineral substances deposited in the optic nerve contain calcium and/or iron.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with Glaucoma.
In some embodiments, the uses and methods of treatment disclosed herein are suitable for application in humans and non-human mammals.
According to some embodiments, the methods of the invention may encompass use of an article of manufacture which incorporates the composition comprising isolated acidic fraction of mastic gum, as described herein.
In some embodiments, the pharmaceutical composition may be in the form of a coating on the article of manufacture, or may be contained within a vessel which is integral to the article of manufacture.
In some embodiments, the pharmaceutical composition may be incorporated to a delivery device such as a needle, an injection device or a spray dispenser from which the composition is delivered to a body site requiring the therapy.
In some embodiments, articles of manufacture include, but are not limited to a needle, a microneedle, an injection device and a spray dispenser.
The following examples are presented in order to more fully illustrate certain embodiments of the invention. They should in no way, however, be construed as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.
EXAMPLES
Example 1A: Preparation of the isolated acidic fraction of Mastic Gum.
To a 50 gram amount of mastic gum was added absolute ethanol (800 ML) and the mixture was left to stand for 24 hours. The mixture was shaken for 30 minutes at 150 rpm and left to stand for two hours. The obtained ethanol solution was decanted from insoluble material into a 3L round bottom flask. To the insoluble material was added 400 ML of fresh ethanol and the mixture was shaken again 30 minutes at 150 rpm and was left to stand for 30 minutes. The obtained ethanol solution was decanted and added to the first ethanol solution. This step was repeated once more using 200 ML absolute ethanol. This gave 1.4L of ethanol solution. The ethanol was evaporated using a rotary evaporator, and to the remaining material was added n-hexane (1.2 Liter) and the mixture was shaken at 150 rpm for 4 hours. It was then left to stand for 4 hours and the hexane solution was decanted from insoluble material into a 3L Erlenmeyer. To the remaining insoluble material was added 800 ML fresh hexane and the mixture was shaken for 6 hours at 150 rpm and left to stand for 12 hours. The hexane solution was decanted into the Erlenmeyer flask containing the first 1.2L of hexane solution. The hexane was evaporated in a clean 3L round bottom flask to give about 30 grams of extract. (Yields range typically from 50-70% depending on the age and particle size of the used Mastic gum.) The obtained extracted material was subsequently dissolved in diethyl ether (500 ML) and extracted with a 5% aqueous sodium carbonate solution (4x100 ML), the basic aqueous layer and an oily/emulsion layer were carefully separated from the diethyl ether layer. The diethyl ether layer was then additionally extracted with 0.4 N
aqueous sodium hydroxide (3x100 ML) and the basic aqueous layer and an oily/emulsion layer were again carefully separated from the diethyl ether layer. The two basic aqueous extracts (including oily/emulsion layers) were separately acidified to pH 1-2 by slow addition of 10% aqueous hydrochloric acid and were subsequently extracted with fresh diethyl ether (3x200 ML).
The thus obtained etheral fractions were combined and dried over anhydrous sodium sulfate. After filtering off the sodium sulfate, the diethyl ether was removed using a rotary evaporator. This procedure gave ca. 15 gram of isolated acidic fraction of mastic gum as a white solid, corresponding to about 50% yield based on the intermediate extract obtained after the ethanol/hexane extraction. This particular isolated acidic fraction is termed herein "Acidic Mixture 1" or "Acidic-1".
Based on the starting 50 grams of Mastic gum, the yield for this acidic fraction is about 30%. Typical yields of this particular acidic fraction from mastic gum range from about 25% to about 35%. Without wishing to be bound to any theory or mechanism, these variations in yield can occur due to natural (e.g. seasonal) fluctuations in the composition of the Mastic gum and may also be influenced by age and storage conditions of the Mastic gum.
Example 1B
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using methanol instead of ethanol as the polar solvent.
Hexane was used as the non-polar solvent, and diethyl ether as the solvent for the acid-base extraction step.
Example 1C
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using isopropanol as polar solvent. Hexane was used as the non-polar solvent, and diethyl ether as the solvent for the acid-base extraction step.
Example 1D
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using n-heptane instead of hexane as the non-polar solvent. Ethanol was used as the polar solvent and diethyl ether as the solvent for the acid-base extraction.
Example lE
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using n-heptane instead of hexane as the non-polar solvent. Methanol was used as the polar solvent and diethyl ether as the solvent for the acid-base extraction.
Example 1F
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using hexane as the non-polar solvent. Ethanol was used as the polar solvent and methyl-tert-butyl ether (MTBE) as the solvent for the acid-base extraction.
Example G-Isolated acidic fraction and neutral fraction of mastic gum using ion-exchange resin.
To a 50 gram amount of mastic gum was added absolute ethanol (800 ML) and the mixture was left to stand for 24 hours. The mixture was shaken for 30 minutes at 150 rpm and left to stand for two hours. The obtained ethanol solution was decanted from insoluble material into a 3L round bottom flask. To the insoluble material was added 400 ML of fresh ethanol and the mixture was shaken again 30 minutes at 150 rpm and was left to stand for 30 minutes. The obtained ethanol solution was decanted and added to the first ethanol solution. This step was repeated once more using 200 ML absolute ethanol. This gave 1.4L of ethanol solution. The ethanol was evaporated using a rotary evaporator, and to the remaining material was added n-hexane (1.2 Liter) and the mixture was shaken at 150 rpm for 4 hours. It was then left to stand for 4 hours and the hexane solution was decanted from insoluble material into a 3L Erlenmeyer. To the remaining insoluble material was added 800 ML fresh hexane and the mixture was shaken for 6 hours at 150 rpm and left to stand for 12 hours. The hexane solution was decanted into the Erlenmeyer flask containing the first 1.2L of hexane solution. The hexane was evaporated in a clean 3L round bottom flask to give about 30 grams of extract. (Yields range typically from 50-70% depending on the age and particle size of the used Mastic gum.) The obtained extract was dissolved in ethanol (0.5L) and treated with 100 grams of a .. strongly basic ion-exchange resin (e.g.Dowex-1X8-400; Amberlite IRA 400;
Diaion SA10A) on a shaker. The ion-exchange resin was filtered off and washed with methanol until TLC did not show any significant spots. The resin was then treated with 10%
ethanolic acetic acid solution in order to release the carboxylic acids from the resin. The ethanolic acetic acid mixture was evaporated to yield the isolated carboxylic acid fraction.
Typical yields are around 50% of the starting extract (15 grams). This particular isolated acidic fraction obtained from mastic gum as described hereinabove is termed "Acidic Mixture 3" or "Acidic-3".
For comparison, addition of hexane to the acidic fraction as prepared according to the teaching of W02003/092712 or Parachos et al, (2007), Antimacrobial Agents and Chemotherapy, 51(2), 551, showed that a substantial amount of that acidic fraction was insoluble in hexane.
Example 2. Preparation of different formulations in cottonseed oil Example 2A: A 5% (w/w) composition of an isolated acidic fraction of mastic gum in USP/NF grade cottonseed oil.
To 1 gram of the obtained isolated acidic fraction from Example lA ("Acidic-1") was added 19 grams of cottonseed oil (USP/NF) was added and the mixture was shaken at 150 rpm until a clear and homogeneous composition was obtained (ca.2 hours).
In the same way, cottonseed oil formulations can be prepared from the isolated acidic fractions obtained from Examples 1B-1F.
2B: Cottonseed oil formulations prepared from individual triterpenoic acids.
General procedure: The desired amounts of triterpenoic acids are weighed into a round-bottom flask and the mixture is dissolved in a suitable solvent. Non-limited examples of suitable solvents are diethyl ether, dichloromethane and ethanol.
To this solution is added the desired amount of cottonseed oil. The solvent is evaporated from the obtained mixture, providing the cottonseed oil formulation of triterpenoic acids.
As a specific example, 200 mg each of MDA and IMDA are dissolved in 30 ML
diethyl ether in a 100ML round bottom flask. To the clear solution is added 19.6 grams of cottonseed oil, and the mixture is stirred for a few minutes for homogenization. The diethyl ether is removed from the mixture using a rotary evaporator, providing 20 grams of a formulation of 1% (w/w) each of MDA and IMDA in cottonseed oil. Further traces of diethyl ether may be removed via high-vacuum treatment of the formulation.
Using this general procedure, the formulations (compositions) shown in Table 1 were prepared.
Table 1 - Formulations of triterpenoic acids in cottonseed oil prepared by general procedure of Example 2B
Formulation Cmpd. 1 Cmpd.2 Cmpd.3 Cmpd.4 Cmpd.5 Cmpd.6 1 3 -0Ac-MLA 3 - OAc-IMLA
MDA IMDA OA MA
2 3 -0Ac-MLA 3 -0Ac-epi-MDA IMDA OA MA
IMLA
3 3 - OAc- epi- 3 - OAc-IMLA MDA IMDA OA MA
MLA
4 3 - OAc- epi- 3 -0Ac-epi- MDA IMDA OA MA
MLA IMLA
5 3 -0Ac-MLA 3 -0Ac-epi- MDA IMDA OA
IMLA
6 3-0Ac-epi- 3-0Ac-IMLA MDA IMDA OA
MLA
7 3-0Ac-epi- 3-0Ac-epi- MDA IMDA OA
MLA IMLA
8 3 -0Ac-MLA 3-0Ac-epi- MDA IMDA
IMLA
9 3-0Ac-epi- 3-0Ac-IMLA MDA IMDA
MLA
3-0Ac-epi- 3-0Ac-epi- MDA IMDA
MLA IMLA
The term "about" is directed to include the stated value +/- 10% of the stated value.
In some embodiments, the present invention provides compositions comprising specific combinations of terpenoic acids, such as that found in isolated acidic fractions of mastic gum. In some embodiments, the present invention provides compositions consisting of specific triterpenoic acids compounds, these compositions are shown to have an unexpected synergetic effect compared to the same individual triterpenoic acids compounds in the treatment of optic neuropathy. The triterpenoic acid compounds may be from a plant source, in particular mastic gum, or may be the products of chemical synthesis reactions. In some cases, the compositions may correspond to combinations of compounds, in which some are chemically synthesized and some are derived from plant sources.
In some embodiments, any one of the triterpenoic acids may be the product of a biochemical reaction or a product produced by a microbial organism. In some embodiments, any one of the triterpenoic acids may be the product of a fermentation process. In some embodiments, any one of the triterpenoic acids may be produced by a combination of a chemical synthesis and a biochemical reaction. In some embodiments, any one of the triterpenoic acids may be produced by a combination of a chemical synthesis and a fermentation process. In some embodiments, the any one of triterpenoic acids may be produced by a combination of any of the above-indicated options.
In case of a biochemical reaction or microbial process, the biochemical agent and the microbial agent may be a naturally occurring agent or may be a modified agent not naturally occurring.
Modification of these agents may have been achieved using modern biochemical methods such as for example genetic engineering. Said biochemical agents and microbial agents not occurring naturally may also have been created using synthetic biology methods.
In some embodiments, obtaining from a natural source may include isolating from a natural source. In some embodiments, the isolation from the natural source may include isolation as individual compound(s) or as a group(s) of compounds. In some embodiments, the natural source may include a plant material selected from the group consisting of a resin, a gum, leaves, twigs, roots, flowers, seeds, buds, bark, nuts and roots. Each possibility is a separate embodiment. In some embodiments, the natural source may include a resin extracted from at least one plant. In some embodiments, the natural source may include mastic gum.
In some embodiments, the natural source may include at least one plant. In some embodiments, the plant may be classified in the family Anacardiaceae. In some embodiments, the plant may comprise at least one plant classified in the genus/genera Pistacia and/or Schinus. In some embodiments, Pistacia may include species selected from the group consisting of P. lentiscus, P. atlantica, P. palestina, P. saportae, P. terebinthus, P.
vera P. integerrima, and P. lentiscus L. Each possibility is a separate embodiment. In some embodiments, Pistacia may include the species Pistacia lentiscus L. In some embodiments, Schinus may include the species S. molle. In some embodiments, the Pistacia may include the species Pistacia Lentiscus vat-. Chia. In some embodiments, the Pistacia may include the species Pistacia lentiscus L. var. latifolius Coss. Each possibility is a separate embodiment of the invention.
Plant species useful for obtaining the compositions of the invention include without limitation, those of the genera Pistacia, Pinus, Picea, funiperus, Alsies, Larix, Ocimum, Laurus and Lctvendula.
Useful species of Pistacia include without limitation, P. lentiscus, P.
atlantica, P.
palestina, P. saportae, P. terebinthus, P. vera and P. integerrima. .
The method used for obtaining isolated acidic fractions of mastic gum can be described as follows. By way of a general description, collected plant material, for example mastic gum, is combined in a suitable vessel with a suitable solvent, usually a polar solvent. Suitable polar solvents include for example, alcohols, ethers, esters, amides, aldehydes, ketones, nitriles and combinations thereof.
Particular examples of polar organic solvents are methanol, ethanol, propanol, isopropanol, 1-butanol, 2-butanol, sec-butanol, t-butanol, 1-pentanol, 2-pentanol, 3-pentanol, neopentanol, 3-methyl-1-butanol, 2-methyl-1 -butanol, 3-methy1-2-butanol, 2-methy1-2-butanol, ethyleneglycol, ethyleneglycol monomethyl ether, diethyl ether, methylethyl ether, ethylpropyl ether, methylpropyl ether, 1,2-dimethoxyethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran, methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methylformate, ethylformate, ethyl propionate, methyl propionate, dichloromethane, chloroform, dimethylformamide, acetamide, dimethylacetamide, N-methylpyrrolidone, acetone, ethylmethyl ketone, diethyl ketone, acetonitrile, propionitrile, and combinations thereof.
The mastic gum and the solvent are preferably combined such that the solvent is in large excess, for example 10:1 or 20:1. The mixture may be periodically or continuously agitated over a period ranging from a few minutes to a number of hours. The solvent may be decanted without any treatment, or optionally the mixture may be first subjected to low speed centrifugation, for example at 100 to 2000 rpm, as is known in the art.
The insoluble material is recovered from the extract and a fresh aliquot of solvent is added to the insoluble material, such that the extraction and dissolution process is repeated for a number of cycles, in order to obtain as much as possible of the polar solvent soluble compounds. After the final dissolution step, the extracts containing polar solvent soluble material are combined and the polar solvent is evaporated (for example by using a rotary evaporation as is known in the art), so as to yield polar solvent soluble material, which may be referred to as a crude, or "first step" extract.
The first step extract material is combined with a non-polar organic solvent and extracted by shaking over a period of 1 to 2 hours. Suitable non-polar solvents include acyclic or cyclic, saturated or unsaturated aliphatic hydrocarbons and aromatic hydrocarbons, for example, C5-C10 alkanes, C5-C10 cycloalkanes, C6-C14 aromatic hydrocarbons, and combinations thereof. Each of the foregoing may be optionally substituted by one or more halogens, for example, C7-C14 perfluoroalkanes.
Particular examples of non-polar organic solvents are pentanes, hexanes, heptanes, octanes, nonanes, decanes, cyclopentane, cyclohexane, cycloheptane, benzene, toluene, xylene, and isomers and mixtures thereof. Material remaining insoluble or precipitating in the presence of the non-polar solvent is removed and discarded. The non-polar solvent-soluble fraction is then obtained by evaporating the non-polar solvent (for example by rotary evaporation). This fraction may be referred to as purified or "two step" extract, corresponding to an isolated fraction of mastic gum which is characterized by the fact that it is soluble in both a polar solvent and a non-polar solvent, while materials which are soluble in the polar solvent but insoluble in the non-polar solvent, have been removed.
The second step extract material is subsequently dissolved in an organic solvent and this solution is extracted repeatedly (e.g. four times) with a basic aqueous solution. A
second extraction with a different basic aqueous solution may be performed.
The basic fraction thus obtained is acidified with a dilute aqueous acid solution to acidic pH. The acidified aqueous solution is extracted several times with an organic solvent.
The thus obtained combined organic solvent extracts (also referred to as "three step extract") are treated with a drying agent. This isolated acidic fraction of mastic gum is then obtained by evaporating the organic solvent (for example by rotary evaporation). This fraction is referred to as the isolated acidic fraction of mastic gum. Additional intermediate steps of drying and/or solvent removal may be carried out between other steps, as is known in the art. Alternately, the second step extract material may be combined with a basic ion exchange resin e.g. Amberlyst A26. The isolated ion-exchange resin is treated with an non-aqueous acidic solution in order to liberate the acidic fraction from the resin. The isolated acidic fraction is then obtained by evaporating the non-aqueous solvent and any .. excess acid.
The feature that distinguishes the isolated acidic fractions of the invention over prior art extracts of mastic gum is that certain acidic compounds have been removed in the first two steps of the procedure which would otherwise end up in the final acidic fraction.
According to the teachings of the present invention, the acidic compounds removed during the first two steps of the isolation procedure have a detrimental effect on the beneficial biological activities of the isolated acidic fractions disclosed herein.
The three step extract may be dried further, for example by high vacuum treatment (for example <0.01 mbar for up to several days) to remove residual solvent and other volatile material, weighed and combined with a non-polar organic solvent or other carrier to effect its dissolution.
In some embodiments, the isolated fraction of the invention may be obtained by a process comprising one or more of the steps of:
(a) treating mastic gum with a polar organic solvent;
(b) isolating a fraction soluble in said polar organic solvent;
(c) optionally removing said polar organic solvent;
(d) treating the soluble fraction obtained in step (b) or (c) with a non-polar organic solvent, (e) isolating a fraction soluble in said non-polar organic solvent;
(f) optionally removing said non-polar organic solvent;
(g) dissolving the fraction obtained in step (f) in an organic solvent;
(h) treating the solution obtained in step (g) with a basic solution so as to obtain a basic fraction; and (i) acidifying the basic fraction obtained in step (h) with an acid solution.
In some embodiments, the treatment with a basic solution (basifying) in step (h) comprises extracting the solution obtained in step (g) with one or more suitable basic aqueous solution; or contacting the solution obtained in step (g) with a basic ion exchange resin. In case of a basic ion exchange resin, the resin may subsequently be treated with an acidic solution in order to release the captured acidic fraction. The isolated acidic fraction is than obtained by removal of any volatiles using, for example, application of vacuum.
In some embodiments, step (h) comprises contacting the solution obtained in step (g) with a basic ion exchange resin, and thereafter removing the basic ion exchange resin by filtration. The basic ion exchange resin may be subsequently treated with an acidic solution in order to liberate the captured acidic fraction. The isolated acidic fraction is than obtained by removal of any volatiles using e.g. application of vacuum.
In some embodiments, the process further comprises the steps of (j) extracting the acidified fraction obtained in step (i) with an organic solvent;
k) optionally contacting the organic fraction obtained in step (j) with a drying agent so as to remove remaining water;
(1) removing organic solvent and/or excess acid from the fraction obtained in any of steps (i), (j) or (k); and (m) dissolving the isolated fraction obtained in step (1) in a carrier.
The process may further comprise removing the solvent after any of steps (c), (f) or (1). Solvent removal may be carried out by any means known in the art, for example rotary evaporation, application of high vacuum and a combination thereof. In some embodiments, steps (a) to (c) are carried out prior to steps (d) to (f) or vice versa. In some embodiments, the polar organic solvent comprises ethanol, the non-polar organic solvent comprises hexane and the organic solvent used for the acid-base extraction comprises diethyl ether. As is readily understood by one of skill in the art, steps (a) to (c) and steps (d) to (f) may each be independently canied out for a number of cycles to optimize the extraction process and degree of purification of the product.
In some embodiments, step (h) comprises extracting the solution obtained in step (g) with a basic aqueous solution, and collecting the organic fraction obtained therefrom. In some embodiments, the process may further comprise combining the organic fraction obtained from step (h) with a fraction obtained in any of steps (i), (j) or (k).
In some embodiments, the organic fraction obtained in step (h) is combined with a fraction obtained in any of steps (i), (j) or (k) in an amount in the range from about 0.1 to 50% of the organic fraction obtained from step (h). In some embodiments, the amount is in the range from about 0.5-50%; or 2 to 25%; or 0.1 to 10%.
The isolated acidic fraction may comprise at least one terpenoic acid, such as a combination of various triterpenoic acid combinations. Triterpenoic acids include for example, masticadienonic acid; isomasticadienonic acid; isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epi-masticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid;
masticadienolic acid, oleanonic acid; oleanolic acid; ursonic acid; ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
The isolated acidic fraction may comprise at least one terpenoic acid, such as a combination of various triterpenoic acid combinations. Triterpenoic acids include for example, masticadienonic acid; isomasticadienonic acid; masticadienolic acid;
isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epi-masticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid;
oleanonic acid; oleanolic acid; ursonic acid; ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, for example, masticadienonic acid;
isomasticadienonic acid; masticadienolic acid; isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid; oleanolic acid;
ursonic acid;
ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, for example, masticadienonic acid;
isomasticadienonic acid; isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid; oleanolic acid; ursonic acid; ursolic acid; moronic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, for example, masticadienonic acid;
isomasticadienonic acid; masticadienolic acid, isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid; oleanolic acid;
ursonic acid;
ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, for example, masticadienonic acid;
isomasticadienonic acid; masticadienolic acid, isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid; oleanolic acid;
ursonic acid;
ursolic acid; moronic acid.
In some embodiments, the isolated acidic fraction may comprise at least three terpenoic acid compounds, selected from, masticadienonic acid;
isomasticadienonic acid;
isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid;
oleanonic acid; oleanolic acid; ursonic acid; ursolic acid; moronic acid; and 3-oxo-lup-20(29)-en-28-oic acid.
In some embodiments, the isolated acidic fraction may comprise at least two terpenoic acid compounds, selected from, masticadienonic acid, isomasticadienonic acid, and oleanonic acid.
In some embodiments, the isolated acidic fraction may be substantially devoid of particular triterpenoic acids, such as, for example, masticadienolic acid or moronic acid.
Each possibility is a separate embodiment.
In some embodiments, the isolated acidic fraction may be substantially devoid of essential oils.
Furthermore, terpenoic acid and or triterpenoic acids in the isolated acidic fraction may be in monomeric form, or in an oligomeric form, such as a dimer, a trimer, or combinations thereof.
The composition for use in the invention comprises a therapeutically effective amount of an isolated acidic fraction of mastic gum described herein, and a pharmaceutically acceptable hydrophobic carrier.
The invention also provides a composition comprising at least one triterpenoic acid;
and a pharmaceutically acceptable carrier. The triterpenoic acid may be isolated from a plant product, such as mastic gum, as hereinbefore described, or it may be the product of a chemical synthesis. Furthermore, the composition may comprise a combination of triterpenoic acids, some of which are chemically synthesized, and some of which are isolated from one or more plant products. In some embodiments, the composition may .. consist of at least two triterpenoic acids compounds as the pharmaceutically active ingredients, and a pharmaceutically acceptable carrier. In addition, the composition may comprise dimeric, trimeric and higher oligomeric forms of triterpenoic acids;
the oligomers can be formed from both identical and different monomeric triterpenoic acids.
In some embodiments, the composition may consist of at least three triterpenoic acids .. compounds as the pharmaceutically active ingredients, and a pharmaceutically acceptable carrier.
For preparation of a composition for therapeutic use, suitable carriers may be used, such as hydrophobic carriers including pharmaceutically acceptable oils, optionally in combination with waxes, as described herein.
An hydrophobic carrier comprises at least one oil, such as for example a mineral oil, a vegetable oil or combinations thereof.
The term "mineral oil" refers to a clear colorless nearly odorless and tasteless liquid obtained from the distillation of petroleum. It may also be referred to as white oil, white mineral oil, liquid petrolatum, liquid paraffin or white paraffin oil. In accordance with some embodiments of the invention, the mineral oil is light mineral oil, a commercially available product which may be obtained either as a NF (National Formulary) grade product or as a USP (US Pharmacopoeia) grade product. For use in the invention, the mineral oil is preferably free of aromatics and unsaturated compounds.
Suitable vegetable oils include, but are not limited to cottonseed oil, olive oil, almond oil, canola oil, coconut oil, corn oil, grape seed oil, peanut oil, saffron oil, sesame oil, soybean oil, or combinations thereof. In some embodiments, the mineral oil is light mineral oil.
The pharmaceutically acceptable carrier may alternately or in addition comprise an oil replacement. Oil replacements include alkanes having at least 10 carbon (e.g., isohexadecane), benzoate esters, aliphatic esters, noncomodogenic esters, volatile silicone compounds (e.g., cyclomethicone), and volatile silicone substitutes. Examples of benzoate esters include C12C15 alkyl benzoate, isostearyl benzoate, 2-ethyl hexyl benzoate, dipropylene glycol benzoate, octyldodecyl benzoate, stearyl benzoate, and behenyl benzoate. Examples of aliphatic esters include C12C15 alkyl octonoate and dioctyl maleate.
Examples of noncomodogenic esters include isononyl isononanoate, isodecyl isononanoate, dilsostearyl dimer dilinoleate, arachidyl propionate, and isotridecyl isononanoate. Examples of volatile silicone substitutes include isohexyl decanoate, octyl isononanoate, isononyl octanoate, and diethylene glycol dioctanoate.
Cyclomethicone is an evaporative silicone which may be included in the carrier to assist in making the composition amenable to ejection from a spray dispenser.
Furthermore, due to its evaporative property, cyclomethicone may assist in retaining and fixing the formulation on the surface to which it is sprayed e.g. a wound site.
The hydrophobic carrier may further comprise at least one wax. Waxes include for example, beeswax; vegetable waxes, sugar cane waxes, mineral waxes, and synthetic waxes. Vegetable waxes include for example, carnauba, candelilla, ouricury and jojoba wax. Mineral waxes include for example, paraffin wax, lignite wax, microcrystalline waxes and ozokerites. Synthetic waxes include for example, polyethylene waxes.
The pharmaceutical composition may be formulated in any of a number of forms such as for example, a capsule (including a softgel capsule), a tablet, a gel, a liposome, a suppository, a suspension, an ointment, a solution, an emulsion or microemulsion, a film, a cement, a powder, a glue, an aerosol, a spray and a gel.
For preparing the pharmaceutical composition, the isolated acidic fraction of mastic gum may be suitably formulated as inclusion complexes, nanoemulsions, microemulsions, powders and liposomes. In some embodiments, an inclusion complex comprises at least one cyclodextrin. In some embodiments, cyclodextrins comprise hydroxypropy1-13-cyclodextrin. In some embodiments, nanoemulsions comprise droplets having average particle size of less than 800 nm. In some embodiments, the droplets have average particle size of less than 500 nm. In some embodiments, the droplets have average particle size of less than 200 nm. In some embodiments, powders are spray dried powders. In some embodiments, liposomes comprise multilamellar vesicles. In some embodiments, a microemulsion comprises a non-ionic surfactant. Non-ionic surfactants include, without limitation, polyoxyl castor oils, polyoxyethylene sorbitan fatty acid esters (polysorbates), a poloxamer, a vitamin E derivative, polyoxyethylene alkyl ethers, polyoxyethylene sterates, saturated polyglycolyzed glycerides or combinations thereof.
According to some embodiments, various formulations of isolated acidic fraction and preparation thereof are disclosed herein in Example 1. The pharmaceutical compositions of the invention may be administered by any means that achieve their intended purpose. In some embodiments, administration is by parenteral route.
In some embodiments, administration is a parenteral, localized administration. In some embodiments, parenteral administration may be selected from, but not limited to:
intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intraarterial, intrauterine, intraurethral, intracardial, intracerebral, intracerebroventricular, intrarenal, intrahepatic, intratendon, intraosseous, intraocular, and intrathecal routes of administration.
The dosage administered will be dependent upon the age, health, and weight of the subject, the use of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. The amount of the isolated acidic fraction of mastic gum of the present invention in any unit dosage form comprises a therapeutically effective amount which may vary depending on the recipient subject, route and frequency of administration.
The amount of the isolated acidic fraction of mastic gum present in the pharmaceutical composition may be in the range from about 0.01% to about 99%.
In general, the amount of the isolated acidic fraction of mastic gum present in the pharmaceutical composition may conveniently be in the range from about 0.01%
to about 50%, such as, 0.01% to about 25%, such as 0.01% to about 12%, on a weight per weight basis, based on the total weight of the composition. For topical use, the percentage of the isolated acidic fraction of mastic gum in the composition may be in the range from about 0.05% to about 2.5%. For administration by injection, the percentage of the isolated acidic fraction of mastic gum in the composition may be conveniently in the range from about 0.1% to about 7%.
In some embodiments, the triterpenoic acids may comprise from about 1% to about 80% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise up to 99% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 10%
to about 80% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 20% to about 80% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 30% to about 70% of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 35% to about 65%
of the total active ingredients of the composition. In some embodiments, the triterpenoic acids may comprise from about 40% to about 60% of the total active ingredients of the composition.
In some embodiments, the triterpenoic acids may comprise from about 0.01% to about 80% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.01% to about 50% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.01% to about 10% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.1%
to about 10% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.5% to about 4% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.1% to about 0.5% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.1%
to about 1.0% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 0.1% to about 2% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 1% to about 3.5% of the total composition.
In some embodiments, the triterpenoic acids may comprise from about 1.5% to about 3%
of the total composition. In some embodiments, the triterpenoic acids may comprise from about 1.75% to about 2.75% of the total composition. In some embodiments, the triterpenoic acids may comprise from about 2% to about 2.5% of the total composition.
In some embodiments, the combination of triterpenoic acids may include as the main compounds one or more of: Moronic acid, Oleanonic acid, 24-Z-Masticadienonic acid, 24-Z-Isomasticadienonic acid, 24-Z-3-beta-OAc-masticadienolic acid, and/or 24-Z-3-beta-OAc-isomasticadienolic acid. Each possibility is a separate embodiment.
In some embodiments, the combination of triterpenoic acids may include as the main compounds: Moronic acid (12-15%), Oleanonic acid (18-20%), 24-Z-Masticadienonic acid (20-22%), 24-Z-Isomasticadienonic acid (22-26%), 24-Z-3-beta-OAc-masticadienolic acid (4-7%), and/or 24-Z-3-beta-OAc-isomasticadienolic acid (4-7%). Each possibility is a separate embodiment.
In some embodiments, these combinations of triterpenoic acids may further include (in addition to the main compounds) additional other triterpenoic acids in small amounts, typically less than 5%. Such additional possible other triterpenoic acids may be selected from one or more of: MLA: 3-beta-masticadienolic acid , IMLA: 3-beta-isomastic adienolic acid, 3 -b eta- OAc-epimastic adie nolic acid, 3 -beta- OAc-epi-isomasticadienolic acid, Epimasticadienolic acid (3-alpha-masticadienolic acid), Epi-isomasticadienolic acid (3-alpha-isomasticadienolic acid), Dihydromasticadienonic acid and/or Dihydroisomasticadienonic acid. Each possibility is a separate embodiment.
In some embodiments, the triterpenoic acids in an isolated acidic fraction of mastic gum may include as the main compounds one or more of: Moronic acid, Oleanonic acid, 24-Z-Masticadienonic acid, 24-Z-Isomasticadienonic acid, 24-Z-3-beta-OAc-masticadienolic acid, and/or 24-Z-3-beta-OAc-isomasticadienolic acid. Each possibility is a separate embodiment.
In some embodiments, the triterpenoic acids in an isolated acidic fraction of mastic gum may include as the main compounds: Moronic acid (12-15%), Oleanonic acid (18-20%), 24-Z-Masticadienonic acid (20-22%), 24-Z-Isomasticadienonic acid (22-26%), 24-Z-3 -b eta- OAc-masticadieno lic acid (4-7%), and/or 24 -Z-3 -b eta- OAc-isomasticadienolic acid (4-7%). Each possibility is a separate embodiment.
In some embodiments, these triterpenoic acids in an isolated acidic fraction of mastic gum may further include (in addition to the main compounds) additional other triterpenoic acids in small amounts, typically less than 5%. Such additional possible other triterpenoic acids may be selected from one or more of: MLA: 3-beta-masticadienolic acid , IMLA: 3-beta-isomasticadienolic acid, 3-beta-OAc-epimasticadienolic acid, 3-beta-OAc-epi-isomasticadienolic acid, Epimasticadienolic acid (3-alpha-masticadienolic acid), Epi-isomasticadienolic acid (3-alpha-isomasticadienolic acid), Dihydromasticadienonic acid and/or Dihydroisomasticadienonic acid. Each possibility is a separate embodiment.
In some embodiments, the amount of masticadienonic acid and isomasticadienonic acid in compositions consisting of these two compounds as the active ingredients may be in the range of about 0.05% to about 45% for each compound. In exemplary embodiments, the amounts of masticadienonic acid and isomasticadienonic acid in compositions consisting of these two compounds as the active ingredients may be in the range of about 0.05% to about 20% for each compound. For administration by injection, the amount for each may be in the range from about 0.1% to about 10%. For topical administration, the amount for each may be in the range from about 0.5% to about 12%. For oral administration, the amount for each may be in the range from about 0.5% to about 15%.
In some embodiments, the amount of oleanonic acid, masticadienonic acid and isomasticadienonic acid in compositions consisting of these three compounds as the active ingredients may be in the range of about 0.05% to about 30% for each compound.
In exemplary embodiments, the amount of oleanonic acid, masticadienonic acid and isomasticadienonic acid in compositions consisting of these three compounds as the active ingredients may be in the range of about 0.05% to about 15% for each compound.
For administration by injection, the amount for each may be in the range from about 0.1% to about 10%. For topical administration, the amount for each may be in the range from about 0.5% to about 12%. For oral administration, the amount for each may be in the range from about 0.5% to about 15%.
The pharmaceutical compositions of the invention may be manufactured in a manner which is itself known to one skilled in the art, for example, by means of conventional mixing, granulating, dragee-making, softgel encapsulation, dissolving, extracting, or lyophilizing processes. Pharmaceutical compositions for oral use may be obtained by combining the active compounds with solid and semi-solid excipients and suitable preservatives, and/or antioxidants. Optionally, the resulting mixture may be ground and processed. The resulting mixture of granules may be used, after adding suitable auxiliaries, if necessary, to obtain tablets, softgels, capsules, or dragee cores.
Suitable excipients are, in particular, fillers such as saccharides, e.g., lactose or sucrose, mannitol or sorbitol; cellulose preparations and/or calcium phosphates, e.g., tricalcium phosphate or calcium hydrogen phosphate; as well as binders, such as starch paste, using, e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are flow-regulating agents and lubricants, e.g., silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain .. gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate, are used.
Dye stuffs or pigments may be added to the tablets or dragee coatings, e.g., for identification or in order to characterize combinations of active compound doses.
Formulations for parenteral administration include suspensions and microparticle dispersions of the active compounds as appropriate. In some embodiments, oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, e.g., sesame oil, or synthetic fatty acid esters, e.g., ethyl oleate, triglycerides, .. polyethylene glycol-400, cremophor, or cyclodextrins. Injection suspensions may contain substances which increase the viscosity of the suspension include, e.g., sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.
Pharmaceutical compositions can also be prepared using liposomes comprising the active ingredient. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals which are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming liposomes can be used. In general, the preferred lipids are phospholipids and the phosphatidyl cholines .. (lecithins), both natural and synthetic. Methods to form liposomes are known in the art, as disclosed for example, in Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976).
The pharmaceutical composition may comprise an oil-in-water emulsion or microemulsion in order to facilitate its formulation for parenteral use Such emulsions/microemulsions generally include lipids, surfactants, optionally humectants, and water. Suitable lipids include those generally known to be useful for creating oil-in-water emulsions/microemulsions, for example fatty acid glyceride esters.
Suitable surfactants include those generally known to be useful for creating oil-in-water emulsions/microemulsions wherein lipids are used as the oil component in the emulsion.
Non-ionic surfactants may be preferred, such as for example, ethoxylated castor oil, phospholipids, and block copolymers of ethylene oxide and propylene oxide.
Suitable humectants, if used, include for example propylene glycol or polyethylene glycol.
The pharmaceutical composition may be formulated in the form of a gel, such as a hydrogel formed from a gel-forming polymer such as carrageenan, xanthan gum, gum karaya, gum acacia, locust bean gum, guar gum. A hydrogel may be combined with an oil-in-water emulsion comprising the active ingredient.
The pharmaceutical composition may be formulated in the form of a cement such as those comprising polymethylmetacrylate (PMMA) or calcium phosphate, as are used in orthopedic surgery.
The pharmaceutical composition may be formulated in the form of a powder.
According to some embodiments, there are provided therapeutic uses and methods of treating optic neuropathy. The methods comprise administering to the subject a therapeutically effective amount of a composition comprising an isolated acidic fraction of mastic gum, or combination of isolated acidic compounds, as described herein.
In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of a composition comprising an isolated acidic fraction of mastic gum, as described herein. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a combination of at least two triterpenoic acids selected from: masticadienonic acid;
isomasticadienonic acid; isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-epimasticadienolic acid; 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid; oleanonic acid, and moronic acid. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a combination of at least two triterpenoic acids selected from:
masticadienonic acid; isomasticadienonic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-isomasticadienolic acid; oleanonic acid; and moronic acid. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a combination of at least two triterpenoic acids selected from:
masticadienonic acid; isomasticadienonic acid; masticadienolic acid;
isomasticadienolic acid; 3-0-acetyl-masticadienolic acid; 3-0-acetyl-isomasticadienolic acid;
oleanonic acid;
and moronic acid. In further embodiments, the method comprise administering to the subject a therapeutically effective amount of a composition comprising a combination of at least two triterpenoic acids selected from masticadienonic acid;
isomasticadienonic acid and oleanonic acid. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising triterpenoic acids consisting of masticadienonic acid and isomasticadienonic acid. In further exemplary embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising triterpenoic acids consisting of oleanonic acid, masticadienonic acid and isomasticadienonic acid.
In some embodiments, the step of administering the compositions may comprise any acceptable route including parenteral route. Parenteral administration includes, for example, intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intraarterial, intrauterine, intraurethral, intracardial, intracerebral, intracerebroventricular, intrarenal, intrahepatic, intratendon, intraosseous. intraocular and intrathecal routes of administration. Each possibility is a separate embodiment.
In some embodiments, the compositions disclosed herein may be administered by any suitable administration route on any suitable administration regime at any suitable dose, depending on the subject characteristics (including, for example, age, gender, treated condition, severity of the condition, and the like). For example, administration may be performed 1-7 times a week. For example, administration may be performed more than once a day. For example, the compositions may be administered on a twice weekly schedule with even intervals. In some embodiments, the compositions may be administered on a schedule of every second day. In some embodiments, the compositions may be administered on a schedule of once every seventh day (once weekly). In some embodiments, the compositions may be administered once a day.
In some embodiments, the composition may be administered on a twice weekly schedule with even intervals. In some embodiments, the composition may be administered on a schedule of every second day. In some embodiments, the composition may be administered on a schedule of once every seventh day (once weekly). In some embodiments, the composition may be administered once a day.
In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil. In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in stabilized cottonseed oil.
In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in BHT-stabilized cottonseed oil. In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, twice weekly schedule with even intervals. In some embodiments, the composition may be administered as a 5%
(w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, on a once a week schedule with even intervals (every seventh day).
In some embodiments, the composition may be administered as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, on a once daily schedule with even intervals.
In some embodiments, the composition may be administered in a dose of 0.4 milliliter (ML) of a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids. In some embodiments, the composition may be administered in a dose of 0.2 milliliter (ML) of a 5% (w/w) formulation. In some embodiments, the composition may be administered in a dose of 0.8 milliliter (ML) of a 5% (w/w) formulation. In some embodiments, the composition may be administered in a dose of 0.4 milliliter (ML) as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, twice weekly with even intervals. In some embodiments, the composition may be administered in a dose of 0.2 milliliter (ML) as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, twice weekly with even intervals.
In some embodiments, the composition may be administered in a dose of 0.8 milliliter (ML) as a 5% (w/w) formulation of the isolated acidic fraction of mastic gum or combinations of triterpenoic acids in cottonseed oil, twice weekly with even intervals.
It is clear to a person skilled in the art that many variations of the above-indicated administration routes, schedules, doses and regimens can be envisaged and designed. It is to be understood that such variations in administration routes, schedules, doses and regimens are also within the scope of the current invention.
According to some embodiments, the methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve, such as, for example, glaucoma, Traumatic Neuropathy, Ischemic optic neuropathy (such as, for example, NAION
and AION), Glaucoma, Neuropathy caused by tumors, Neuropathy caused by infections, Mitochondrial optic neuropathies, Nutritional optic neuropathies, Radiation optic neuropathy, Toxic optic neuropathy, Retinal diabetic complications, damage caused by deposition disease, and the like, or combinations thereof.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve as a result of a deposition disease, such as, deposition of lipoproteinaceous substances in the optic nerve, deposition of lipofuscin.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with deposition of lipoproteinaceous substances in the optic nerve.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve, wherein the deposition of lipoproteinaceous substances is the result of a storage disease.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve as a result of deposition of lipoproteinaceous substances in the optic nerve, wherein the deposition of lipoproteinaceous substances is the result of a storage disease, and wherein the deposited lipoproteinaceous substance is lipofuscin.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with conditions resulting from or associated with damage to the optical nerve as a result of deposition of mineral substances in the optic nerve, wherein the deposition of mineral substances is the result of a storage disease, and wherein the mineral substances deposited in the optic nerve contain calcium and/or iron.
In some embodiments, the uses and methods disclosed herein for treating optic neuropathy are particularly advantageous for subjects afflicted with Glaucoma.
In some embodiments, the uses and methods of treatment disclosed herein are suitable for application in humans and non-human mammals.
According to some embodiments, the methods of the invention may encompass use of an article of manufacture which incorporates the composition comprising isolated acidic fraction of mastic gum, as described herein.
In some embodiments, the pharmaceutical composition may be in the form of a coating on the article of manufacture, or may be contained within a vessel which is integral to the article of manufacture.
In some embodiments, the pharmaceutical composition may be incorporated to a delivery device such as a needle, an injection device or a spray dispenser from which the composition is delivered to a body site requiring the therapy.
In some embodiments, articles of manufacture include, but are not limited to a needle, a microneedle, an injection device and a spray dispenser.
The following examples are presented in order to more fully illustrate certain embodiments of the invention. They should in no way, however, be construed as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.
EXAMPLES
Example 1A: Preparation of the isolated acidic fraction of Mastic Gum.
To a 50 gram amount of mastic gum was added absolute ethanol (800 ML) and the mixture was left to stand for 24 hours. The mixture was shaken for 30 minutes at 150 rpm and left to stand for two hours. The obtained ethanol solution was decanted from insoluble material into a 3L round bottom flask. To the insoluble material was added 400 ML of fresh ethanol and the mixture was shaken again 30 minutes at 150 rpm and was left to stand for 30 minutes. The obtained ethanol solution was decanted and added to the first ethanol solution. This step was repeated once more using 200 ML absolute ethanol. This gave 1.4L of ethanol solution. The ethanol was evaporated using a rotary evaporator, and to the remaining material was added n-hexane (1.2 Liter) and the mixture was shaken at 150 rpm for 4 hours. It was then left to stand for 4 hours and the hexane solution was decanted from insoluble material into a 3L Erlenmeyer. To the remaining insoluble material was added 800 ML fresh hexane and the mixture was shaken for 6 hours at 150 rpm and left to stand for 12 hours. The hexane solution was decanted into the Erlenmeyer flask containing the first 1.2L of hexane solution. The hexane was evaporated in a clean 3L round bottom flask to give about 30 grams of extract. (Yields range typically from 50-70% depending on the age and particle size of the used Mastic gum.) The obtained extracted material was subsequently dissolved in diethyl ether (500 ML) and extracted with a 5% aqueous sodium carbonate solution (4x100 ML), the basic aqueous layer and an oily/emulsion layer were carefully separated from the diethyl ether layer. The diethyl ether layer was then additionally extracted with 0.4 N
aqueous sodium hydroxide (3x100 ML) and the basic aqueous layer and an oily/emulsion layer were again carefully separated from the diethyl ether layer. The two basic aqueous extracts (including oily/emulsion layers) were separately acidified to pH 1-2 by slow addition of 10% aqueous hydrochloric acid and were subsequently extracted with fresh diethyl ether (3x200 ML).
The thus obtained etheral fractions were combined and dried over anhydrous sodium sulfate. After filtering off the sodium sulfate, the diethyl ether was removed using a rotary evaporator. This procedure gave ca. 15 gram of isolated acidic fraction of mastic gum as a white solid, corresponding to about 50% yield based on the intermediate extract obtained after the ethanol/hexane extraction. This particular isolated acidic fraction is termed herein "Acidic Mixture 1" or "Acidic-1".
Based on the starting 50 grams of Mastic gum, the yield for this acidic fraction is about 30%. Typical yields of this particular acidic fraction from mastic gum range from about 25% to about 35%. Without wishing to be bound to any theory or mechanism, these variations in yield can occur due to natural (e.g. seasonal) fluctuations in the composition of the Mastic gum and may also be influenced by age and storage conditions of the Mastic gum.
Example 1B
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using methanol instead of ethanol as the polar solvent.
Hexane was used as the non-polar solvent, and diethyl ether as the solvent for the acid-base extraction step.
Example 1C
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using isopropanol as polar solvent. Hexane was used as the non-polar solvent, and diethyl ether as the solvent for the acid-base extraction step.
Example 1D
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using n-heptane instead of hexane as the non-polar solvent. Ethanol was used as the polar solvent and diethyl ether as the solvent for the acid-base extraction.
Example lE
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using n-heptane instead of hexane as the non-polar solvent. Methanol was used as the polar solvent and diethyl ether as the solvent for the acid-base extraction.
Example 1F
A further isolated acidic fraction of mastic gum was prepared according to the same method as Example 1A, but using hexane as the non-polar solvent. Ethanol was used as the polar solvent and methyl-tert-butyl ether (MTBE) as the solvent for the acid-base extraction.
Example G-Isolated acidic fraction and neutral fraction of mastic gum using ion-exchange resin.
To a 50 gram amount of mastic gum was added absolute ethanol (800 ML) and the mixture was left to stand for 24 hours. The mixture was shaken for 30 minutes at 150 rpm and left to stand for two hours. The obtained ethanol solution was decanted from insoluble material into a 3L round bottom flask. To the insoluble material was added 400 ML of fresh ethanol and the mixture was shaken again 30 minutes at 150 rpm and was left to stand for 30 minutes. The obtained ethanol solution was decanted and added to the first ethanol solution. This step was repeated once more using 200 ML absolute ethanol. This gave 1.4L of ethanol solution. The ethanol was evaporated using a rotary evaporator, and to the remaining material was added n-hexane (1.2 Liter) and the mixture was shaken at 150 rpm for 4 hours. It was then left to stand for 4 hours and the hexane solution was decanted from insoluble material into a 3L Erlenmeyer. To the remaining insoluble material was added 800 ML fresh hexane and the mixture was shaken for 6 hours at 150 rpm and left to stand for 12 hours. The hexane solution was decanted into the Erlenmeyer flask containing the first 1.2L of hexane solution. The hexane was evaporated in a clean 3L round bottom flask to give about 30 grams of extract. (Yields range typically from 50-70% depending on the age and particle size of the used Mastic gum.) The obtained extract was dissolved in ethanol (0.5L) and treated with 100 grams of a .. strongly basic ion-exchange resin (e.g.Dowex-1X8-400; Amberlite IRA 400;
Diaion SA10A) on a shaker. The ion-exchange resin was filtered off and washed with methanol until TLC did not show any significant spots. The resin was then treated with 10%
ethanolic acetic acid solution in order to release the carboxylic acids from the resin. The ethanolic acetic acid mixture was evaporated to yield the isolated carboxylic acid fraction.
Typical yields are around 50% of the starting extract (15 grams). This particular isolated acidic fraction obtained from mastic gum as described hereinabove is termed "Acidic Mixture 3" or "Acidic-3".
For comparison, addition of hexane to the acidic fraction as prepared according to the teaching of W02003/092712 or Parachos et al, (2007), Antimacrobial Agents and Chemotherapy, 51(2), 551, showed that a substantial amount of that acidic fraction was insoluble in hexane.
Example 2. Preparation of different formulations in cottonseed oil Example 2A: A 5% (w/w) composition of an isolated acidic fraction of mastic gum in USP/NF grade cottonseed oil.
To 1 gram of the obtained isolated acidic fraction from Example lA ("Acidic-1") was added 19 grams of cottonseed oil (USP/NF) was added and the mixture was shaken at 150 rpm until a clear and homogeneous composition was obtained (ca.2 hours).
In the same way, cottonseed oil formulations can be prepared from the isolated acidic fractions obtained from Examples 1B-1F.
2B: Cottonseed oil formulations prepared from individual triterpenoic acids.
General procedure: The desired amounts of triterpenoic acids are weighed into a round-bottom flask and the mixture is dissolved in a suitable solvent. Non-limited examples of suitable solvents are diethyl ether, dichloromethane and ethanol.
To this solution is added the desired amount of cottonseed oil. The solvent is evaporated from the obtained mixture, providing the cottonseed oil formulation of triterpenoic acids.
As a specific example, 200 mg each of MDA and IMDA are dissolved in 30 ML
diethyl ether in a 100ML round bottom flask. To the clear solution is added 19.6 grams of cottonseed oil, and the mixture is stirred for a few minutes for homogenization. The diethyl ether is removed from the mixture using a rotary evaporator, providing 20 grams of a formulation of 1% (w/w) each of MDA and IMDA in cottonseed oil. Further traces of diethyl ether may be removed via high-vacuum treatment of the formulation.
Using this general procedure, the formulations (compositions) shown in Table 1 were prepared.
Table 1 - Formulations of triterpenoic acids in cottonseed oil prepared by general procedure of Example 2B
Formulation Cmpd. 1 Cmpd.2 Cmpd.3 Cmpd.4 Cmpd.5 Cmpd.6 1 3 -0Ac-MLA 3 - OAc-IMLA
MDA IMDA OA MA
2 3 -0Ac-MLA 3 -0Ac-epi-MDA IMDA OA MA
IMLA
3 3 - OAc- epi- 3 - OAc-IMLA MDA IMDA OA MA
MLA
4 3 - OAc- epi- 3 -0Ac-epi- MDA IMDA OA MA
MLA IMLA
5 3 -0Ac-MLA 3 -0Ac-epi- MDA IMDA OA
IMLA
6 3-0Ac-epi- 3-0Ac-IMLA MDA IMDA OA
MLA
7 3-0Ac-epi- 3-0Ac-epi- MDA IMDA OA
MLA IMLA
8 3 -0Ac-MLA 3-0Ac-epi- MDA IMDA
IMLA
9 3-0Ac-epi- 3-0Ac-IMLA MDA IMDA
MLA
3-0Ac-epi- 3-0Ac-epi- MDA IMDA
MLA IMLA
11 3 -0Ac-MLA 3-0Ac-epi-IMLA
12 3-0Ac-epi- 3-0Ac-IMLA
MLA
MLA
13 3-0Ac-epi- 3-0Ac-epi-MLA IMLA
14 MDA IMDA OLN MA
MDA IMDA OLN
3 -0Ac-MLA 3-0Ac-epi- IMDA
IMLA
21 3-0Ac-epi- 3-0Ac-IMLA IMDA
MLA
22 3-0Ac-epi- 3-0Ac-epi- IMDA
MLA IMLA
23 3 -0Ac-MLA 3-0Ac-epi- MDA
IMLA
24 3-0Ac-epi- 3-0Ac-IMLA MDA
MLA
3-0Ac-epi- 3-0Ac-epi- MDA
MLA IMLA
It is clear to a person skilled in the art that this procedure can be used to make additional formulations of triterpenoic acids in cottonseed oil. In addition, it is also clear to a person skilled in the art that instead of cottonseed oil other suitable oils and hydrophobic carriers can be used with this procedure to prepare the corresponding formulations of 5 triterpenoic acids.
Example 3A. Isolation and chemical characterization of isolated acidic fraction of mastic gum.
Mastic resin from Pistacia lentiscus L. was extracted according to any of the methods described Examples 1A-1F to obtain the fraction which was analyzed by reversed phase HPLC in order to identify the major constituents. The HPLC analysis is consistent with the presence the isolated fraction of moronic acid and oleanonic acid in the isolated fraction, on the basis of comparison with analytical standards.
In order to isolate and determine the structure of further main constituents of the isolated acidic fraction, a preparative HPLC method was developed. Using this method, six major constituents of the isolated acidic fraction (For example "Acidic-1"
obtained according to Example 1A) were subsequently isolated by preparative HPLC. A
preparative HPLC method was developed on a 30x250 mm preparative column (ACE-121-2530).
Samples of the isolated fraction (ca. 75 mg per run) were injected using a 5ML
loop.
Identified compounds include such compounds as, moronic acid, oleanonic acid, masticadienonic acid, isomasticadienonic acid, 3-0Acetyl-masticadienolic acid, and 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, masticadienolic acid and isomasticadienolic acid.
Further isolation efforts yielded several additional minor constituents (<5%
of isolated fraction), whose presence varied in isolated acidic fraction preparations from different mastic gum batches. The following minor constituent compounds may or may not be present in the isolated acidic fractions:
- MLA: 3-beta-masticadienolic acid - IMLA: 3-beta-isomasticadienolic acid - Epimasticadienolic acid (3-alpha-masticadienolic acid) - Epi-isomasticadienolic acid (3-alpha-isomasticadienolic acid) - Dihydromasticadienonic acid - Dihydroisomasticadienonic acid Example 3B Synthesis of some triterpenoic acids found in the isolated acidic fractions of mastic gum.
Oleanonic acid (OA) Oleanonic acid was obtained in three steps from commercially available oleanolic acid.
Me Ye me ye Me CO2H
Mel, K2CO3 Me CO2Me Dess-Martin 00 el DMF, rt HO
Me overnight HO OO Me Me -Me Me Me Me Ye Me Ye LiOH
Me O. CO2Me H20/THF Me OM) CO2H
OO Me rt, 2 days OO Me 0 . 0 Me -Me Me -Me Oleanolic acid was first converted to the corresponding methyl ester by treatment with methyl iodide and potassium carbonate in dimethylformamide (DMF).
Oxidation of oleanolic acid methyl ester to oleanonic acid methyl ester was performed using Dess-Martin periodane reagent in dichloromethane (DCM). Hydrolysis of oleanonic acid methyl ester with lithium hydroxide in aqueous THF gave upon acidification the desired oleanonic acid.
Masticadienolic acid (MLA) Masticadienonic acid (500 mg) was dissolved in methanol (30ML) and cooled to 0 C. NaBH4 (83 mg; 2.0 eq.) was added and the mixture was stirred overnight at room temperature. After TLC (hexane : ethylacetate) showed full conversion, the reaction mixture cooled to 0 C and quenched by addition of 20 ML cold water. The methanol was evaporated from the mixture, which was then extracted with diethyl ether. The crude product was purified by column chromatography over silica gel (DCM:Me0H=95:5 to 90:10) to give MLA as white solid (400mg; 80%).
Isomasticadienolic acid (IMLA) Isomasticadienonic acid (500 mg) was dissolved in methanol (30ML) and cooled to 0 C. NaBH4 (83 mg; 2.0 eq.) was added and the mixture was stirred overnight at room temperature. After TLC (hexane : ethylacetate) showed full conversion, the reaction mixture cooled to 0 C and quenched by addition of 20 ML cold water. The methanol was evaporated from the mixture, which was then extracted with diethyl ether. The crude product was purified by column chromatography over silica gel (DCM:Me0H=95:5 to 90:10) to give IMLA as white solid (420mg; 82%).
3-0Ac-MLA
MLA (400 mg) was dissolved in anhydrous pyridine (5 ML), and acetic anhydride (160mg; 3.55 eq.) was added in one portion. The mixture was stirred overnight at room temperature and monitored by TLC (hexane/ethylacetate). The reaction mixture was diluted with ethylacetate (15ML) and 1M aqueous HC1 (20ML) and the mixture was stirred vigorously for 1 hour. The layers were separated, the organic layer was dried over MgSO4 and evaporated. The crude product was purified by column chromatography over silicagel (hexane/ethylacetate=10:1 to 9:1) to yield 3-0Ac-MLA as a white solid (220 mg;
55%).
3-0Ac-IMLA
IMLA (400 mg) was dissolved in anhydrous pyridine (5 ML), and acetic anhydride (160mg; 3.55 eq.) was added in one portion. The mixture was stirred overnight at room temperature and monitored by TLC (hexane/ethylacetate). The reaction mixture was diluted with ethylacetate (15ML) and 1M aqueous HC1 (20ML) and the mixture was stirred vigorously for 1 hour. The layers were separated, the organic layer was dried over MgSO4 and evaporated. The crude product was purified by column chromatography over silicagel (hexane/ethylacetate=10:1 to 9:1) to yield 3-0Ac-IMLA as a white solid (190 mg; 47%).
3-0Ac-epi-MLA
MLA (400 mg) was dissolved in anhydrous pyridine (5 ML), and acetic anhydride (160mg; 3.55 eq.) was added in one portion, followed by 4-N,N-dimethylaminopyridine (DMAP; 20 mg). The mixture was stirred overnight at room temperature and monitored by TLC (hexane/ethylacetate). The reaction mixture was diluted with ethylacetate (15ML) and 1M aqueous HC1 (20ML) and the mixture was stirred vigorously for 1 hour.
The layers were separated, the organic layer was dried over MgSO4 and evaporated.
The crude product was purified by column chromatography over silicagel (hexane/ethylacetate=10:1 to 9:1) to yield a mixture of 3-0Ac-MLA and 3-0Ac-epi-MLA as a white solid (330 mg;
%). The isomers were separated using preparative HPLC to provide 3-0Ac-epi-MLA
(120 mg) as a white solid.
3-0Ac-epi-IMLA
IMLA (400 mg) was dissolved in anhydrous pyridine (5 ML), and acetic anhydride (160mg; 3.55 eq.) was added in one portion, followed by 4-N,N-dimethylaminopyridine (DMAP; 20 mg). The mixture was stirred overnight at room temperature and monitored by TLC (hexane/ethylacetate). The reaction mixture was diluted with ethylacetate (15ML) and 1M aqueous HC1 (20ML) and the mixture was stirred vigorously for 1 hour.
The layers were separated, the organic layer was dried over MgSO4 and evaporated.
The crude product was purified by column chromatography over silicagel (hexane/ethylacetate=10:1 to 9:1) to yield a mixture of 3-0Ac-IMLA and 3-0Ac-epi-IMLA as a white solid (310 mg;
%). The isomers were separated using preparative HPLC to provide 3-0Ac-epi-IMLA
(110 mg) as a white solid.
Epi-MLA and epi-IMLA were prepared by hydrolysis of the corresponding acetates with LiOH in aqueous THF. Standard work-up provided the compounds in respective yields of 45% and 53% as white solids.
Dihydromasticadienonic acid and dihydroisomasticadienonic acid can be prepared according to D .Barton, E. Seoane. J.Chem.Soc. 1956, 4150; and E. Seoane ibid.
4158.
Example 4 - Effect of using isolated acidic fractions and/or specific triterpenoois compounds of the isolated acidic fraction compositions of the invention on Retinal Ganglion Cells (RGC) upon optic nerve axotomy.
Axotomy of the optic nerve is performed on the right eye of deeply anesthetized rats (19 rats per group). The test groups receive a sub-dermal injection in the posterior neck area of various tested compositions (0.025ml/injection), and the control group is similarly injected with the same volume of vehicle. The first injection is given to all the animals directly after surgery. Subsequent injections (same dosage and method of administration) are administered twice a week, every 3 to 4 days.
Fourteen days after axotomy, a fluorescent retrograde neurotracer (Di-Asp) is inserted into the axotomized optic nerve in order to stain surviving Retinal Ganglion Cells (RGC), and 24 hours later, the rats are sacrificed in a CO2 saturated chamber and the injured right eye is enucleated. The retinas are isolated, and flattened on a slide and fixed with xylene based mounting medium.
Whole-mount retinas are evaluated with a fluorescent microscope. Dyed cells are counted manually.
Compositions used include:
- Isolated acidic fraction of mastic gum (for example "Acidic-1" from Example lA
and its corresponding cottonseed oil formulation prepared according to Example 2A), - The following compounds and combinations, prepared according to Example 2B, are tested:
OA: Oleanonic acid MDA: Masticadienonic acid IMDA: Isomasticadienonic acid The following formulations were used for injection:
- Vehicle: cottonseed oil - IMDA: 1% (w/w) in cottonseed oil - MDA: 1% (w/w) in cottonseed oil - IMDA and MDA: each 1% (w/w) in cottonseed oil - IMDA, MDA and OA: each 1% % (w/w) in cottonseed oil Example 5 - Retinal Detachment (RD) model ¨ effect of using isolated acidic fractions and/or specific triterpenoids compounds of the isolated acidic fraction compositions of the invention.
Retinal detachment (RD) is performed on the right eye of deeply anesthetized animals (xylazine 50mg/kg and ketamine 35mg/kg) following dilatation of the pupil with Tropicamide drops 0.5%. RD is induced through the generation of a small opening in the retina at the ora serata followed by a sub-retinal injection of 5 1 saline with a 30G syringe needle. Approximately half of the retinal area is detached by this procedure.
Rats with RD are divided into six experimental groups, five test groups receiving a sub-dermal injection in the posterior neck area of pharmaceutical compositions as disclosed in Example 4, and the control group injected is administered with the same volume of vehicle. The first injection is given to all the animals directly after surgery. The second injection (same dosage and method of administration) is administered 48 hours after surgery.
On days 3 and 14 days after RD, the operated rats are euthanized in a CO2 saturated chamber. The injured right eye and the untreated left eye are enucleated. The retinas are isolated, frozen on dry ice and processed for Western blot analysis or immunohistochemical analysis. The left eye retinas serve as non-operated controls.
The expression levels of Semaphorin3A (Sema3A), Neuropilinl (NP1), and GAP43 are determined. Caspase3 is used as an apoptotic marker, and morphological changes in Muller and microglial cells are examined.
The morphological changes of the Muller cells are studied by staining for glial fibrillary acidic protein (GFAP). GFAP labels Muller cells in the retina, and is commonly used as a stress indicator. Microglial invasion and activation are regarded as harmful or beneficial to neurons. Microglial activation after acute CNS injury is primarily a reactive and adaptive glial cell response, which is triggered by injured neurons and which is designed to ameliorate primary tissue damage and to promote subsequent repair and gliosis (glial scar) as a result. Microglia become activated in the retina usually after injury, stimulate and recruit endothelial cells and fibroblasts. Immunohistochemical analysis of sections of detached and non-injured retinas labeled with IB4 and stained with the nuclear dye PI are used to identify any signs of activated microglial cells in the retina.
Example 6: rAION, a rodent model of NAION (Nonarteritic Anterior Ischemic Optic Neuropathy) ¨ Effect of isolated acidic fractions and/or specific triterpenoids compounds of the isolated acidic fraction compositions of the invention Optic nerve ischemia effected by NAION results in myelin and axonal damage. In the rodent model of NAION (rAION), the optic nerve ischemia (in anesthetized rats) is laser-induced using a nd-YAG laser at 532nm with 500micron spot size and 50mW
power with 1 second pulses. This results in optic nerve ischemia without causing direct thermal damage. The induction results in postinfarct demyelation and oligodendricyte death in the following days. Demyelation results in the release of soluble factors that can inhibit axonal regeneration. These factors include myelin-associated glycoprotein (MAG) and N0G066.
These factors activate the axonal membrane protein complex (LINGO-1), which in turn activates the axonal kinase RAS homolog A (RhoA) via phosphorylation.
Activated RhoA
inhibits cytoskeleton polymerization, which results in axonal growth cone collapse.
Animals are divided over several groups with 10-12 animals per group.
Three days post-induction, treatment of the animal groups with the different compositions of the invention and placebo control (as detailed in Example 4) is commenced. A twice-weekly regimen with 50 microliter subcutaneous injections is applied. Treatment is elicited for 28 days or 56 days.
Improvement of axonal regeneration is detected by GAP43 immunostaining. Optic nerve ultrastructure is evaluated after treatment in order to detect myelation profiles of different axon fiber sizes. Results of treatment and placebo groups are compared.
Example 7 ¨ In vitro Glaucoma model - Effect of various compositions Primary acutely dissociated retinal cell culture are prepared from adult Wistar rats.
The neuroprotective effects of the test compositions (combinations) on RGC
survival is determined by pre-treatment prior to trophic factor withdrawal. Cell viability is assessed by double-label immunocytochemistry.
Adult Wistar rats are euthanized and retinal cell suspensions are prepared by dissecting the retinas and incubating (37 C, 30 min) in digestion buffer containing neurobasal medium supplemented with 2 mg/mL papain, 0.4 mg/mL dl-cysteine, and 0.4 mg/mL bovine serum albumin (BSA).
Retinas are processed in order obtain a suspension of single cells. Retinal cells are seeded on poly-d-lysine- and laminin-coated 8-well culture slides at a density of approximately 1 x106 cells/well with 0.5 mL/well RGC culture medium and cultured in 95% air and 5% CO2 at 37 C for 3 days.
Cells are treated with either test composition or vehicle (control) immediately after dissociation and exposed to RGC culture medium as above, but without BDNF, CNTF, and bFGF (TFW RGC medium).
Table 2 Condition Media Drug treatment Control (3 technical replicates) Complete RGC medium N/A
Test compound (12 compounds, 3 Complete RGC medium Test compound technical replicates each) Control (3 technical triplicates) TFW RGC medium N/A
Test compounds (12 compounds, 3 TFW RGC medium Test compound technical replicates and 2 concentrations each) Test compound specific vehicle TFW RGC medium Vehicle (3 technical replicates per vehicle) On Day 3, cultures of retinal cells are subjected to double-label immunocytochemistry. Cultures are immunoreacted with primary antibodies against Thy-1 and neurofilament-1 68 kDa. Cells are co-labelled with DAPI to visualize nuclei.
Healthy RGCs are identified based on double-positive immunoreactivity for both Thy-1 and neurofilament-1 68kDa, as well as the following four morphological criteria:
presence of continuous membranes; no signs of vacuolation; no signs of perikaryal swelling; and no signs of nuclear pyknosis or fragmentation. Cells are counted manually.
Example 8 ¨ Treatment of Glaucoma using various compositions of the invention Various compositions are tested for their efficacy in Glaucoma treatment in rats.
Glaucoma symptoms are induced in rats by intraocular (intravitreal) injection of excitotoxic agents such as N-methyl-d-aspartate (NMDA), alpha-amino-3-hydroxy-methy1-4-isoxazoleproprionic acid (AMPA) or kainic acid, or by other means, such as, photocoagulation, for example, by irradiation with a laser beam. These agents induce degenerative conditions in the eye that are similar to glaucoma. The extent to which the compositions of the invention are able to ameliorate and/or reverse the degenerative symptoms caused by the excitotoxic agents is a measure of their effect in the treatment of glaucoma.
Degeneration of retinal ganglion cells (RGCs) in human and experimental glaucoma is accompanied by a neuroinflammatory process involving retinal microglial cells and increased production of inflammatory mediators. In addition, early and exacerbated activation of retinal microglial cells has been proposed to contribute to the degenerative process, suggesting that the control of microglia reactivity can prevent the glaucomatous loss of RGCs. A wide variety of animal models of glaucoma including pigs, dogs, monkeys and rodents, most of these models involve optic nerve damage mediated through ocular hypertension. Other established models available to study glaucoma rely on RGC
induced-death upon genetic mutations, mechanical trauma to the optic nerve, toxic insult to retinal neurons, or the induction of retinal ischemia.
In this study the rat laser photocoagulation (GL) model is used in order to evaluate the neuroprotective and neuroregenerative effects of the tested compositions.
Study design:
Briefly, high TOP is unilaterally induced by laser photocoagulation of episcleral veins on day 0 and day 7. The contralateral eye serves as control. The compositions are delivered subcutaneously (s.c) twice a week starting on day 1 only in animals with TOP of 16 mmHg or higher. TOP is monitored on the next day after the lasering (study day 1), on day 4, day 7 and once a week afterwards. The function of retinal ganglion cells (RGCs) is evaluated in vivo using pattern electroretinography (pERG) at the baseline, on day 14 and on day 28. Measurements at day 28 serve as milestone decision for an optional follow-up period of 2¨ 4 weeks, at the end of which an additional pERG measurement is performed.
The retinas and optic nerves are collected and processed for retinal ganglion cell counts and optic nerve axon counts. In addition, immunohistochemical evaluation of retinal tissue is performed for markers of inflammation.
The following treatment arms (n=12 rats in each arm) are used:
Group 1: Naïve rats (n=12); (Naïve) Group 2: Vehicle- treated GL model (n=12); (Vehicle) Group 3: Test formulation 1- treated GL model (n=12); Composition D (MDA
(1% w/w) + IMDA (1% w/w)) prepared as described in Example 2B.
Group 4: Test formulation 2- treated GL model (n=12); Composition E (Acidic Mixture 1 ("Acidic-1") of Example 1A, as a 2.5% (w/w) formulation in cottonseed oil, prepared as described in Example 2A) Materials and methods Rat glaucoma model Experimental increase in TOP was induced unilaterally by laser photocoagulation of episcleral veins as previously described (Kalesnykas et al., 2007, Neuroscience 150:
692-704). The contralateral eye serves as control. Five-to-seven months old Long Evans rats are used. The intraocular pressure (TOP) was monitored at the baseline, on the first day after lasering (day 1), day 4, day 7 and once a week for the remaining follow-up period.
Only rats with TOP of 16 mmHg or higher as assessed on day 1 are admitted to the study groups.
Administration The test compositions are administered subcutaneously (s.c.) twice a week starting from day 1.
pERG measurements Recordings were performed using Celeris system (Diagnosys LLC). A single drop of drop oxybuprocaine (Oftanucain , Santen, Finland) wass applied to the cornea for local anesthesia. Animals were placed on a controlled heating-pad to maintain body temperature at approximately 37 C.
Animal Sacrifice and Tissue Collection At the end of the study, the rats were sacrificed by transcardial perfusion first with 0.9% NaCl solution, then with 4% paraformaldehyde in 0.1M phosphate buffer solution, pH 7.4. The eyeballs and optic nerves (n=4 rats from each group, collected in a randomized manner) were collected and embedded into optimal cutting temperature (OCT) for cryosectioning/retinal wholemounts (n=8 rats from each group) were prepared for further estimation of the total number of RGCs.
Morphological Assessment of Optic Nerves After the optic nerves (from 8 rats/treatment group) were postfixed in 4% PFA
(in 0.1M phosphate buffer, pH 7.4) solution, they were placed in 1% osmium, dehydrated in ascending alcohol concentration and placed in 1% uranyl acetate in 100%
ethanol for 1 hour (Cone et al., 2012 . Exp Eye Res. Jun;99:27-35.; Ragauskas et at, 2014, PLoS One.
3;9(12)). Then the optic nerves were embedded in epoxy resin mixture at 60 C
for 48 hours and semi-thin sections (1 pm-thick) of optic nerves were serially sectioned through the optic nerve damage site. Optic nerve damage/number of axons was estimated under the light microscope.
Results:
pERG measurements (recordings) that reflect functionality of RGCs were performed at follow-up days 14 and 28. The results presented below in Table 3 and in the bar graphs shown in Fig. 1, demonstrate that treatment with the indicated combinations exhibit an increase in mean amplitude on both follow up days, as compared to the vehicle-treated group.
Table 3- Lasered eye relative increase in mean amplitudes at the follow-up day, 28 adjusted to baseline.
Treatment group Relative increase in mean amplitude on day 28, %
(Compared to Vehicle) 24.0%
18.8%
Analysis of the total number of Brn3-a positive RGCs (relative to Naïve rats).
revealed an effect of the tested compositions. For example, rats treated with the tested compositions had a higher RGC count as compared to the vehicle-treated group (Fig. 2).
Higher number of Brn3a-positive cell is indicative of lower cell loss, wherein the cell loss is triggered by the Laser photocoagulation. These results are in line with the pERG
measurements results and supports neuroprotective effect of the test compositions on RGC
survival.
Next, optic nerve axon in samples from the tested rats were counted under the light microscope, to estimate the optic nerve damage. The results are presented in Fig. 3. As shown, administration of test compositions D and E tend to protect axons from degeneration triggered by Laser photocoagulation Further supporting results demonstrating the protective effect of the tested compositions can be seen in Fig, 4, which show representative images of semi thin sections of the optic nerves. The results clearly demonstrate differences in the degeneration processes between the treated groups and vehicle treated group (Fig. 4).
Conclusions: The study presented herein demonstrates the neuroprotective and neurodegenerative effect of the tested compositions in treating glaucoma.
The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention.
MDA IMDA OLN
3 -0Ac-MLA 3-0Ac-epi- IMDA
IMLA
21 3-0Ac-epi- 3-0Ac-IMLA IMDA
MLA
22 3-0Ac-epi- 3-0Ac-epi- IMDA
MLA IMLA
23 3 -0Ac-MLA 3-0Ac-epi- MDA
IMLA
24 3-0Ac-epi- 3-0Ac-IMLA MDA
MLA
3-0Ac-epi- 3-0Ac-epi- MDA
MLA IMLA
It is clear to a person skilled in the art that this procedure can be used to make additional formulations of triterpenoic acids in cottonseed oil. In addition, it is also clear to a person skilled in the art that instead of cottonseed oil other suitable oils and hydrophobic carriers can be used with this procedure to prepare the corresponding formulations of 5 triterpenoic acids.
Example 3A. Isolation and chemical characterization of isolated acidic fraction of mastic gum.
Mastic resin from Pistacia lentiscus L. was extracted according to any of the methods described Examples 1A-1F to obtain the fraction which was analyzed by reversed phase HPLC in order to identify the major constituents. The HPLC analysis is consistent with the presence the isolated fraction of moronic acid and oleanonic acid in the isolated fraction, on the basis of comparison with analytical standards.
In order to isolate and determine the structure of further main constituents of the isolated acidic fraction, a preparative HPLC method was developed. Using this method, six major constituents of the isolated acidic fraction (For example "Acidic-1"
obtained according to Example 1A) were subsequently isolated by preparative HPLC. A
preparative HPLC method was developed on a 30x250 mm preparative column (ACE-121-2530).
Samples of the isolated fraction (ca. 75 mg per run) were injected using a 5ML
loop.
Identified compounds include such compounds as, moronic acid, oleanonic acid, masticadienonic acid, isomasticadienonic acid, 3-0Acetyl-masticadienolic acid, and 3-0-acetyl-isomasticadienolic acid, 3-0-acetyl-epimasticadienolic acid, 3-0-acetyl-epi-isomasticadienolic acid, masticadienolic acid and isomasticadienolic acid.
Further isolation efforts yielded several additional minor constituents (<5%
of isolated fraction), whose presence varied in isolated acidic fraction preparations from different mastic gum batches. The following minor constituent compounds may or may not be present in the isolated acidic fractions:
- MLA: 3-beta-masticadienolic acid - IMLA: 3-beta-isomasticadienolic acid - Epimasticadienolic acid (3-alpha-masticadienolic acid) - Epi-isomasticadienolic acid (3-alpha-isomasticadienolic acid) - Dihydromasticadienonic acid - Dihydroisomasticadienonic acid Example 3B Synthesis of some triterpenoic acids found in the isolated acidic fractions of mastic gum.
Oleanonic acid (OA) Oleanonic acid was obtained in three steps from commercially available oleanolic acid.
Me Ye me ye Me CO2H
Mel, K2CO3 Me CO2Me Dess-Martin 00 el DMF, rt HO
Me overnight HO OO Me Me -Me Me Me Me Ye Me Ye LiOH
Me O. CO2Me H20/THF Me OM) CO2H
OO Me rt, 2 days OO Me 0 . 0 Me -Me Me -Me Oleanolic acid was first converted to the corresponding methyl ester by treatment with methyl iodide and potassium carbonate in dimethylformamide (DMF).
Oxidation of oleanolic acid methyl ester to oleanonic acid methyl ester was performed using Dess-Martin periodane reagent in dichloromethane (DCM). Hydrolysis of oleanonic acid methyl ester with lithium hydroxide in aqueous THF gave upon acidification the desired oleanonic acid.
Masticadienolic acid (MLA) Masticadienonic acid (500 mg) was dissolved in methanol (30ML) and cooled to 0 C. NaBH4 (83 mg; 2.0 eq.) was added and the mixture was stirred overnight at room temperature. After TLC (hexane : ethylacetate) showed full conversion, the reaction mixture cooled to 0 C and quenched by addition of 20 ML cold water. The methanol was evaporated from the mixture, which was then extracted with diethyl ether. The crude product was purified by column chromatography over silica gel (DCM:Me0H=95:5 to 90:10) to give MLA as white solid (400mg; 80%).
Isomasticadienolic acid (IMLA) Isomasticadienonic acid (500 mg) was dissolved in methanol (30ML) and cooled to 0 C. NaBH4 (83 mg; 2.0 eq.) was added and the mixture was stirred overnight at room temperature. After TLC (hexane : ethylacetate) showed full conversion, the reaction mixture cooled to 0 C and quenched by addition of 20 ML cold water. The methanol was evaporated from the mixture, which was then extracted with diethyl ether. The crude product was purified by column chromatography over silica gel (DCM:Me0H=95:5 to 90:10) to give IMLA as white solid (420mg; 82%).
3-0Ac-MLA
MLA (400 mg) was dissolved in anhydrous pyridine (5 ML), and acetic anhydride (160mg; 3.55 eq.) was added in one portion. The mixture was stirred overnight at room temperature and monitored by TLC (hexane/ethylacetate). The reaction mixture was diluted with ethylacetate (15ML) and 1M aqueous HC1 (20ML) and the mixture was stirred vigorously for 1 hour. The layers were separated, the organic layer was dried over MgSO4 and evaporated. The crude product was purified by column chromatography over silicagel (hexane/ethylacetate=10:1 to 9:1) to yield 3-0Ac-MLA as a white solid (220 mg;
55%).
3-0Ac-IMLA
IMLA (400 mg) was dissolved in anhydrous pyridine (5 ML), and acetic anhydride (160mg; 3.55 eq.) was added in one portion. The mixture was stirred overnight at room temperature and monitored by TLC (hexane/ethylacetate). The reaction mixture was diluted with ethylacetate (15ML) and 1M aqueous HC1 (20ML) and the mixture was stirred vigorously for 1 hour. The layers were separated, the organic layer was dried over MgSO4 and evaporated. The crude product was purified by column chromatography over silicagel (hexane/ethylacetate=10:1 to 9:1) to yield 3-0Ac-IMLA as a white solid (190 mg; 47%).
3-0Ac-epi-MLA
MLA (400 mg) was dissolved in anhydrous pyridine (5 ML), and acetic anhydride (160mg; 3.55 eq.) was added in one portion, followed by 4-N,N-dimethylaminopyridine (DMAP; 20 mg). The mixture was stirred overnight at room temperature and monitored by TLC (hexane/ethylacetate). The reaction mixture was diluted with ethylacetate (15ML) and 1M aqueous HC1 (20ML) and the mixture was stirred vigorously for 1 hour.
The layers were separated, the organic layer was dried over MgSO4 and evaporated.
The crude product was purified by column chromatography over silicagel (hexane/ethylacetate=10:1 to 9:1) to yield a mixture of 3-0Ac-MLA and 3-0Ac-epi-MLA as a white solid (330 mg;
%). The isomers were separated using preparative HPLC to provide 3-0Ac-epi-MLA
(120 mg) as a white solid.
3-0Ac-epi-IMLA
IMLA (400 mg) was dissolved in anhydrous pyridine (5 ML), and acetic anhydride (160mg; 3.55 eq.) was added in one portion, followed by 4-N,N-dimethylaminopyridine (DMAP; 20 mg). The mixture was stirred overnight at room temperature and monitored by TLC (hexane/ethylacetate). The reaction mixture was diluted with ethylacetate (15ML) and 1M aqueous HC1 (20ML) and the mixture was stirred vigorously for 1 hour.
The layers were separated, the organic layer was dried over MgSO4 and evaporated.
The crude product was purified by column chromatography over silicagel (hexane/ethylacetate=10:1 to 9:1) to yield a mixture of 3-0Ac-IMLA and 3-0Ac-epi-IMLA as a white solid (310 mg;
%). The isomers were separated using preparative HPLC to provide 3-0Ac-epi-IMLA
(110 mg) as a white solid.
Epi-MLA and epi-IMLA were prepared by hydrolysis of the corresponding acetates with LiOH in aqueous THF. Standard work-up provided the compounds in respective yields of 45% and 53% as white solids.
Dihydromasticadienonic acid and dihydroisomasticadienonic acid can be prepared according to D .Barton, E. Seoane. J.Chem.Soc. 1956, 4150; and E. Seoane ibid.
4158.
Example 4 - Effect of using isolated acidic fractions and/or specific triterpenoois compounds of the isolated acidic fraction compositions of the invention on Retinal Ganglion Cells (RGC) upon optic nerve axotomy.
Axotomy of the optic nerve is performed on the right eye of deeply anesthetized rats (19 rats per group). The test groups receive a sub-dermal injection in the posterior neck area of various tested compositions (0.025ml/injection), and the control group is similarly injected with the same volume of vehicle. The first injection is given to all the animals directly after surgery. Subsequent injections (same dosage and method of administration) are administered twice a week, every 3 to 4 days.
Fourteen days after axotomy, a fluorescent retrograde neurotracer (Di-Asp) is inserted into the axotomized optic nerve in order to stain surviving Retinal Ganglion Cells (RGC), and 24 hours later, the rats are sacrificed in a CO2 saturated chamber and the injured right eye is enucleated. The retinas are isolated, and flattened on a slide and fixed with xylene based mounting medium.
Whole-mount retinas are evaluated with a fluorescent microscope. Dyed cells are counted manually.
Compositions used include:
- Isolated acidic fraction of mastic gum (for example "Acidic-1" from Example lA
and its corresponding cottonseed oil formulation prepared according to Example 2A), - The following compounds and combinations, prepared according to Example 2B, are tested:
OA: Oleanonic acid MDA: Masticadienonic acid IMDA: Isomasticadienonic acid The following formulations were used for injection:
- Vehicle: cottonseed oil - IMDA: 1% (w/w) in cottonseed oil - MDA: 1% (w/w) in cottonseed oil - IMDA and MDA: each 1% (w/w) in cottonseed oil - IMDA, MDA and OA: each 1% % (w/w) in cottonseed oil Example 5 - Retinal Detachment (RD) model ¨ effect of using isolated acidic fractions and/or specific triterpenoids compounds of the isolated acidic fraction compositions of the invention.
Retinal detachment (RD) is performed on the right eye of deeply anesthetized animals (xylazine 50mg/kg and ketamine 35mg/kg) following dilatation of the pupil with Tropicamide drops 0.5%. RD is induced through the generation of a small opening in the retina at the ora serata followed by a sub-retinal injection of 5 1 saline with a 30G syringe needle. Approximately half of the retinal area is detached by this procedure.
Rats with RD are divided into six experimental groups, five test groups receiving a sub-dermal injection in the posterior neck area of pharmaceutical compositions as disclosed in Example 4, and the control group injected is administered with the same volume of vehicle. The first injection is given to all the animals directly after surgery. The second injection (same dosage and method of administration) is administered 48 hours after surgery.
On days 3 and 14 days after RD, the operated rats are euthanized in a CO2 saturated chamber. The injured right eye and the untreated left eye are enucleated. The retinas are isolated, frozen on dry ice and processed for Western blot analysis or immunohistochemical analysis. The left eye retinas serve as non-operated controls.
The expression levels of Semaphorin3A (Sema3A), Neuropilinl (NP1), and GAP43 are determined. Caspase3 is used as an apoptotic marker, and morphological changes in Muller and microglial cells are examined.
The morphological changes of the Muller cells are studied by staining for glial fibrillary acidic protein (GFAP). GFAP labels Muller cells in the retina, and is commonly used as a stress indicator. Microglial invasion and activation are regarded as harmful or beneficial to neurons. Microglial activation after acute CNS injury is primarily a reactive and adaptive glial cell response, which is triggered by injured neurons and which is designed to ameliorate primary tissue damage and to promote subsequent repair and gliosis (glial scar) as a result. Microglia become activated in the retina usually after injury, stimulate and recruit endothelial cells and fibroblasts. Immunohistochemical analysis of sections of detached and non-injured retinas labeled with IB4 and stained with the nuclear dye PI are used to identify any signs of activated microglial cells in the retina.
Example 6: rAION, a rodent model of NAION (Nonarteritic Anterior Ischemic Optic Neuropathy) ¨ Effect of isolated acidic fractions and/or specific triterpenoids compounds of the isolated acidic fraction compositions of the invention Optic nerve ischemia effected by NAION results in myelin and axonal damage. In the rodent model of NAION (rAION), the optic nerve ischemia (in anesthetized rats) is laser-induced using a nd-YAG laser at 532nm with 500micron spot size and 50mW
power with 1 second pulses. This results in optic nerve ischemia without causing direct thermal damage. The induction results in postinfarct demyelation and oligodendricyte death in the following days. Demyelation results in the release of soluble factors that can inhibit axonal regeneration. These factors include myelin-associated glycoprotein (MAG) and N0G066.
These factors activate the axonal membrane protein complex (LINGO-1), which in turn activates the axonal kinase RAS homolog A (RhoA) via phosphorylation.
Activated RhoA
inhibits cytoskeleton polymerization, which results in axonal growth cone collapse.
Animals are divided over several groups with 10-12 animals per group.
Three days post-induction, treatment of the animal groups with the different compositions of the invention and placebo control (as detailed in Example 4) is commenced. A twice-weekly regimen with 50 microliter subcutaneous injections is applied. Treatment is elicited for 28 days or 56 days.
Improvement of axonal regeneration is detected by GAP43 immunostaining. Optic nerve ultrastructure is evaluated after treatment in order to detect myelation profiles of different axon fiber sizes. Results of treatment and placebo groups are compared.
Example 7 ¨ In vitro Glaucoma model - Effect of various compositions Primary acutely dissociated retinal cell culture are prepared from adult Wistar rats.
The neuroprotective effects of the test compositions (combinations) on RGC
survival is determined by pre-treatment prior to trophic factor withdrawal. Cell viability is assessed by double-label immunocytochemistry.
Adult Wistar rats are euthanized and retinal cell suspensions are prepared by dissecting the retinas and incubating (37 C, 30 min) in digestion buffer containing neurobasal medium supplemented with 2 mg/mL papain, 0.4 mg/mL dl-cysteine, and 0.4 mg/mL bovine serum albumin (BSA).
Retinas are processed in order obtain a suspension of single cells. Retinal cells are seeded on poly-d-lysine- and laminin-coated 8-well culture slides at a density of approximately 1 x106 cells/well with 0.5 mL/well RGC culture medium and cultured in 95% air and 5% CO2 at 37 C for 3 days.
Cells are treated with either test composition or vehicle (control) immediately after dissociation and exposed to RGC culture medium as above, but without BDNF, CNTF, and bFGF (TFW RGC medium).
Table 2 Condition Media Drug treatment Control (3 technical replicates) Complete RGC medium N/A
Test compound (12 compounds, 3 Complete RGC medium Test compound technical replicates each) Control (3 technical triplicates) TFW RGC medium N/A
Test compounds (12 compounds, 3 TFW RGC medium Test compound technical replicates and 2 concentrations each) Test compound specific vehicle TFW RGC medium Vehicle (3 technical replicates per vehicle) On Day 3, cultures of retinal cells are subjected to double-label immunocytochemistry. Cultures are immunoreacted with primary antibodies against Thy-1 and neurofilament-1 68 kDa. Cells are co-labelled with DAPI to visualize nuclei.
Healthy RGCs are identified based on double-positive immunoreactivity for both Thy-1 and neurofilament-1 68kDa, as well as the following four morphological criteria:
presence of continuous membranes; no signs of vacuolation; no signs of perikaryal swelling; and no signs of nuclear pyknosis or fragmentation. Cells are counted manually.
Example 8 ¨ Treatment of Glaucoma using various compositions of the invention Various compositions are tested for their efficacy in Glaucoma treatment in rats.
Glaucoma symptoms are induced in rats by intraocular (intravitreal) injection of excitotoxic agents such as N-methyl-d-aspartate (NMDA), alpha-amino-3-hydroxy-methy1-4-isoxazoleproprionic acid (AMPA) or kainic acid, or by other means, such as, photocoagulation, for example, by irradiation with a laser beam. These agents induce degenerative conditions in the eye that are similar to glaucoma. The extent to which the compositions of the invention are able to ameliorate and/or reverse the degenerative symptoms caused by the excitotoxic agents is a measure of their effect in the treatment of glaucoma.
Degeneration of retinal ganglion cells (RGCs) in human and experimental glaucoma is accompanied by a neuroinflammatory process involving retinal microglial cells and increased production of inflammatory mediators. In addition, early and exacerbated activation of retinal microglial cells has been proposed to contribute to the degenerative process, suggesting that the control of microglia reactivity can prevent the glaucomatous loss of RGCs. A wide variety of animal models of glaucoma including pigs, dogs, monkeys and rodents, most of these models involve optic nerve damage mediated through ocular hypertension. Other established models available to study glaucoma rely on RGC
induced-death upon genetic mutations, mechanical trauma to the optic nerve, toxic insult to retinal neurons, or the induction of retinal ischemia.
In this study the rat laser photocoagulation (GL) model is used in order to evaluate the neuroprotective and neuroregenerative effects of the tested compositions.
Study design:
Briefly, high TOP is unilaterally induced by laser photocoagulation of episcleral veins on day 0 and day 7. The contralateral eye serves as control. The compositions are delivered subcutaneously (s.c) twice a week starting on day 1 only in animals with TOP of 16 mmHg or higher. TOP is monitored on the next day after the lasering (study day 1), on day 4, day 7 and once a week afterwards. The function of retinal ganglion cells (RGCs) is evaluated in vivo using pattern electroretinography (pERG) at the baseline, on day 14 and on day 28. Measurements at day 28 serve as milestone decision for an optional follow-up period of 2¨ 4 weeks, at the end of which an additional pERG measurement is performed.
The retinas and optic nerves are collected and processed for retinal ganglion cell counts and optic nerve axon counts. In addition, immunohistochemical evaluation of retinal tissue is performed for markers of inflammation.
The following treatment arms (n=12 rats in each arm) are used:
Group 1: Naïve rats (n=12); (Naïve) Group 2: Vehicle- treated GL model (n=12); (Vehicle) Group 3: Test formulation 1- treated GL model (n=12); Composition D (MDA
(1% w/w) + IMDA (1% w/w)) prepared as described in Example 2B.
Group 4: Test formulation 2- treated GL model (n=12); Composition E (Acidic Mixture 1 ("Acidic-1") of Example 1A, as a 2.5% (w/w) formulation in cottonseed oil, prepared as described in Example 2A) Materials and methods Rat glaucoma model Experimental increase in TOP was induced unilaterally by laser photocoagulation of episcleral veins as previously described (Kalesnykas et al., 2007, Neuroscience 150:
692-704). The contralateral eye serves as control. Five-to-seven months old Long Evans rats are used. The intraocular pressure (TOP) was monitored at the baseline, on the first day after lasering (day 1), day 4, day 7 and once a week for the remaining follow-up period.
Only rats with TOP of 16 mmHg or higher as assessed on day 1 are admitted to the study groups.
Administration The test compositions are administered subcutaneously (s.c.) twice a week starting from day 1.
pERG measurements Recordings were performed using Celeris system (Diagnosys LLC). A single drop of drop oxybuprocaine (Oftanucain , Santen, Finland) wass applied to the cornea for local anesthesia. Animals were placed on a controlled heating-pad to maintain body temperature at approximately 37 C.
Animal Sacrifice and Tissue Collection At the end of the study, the rats were sacrificed by transcardial perfusion first with 0.9% NaCl solution, then with 4% paraformaldehyde in 0.1M phosphate buffer solution, pH 7.4. The eyeballs and optic nerves (n=4 rats from each group, collected in a randomized manner) were collected and embedded into optimal cutting temperature (OCT) for cryosectioning/retinal wholemounts (n=8 rats from each group) were prepared for further estimation of the total number of RGCs.
Morphological Assessment of Optic Nerves After the optic nerves (from 8 rats/treatment group) were postfixed in 4% PFA
(in 0.1M phosphate buffer, pH 7.4) solution, they were placed in 1% osmium, dehydrated in ascending alcohol concentration and placed in 1% uranyl acetate in 100%
ethanol for 1 hour (Cone et al., 2012 . Exp Eye Res. Jun;99:27-35.; Ragauskas et at, 2014, PLoS One.
3;9(12)). Then the optic nerves were embedded in epoxy resin mixture at 60 C
for 48 hours and semi-thin sections (1 pm-thick) of optic nerves were serially sectioned through the optic nerve damage site. Optic nerve damage/number of axons was estimated under the light microscope.
Results:
pERG measurements (recordings) that reflect functionality of RGCs were performed at follow-up days 14 and 28. The results presented below in Table 3 and in the bar graphs shown in Fig. 1, demonstrate that treatment with the indicated combinations exhibit an increase in mean amplitude on both follow up days, as compared to the vehicle-treated group.
Table 3- Lasered eye relative increase in mean amplitudes at the follow-up day, 28 adjusted to baseline.
Treatment group Relative increase in mean amplitude on day 28, %
(Compared to Vehicle) 24.0%
18.8%
Analysis of the total number of Brn3-a positive RGCs (relative to Naïve rats).
revealed an effect of the tested compositions. For example, rats treated with the tested compositions had a higher RGC count as compared to the vehicle-treated group (Fig. 2).
Higher number of Brn3a-positive cell is indicative of lower cell loss, wherein the cell loss is triggered by the Laser photocoagulation. These results are in line with the pERG
measurements results and supports neuroprotective effect of the test compositions on RGC
survival.
Next, optic nerve axon in samples from the tested rats were counted under the light microscope, to estimate the optic nerve damage. The results are presented in Fig. 3. As shown, administration of test compositions D and E tend to protect axons from degeneration triggered by Laser photocoagulation Further supporting results demonstrating the protective effect of the tested compositions can be seen in Fig, 4, which show representative images of semi thin sections of the optic nerves. The results clearly demonstrate differences in the degeneration processes between the treated groups and vehicle treated group (Fig. 4).
Conclusions: The study presented herein demonstrates the neuroprotective and neurodegenerative effect of the tested compositions in treating glaucoma.
The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention.
Claims (42)
1. A method of treating an optic neuropathy condition in a subject in need thereof, the method comprising administering a composition comprising an effective amount of an isolated acidic fraction of mastic gum, and a pharmaceutically acceptable carrier, wherein the fraction is characterized in that it is soluble in at least one polar organic solvent and in at least one non-polar organic solvent, and wherein said fraction is substantially devoid of compounds which are soluble in said polar organic solvent but insoluble in said non-polar organic solvent.
2. The method according to claim 1 wherein the acidic fraction is obtained from an isolated fraction of mastic gum that is soluble in at least one polar organic solvent and at least one non-polar organic solvent by an acid-base extraction, thereby separating the isolated acidic fraction from the non-acidic fraction of mastic gum that is soluble in at least one polar organic solvent and one non-polar organic solvent.
3. The method according to claim 1, wherein the isolated acidic fraction comprises at least two of: masticadienolic acid, masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, 3-O-acetyl-masticadienolic acid, 3-O-acetyl-epimasticadienolic acid, 3-O-acetyl-isomasticadienolic acid, 3-O-acetyl-epi-isomasticadienolic acid, oleanonic acid and moronic acid.
4. The method according to claim 1, wherein the optic neuropathy condition is selected from traumatic neuropathy, ischemic neuropathy; Radiation optic neuropathy (RON), Glaucoma, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, Hereditary optic neuropathy and combinations thereof.
5. The method according to claim 4, wherein the ischemic optic neuropathy is selected from: Nonarteritic Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION) and Posterior ischemic optic neuropathy.
6. The method according to claim 1, wherein the optic neuropathy condition resulted from a storage disease.
7. The method according to claim 6, wherein the storage disease caused the deposition of lipoprotenaceous substances in the optical nerve.
8. The method according to claim 1, wherein the composition is administered by parenteral route.
9. The method according to claim 8, wherein the parenteral route is selected from the group consisting of intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intraarterial, intrauterine, intraurethral, intracardial, intracerebral, intracerebroventricular, intrarenal, intrahepatic, intratendon, intraosseous.
intraocular and intrathecal.
intraocular and intrathecal.
10. The method according to claim 1, wherein the at least one polar organic solvent is selected from the group consisting of an alcohol, an ether, an ester, an amide, an aldehyde, a ketone, a nitrile, and combinations thereof.
11. The method according to claim 10, wherein the polar organic solvent is selected from the group consisting of methanol, ethanol, propanol, isopropanol, 1-butanol, 2-butanol, sec-butanol, t-butanol, 1-pentanol, 2-pentanol, 3-pentanol, neopentanol, 3-methyl-1-butanol, 2-methyl-1-butanol, 3-methyl-2-butanol, 2-methyl-2-butanol, ethyleneglycol, ethyleneglycol monomethyl ether, diethyl ether, methylethyl ether, ethylpropyl ether, methylpropyl ether, 1,2-dimethoxyethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran, methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methylformate, ethylformate, ethyl propionate, methyl propionate, dichloromethane, chloroform, dimethylformamide, acetamide, dimethylacetamide, N-methylpyrrolidone, acetone, ethylmethyl ketone, diethyl ketone, acetonitrile, propionitrile, and combinations thereof.
12. The method according to claim 1, wherein the at least one non-polar organic solvent is selected from the group consisting of acyclic or cyclic, saturated or unsaturated aliphatic hydrocarbons and aromatic hydrocarbons, each of which is optionally substituted by one or more halogens, and combinations thereof.
13. The method according to claim 12, wherein the non-polar organic solvent is selected from the group consisting of C5-C10 alkanes, C5-C10 cycloalkanes, C6-C14 aromatic hydrocarbons and C7-C14 perfluoroalkanes, and combinations thereof.
14. The method according to claim 12, wherein the non-polar organic solvent is selected from the group consisting of pentanes, hexanes, heptanes, octanes, nonanes, decanes, cyclopentane, cyclohexane, cycloheptane, benzene, toluene, xylene, and isomers and mixtures thereof.
15. The method according to claim 1 wherein the composition comprises from about 0.01 to about 50% (w/w), or about 0.01 to about 12% (w/w), of the isolated acidic fraction of mastic gum, based on the total weight of the composition.
16. The method according to claim 1, wherein the composition is obtained by a process comprising the steps of:
(a) treating the mastic gum with a polar organic solvent;
(b) isolating a fraction soluble in said polar organic solvent;
(c) optionally removing said polar organic solvent;
(d) treating the soluble fraction obtained in step (b) or (c) with a non-polar organic solvent, (e) isolating a fraction soluble in said non-polar organic solvent;
(f) optionally removing said non-polar organic solvent;
(g) dissolving the fraction obtained in step (f) in an organic solvent;
(h) treating the solution obtained in step (g) with a basic aqueous solution so as to obtain a basic aqueous fraction; and (i) acidifying the basic aqueous fraction obtained in step (h) with an acid solution so as to obtain an acidified aqueous solution.
(a) treating the mastic gum with a polar organic solvent;
(b) isolating a fraction soluble in said polar organic solvent;
(c) optionally removing said polar organic solvent;
(d) treating the soluble fraction obtained in step (b) or (c) with a non-polar organic solvent, (e) isolating a fraction soluble in said non-polar organic solvent;
(f) optionally removing said non-polar organic solvent;
(g) dissolving the fraction obtained in step (f) in an organic solvent;
(h) treating the solution obtained in step (g) with a basic aqueous solution so as to obtain a basic aqueous fraction; and (i) acidifying the basic aqueous fraction obtained in step (h) with an acid solution so as to obtain an acidified aqueous solution.
17. The method according to claim 16, wherein the process further comprises the steps of:
(j) extracting the acidified aqueous fraction obtained in step (i) with an organic solvent;
(k) optionally contacting the organic fraction obtained in step (j) with a drying agent so as to remove remaining water;
(l) removing organic solvent and/or excess acid from the fraction obtained in any of steps (i), (j) or (k); and (m) dissolving the isolated fraction obtained in step (1) in a pharmaceutically acceptable carrier.
(j) extracting the acidified aqueous fraction obtained in step (i) with an organic solvent;
(k) optionally contacting the organic fraction obtained in step (j) with a drying agent so as to remove remaining water;
(l) removing organic solvent and/or excess acid from the fraction obtained in any of steps (i), (j) or (k); and (m) dissolving the isolated fraction obtained in step (1) in a pharmaceutically acceptable carrier.
18. The method according to claim 17, wherein steps (a) to (c) are carried out prior to steps (d) to (f); or wherein steps (d) to (f) are carried out prior to steps (a) to (c).
19. The method according to claim 16, wherein the polar organic solvent comprises ethanol, the non-polar organic solvent comprises hexane and the organic solvent for the acid-base extraction comprises diethyl ether.
20. The method according to claim 1, wherein the carrier is a hydrophobic carrier selected from the group consisting of at least one oil, at least one wax and combinations thereof.
21. A method of treating an optic neuropathy condition, the method comprising administering a composition consisting essentially of a mixture of triterpenoids comprising at least two triterpenoic acids, selected from the group consisting of:
masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, 3-O-acetyl-masticadienolic acid, 3-O-acetyl-epimasticadienolic acid, 3-O-acetyl-isomasticadienolic acid, 3-O-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof; and a pharmaceutically acceptable carrier.
masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, 3-O-acetyl-masticadienolic acid, 3-O-acetyl-epimasticadienolic acid, 3-O-acetyl-isomasticadienolic acid, 3-O-acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof; and a pharmaceutically acceptable carrier.
22. The method of claim 21 consisting essentially of masticadienonic acid;
isomasticadienonic acid.
isomasticadienonic acid.
23. The method of claim 21 consisting essentially of masticadienonic acid;
isomasticadienonic acid and oleanonic acid.
isomasticadienonic acid and oleanonic acid.
24. The method of claim 21, wherein at least one of the triterpenoic acids is derived from a plant source.
25. The method of claim 21, wherein the optic neuropathy condition is selected from traumatic neuropathy, ischemic neuropathy; Radiation optic neuropathy (RON), Glaucoma, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, Hereditary optic neuropathy and combinations thereof.
26. The method of claim 21, wherein the ischemic optic neuropathy is selected from:
Nonarteritic Anterior Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION) and Posterior ischemic optic neuropathy.
Nonarteritic Anterior Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION) and Posterior ischemic optic neuropathy.
27. The method of claim 21, wherein the composition is in a form suitable for administration via parenteral route.
28. Use of a composition comprising an effective amount of an isolated acidic fraction of mastic gum, and a pharmaceutically acceptable carrier; for treating an optic neuropathy condition, wherein the fraction is characterized in that it is soluble in at least one polar organic solvent and in at least one non-polar organic solvent, and wherein said fraction is substantially devoid of compounds which are soluble in said polar organic solvent but insoluble in said non-polar organic solvent.
29. The use according to claim 28, wherein the acidic fraction is obtained from an isolated fraction of mastic gum that is soluble in at least one polar organic solvent and at least one non-polar organic solvent by an acid-base extraction, thereby separating the isolated acidic fraction from the non-acidic fraction of mastic gum that is soluble in at least one polar organic solvent and one non-polar organic solvent.
30. The use according to claim 28, wherein the isolated acidic fraction comprises at least two of: masticadienolic acid, masticadienoic acid, isomasticadienoic acid, isomasticadienolic acid, 3-O-acetyl-masticadienolic acid, 3-O-acetyl-epimasticadienolic acid, 3 -O- acetyl-isomasticadienolic acid, 3-O- acetyl-epi-isomasticadienolic acid, oleanonic acid and moronic acid.
31. The use according to claim 28, wherein the optic neuropathy condition is selected from traumatic neuropathy, ischemic neuropathy; Radiation optic neuropathy (RON), Glaucoma, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, Hereditary optic neuropathy and combinations thereof.
32. The use according to claim 31, wherein the ischemic optic neuropathy is selected from: Nonarteritic Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION) and Posterior ischemic optic neuropathy.
33. The use according to claim 28, wherein the optic neuropathy condition resulted from a storage disease.
34. The use according to claim 33, wherein the storage disease caused the deposition of lipoprotenaceous substances in the optical nerve.
35. The use according to claim 28, wherein the composition is administered by parenteral route.
36. Use of a composition consisting essentially of a mixture of triterpenoids comprising at least two triterpenoic acids, selected from the group consisting of:
masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, acetyl masticadienolic acid, 3-O-acetyl-epimasticadienolic acid, 3-O-acetyl-isomasticadienolic acid, 3-O- acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof; and a pharmaceutically acceptable carrier, for treating an optic neuropathy condition in a subject in need thereof.
masticadienonic acid, isomasticadienonic acid, isomasticadienolic acid, masticadienolic acid, acetyl masticadienolic acid, 3-O-acetyl-epimasticadienolic acid, 3-O-acetyl-isomasticadienolic acid, 3-O- acetyl-epi-isomasticadienolic acid, oleanonic acid, moronic acid and combinations thereof; and a pharmaceutically acceptable carrier, for treating an optic neuropathy condition in a subject in need thereof.
37. The use according to claim 36 consisting essentially of masticadienonic acid;
isomasticadienonic acid.
isomasticadienonic acid.
38. The use according to claim 36 consisting essentially of masticadienonic acid;
isomasticadienonic acid and oleanonic acid.
isomasticadienonic acid and oleanonic acid.
39. The use according to claim 36, wherein at least one of the triterpenoic acids is derived from a plant source.
40. The use according to claim 36, wherein the optic neuropathy condition is selected from traumatic neuropathy, ischemic neuropathy; Radiation optic neuropathy (RON), Glaucoma, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, Hereditary optic neuropathy and combinations thereof.
41. The use according to claim 36, wherein the ischemic optic neuropathy is selected from: Nonarteritic Anterior Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION) and Posterior ischemic optic neuropathy.
42. The use according to claim 36, which is in a form suitable for administration via parenteral route.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662384718P | 2016-09-08 | 2016-09-08 | |
US62/384,718 | 2016-09-08 | ||
PCT/IL2017/051008 WO2018047176A1 (en) | 2016-09-08 | 2017-09-07 | Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3036041A1 true CA3036041A1 (en) | 2018-03-15 |
Family
ID=61561421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3036041A Abandoned CA3036041A1 (en) | 2016-09-08 | 2017-09-07 | Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy |
Country Status (10)
Country | Link |
---|---|
US (1) | US10751347B2 (en) |
EP (1) | EP3509577A4 (en) |
JP (1) | JP7074352B2 (en) |
KR (1) | KR20190049757A (en) |
CN (1) | CN109922798A (en) |
AU (1) | AU2017322654A1 (en) |
BR (1) | BR112019004500A2 (en) |
CA (1) | CA3036041A1 (en) |
EA (1) | EA201990561A1 (en) |
WO (1) | WO2018047176A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116889618B (en) * | 2023-09-08 | 2023-12-01 | 四川大学华西医院 | Medicine for treating diabetic skin wound and preparation method thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2437578A1 (en) | 2001-02-13 | 2002-08-22 | Rivka Cohen | Carotenoid-loaded liposomes |
DE60329098D1 (en) | 2002-05-01 | 2009-10-15 | Lavipharm Sa | USE OF MASTIX AND ITS ESSENTIAL OILS TO PREVENT OR PREVENT MICROBIAL INFECTIONS |
US20050074509A1 (en) | 2003-10-02 | 2005-04-07 | Data Medica Padova S.P.A. | Cancer treatment using natural plant products or essential oils extracted from some pistacia species or components |
FR2867980B1 (en) | 2004-03-23 | 2006-07-14 | Pierre Fabre Medicament Sa | USE OF MASTICADIENONIC ACID AS BETA DNA POLYMERASE INHIBITOR |
WO2005112967A2 (en) | 2004-05-19 | 2005-12-01 | Balfour Marketing Corp. | Anticancer activity of chios mastic gum |
CN106619700A (en) | 2009-03-04 | 2017-05-10 | 瑞吉纳拉制药公司 | Therapeutic uses of mastic gum fractions |
EP3578191A1 (en) | 2009-03-04 | 2019-12-11 | Regenera Pharma Ltd. | Compositions of polymeric myrcene |
EP2613777B1 (en) | 2010-09-07 | 2019-05-01 | Regenera Pharma Ltd. | Compositions comprising acidic extracts of mastic gum |
WO2013186766A1 (en) | 2012-06-11 | 2013-12-19 | Regenera Pharma Ltd. | Extracts and therapeutic uses thereof |
CN103656290B (en) | 2013-12-11 | 2015-07-01 | 张有富 | Medicine for treating optic atrophy and preparation method of medicine |
IL237621A0 (en) | 2015-03-08 | 2015-06-30 | Regenera Pharma Ltd | Use of isolated fractions of mastic gum for treating optic neuropathy |
WO2018047175A1 (en) * | 2016-09-08 | 2018-03-15 | Regenera Pharma Ltd. | Compositions comprising triterpenoids and uses thereof for treating optic neuropathy |
-
2017
- 2017-09-07 EA EA201990561A patent/EA201990561A1/en unknown
- 2017-09-07 CA CA3036041A patent/CA3036041A1/en not_active Abandoned
- 2017-09-07 WO PCT/IL2017/051008 patent/WO2018047176A1/en unknown
- 2017-09-07 JP JP2019510448A patent/JP7074352B2/en active Active
- 2017-09-07 BR BR112019004500A patent/BR112019004500A2/en not_active Application Discontinuation
- 2017-09-07 KR KR1020197008742A patent/KR20190049757A/en unknown
- 2017-09-07 CN CN201780068419.2A patent/CN109922798A/en active Pending
- 2017-09-07 AU AU2017322654A patent/AU2017322654A1/en not_active Abandoned
- 2017-09-07 EP EP17848288.1A patent/EP3509577A4/en active Pending
- 2017-09-07 US US16/330,491 patent/US10751347B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2017322654A1 (en) | 2019-04-04 |
JP7074352B2 (en) | 2022-05-24 |
US20190224216A1 (en) | 2019-07-25 |
WO2018047176A1 (en) | 2018-03-15 |
JP2019529363A (en) | 2019-10-17 |
EP3509577A1 (en) | 2019-07-17 |
BR112019004500A2 (en) | 2019-05-28 |
US10751347B2 (en) | 2020-08-25 |
EP3509577A4 (en) | 2020-04-08 |
CN109922798A (en) | 2019-06-21 |
KR20190049757A (en) | 2019-05-09 |
EA201990561A1 (en) | 2019-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10561670B2 (en) | Compositions comprising acidic extracts of mastic gum | |
US11207333B2 (en) | Compositions comprising triterpenoids and uses thereof for treating optic neuropathy | |
US10751347B2 (en) | Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy | |
ES2904263T3 (en) | Compositions comprising triterpenoids for the treatment of Alzheimer's disease and Parkinson's disease | |
JP6934421B2 (en) | Use of isolated fractions of mastic gum to treat optic neuropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20231219 |